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Introduction and outline 
Type 2 diabetes mellitus (DM2) is a heterogeneous group of disorders characterized 
by variable degrees of insulin resistance, impaired insulin secretion, and increased 
glucose production resulting in a raised blood glucose (1). DM2 goes hand in hand 
with adiposity, hypertension and dyslipidemia, all components of the 'metabolic 
syndrome'. The majority of patients with DM2 die of atherosclerosis and its 
comphcations (2). 
DM2 and other diseases such as heart diseases and cancer are an increasing 
problem around the globe, especially in the developed world (3). Currently, in the 
Netherlands the prevalence of DM2 is approximately 3.5% and this number is 
expected to increase by at least 32% in the next decades. This is due to the changing 
demographic characteristics (more elderly people), increasing problem of overweight 
and the improved and early detection of patients with DM (4). 
In the Netherlands, patients with DM2 are predominandy managed by their 
general practitioner (GP). The management of DM2 confronts the GP with many 
challenges with respect to prevention, diagnosis and treatment. The GP has a role in 
promoting a healthy life style m all individuals, and especially those at risk for DM2 
(Table 1.1). Next, the G P should diagnose DM2 as early as possible because a large 
proportion of patients have already developed complications at diagnosis, and the 
existence of such complications showed to be an unfavourable prognostic factor (5). 
For an early diagnosis the recognition of signs and symptoms of diabetes (e.g., thirst, 
unexplained weight loss, unexplained pruritus), and blood glucose screening in 
patients with an increased risk for DM2 is warranted (6). Once the diagnosis has been 
estabbshed, the G P has to closely monitor the patients' metabolic, cardiovascular, 
renal and ophthalmic status. The GP also has to screen for other complications, such 
as neuropathy, foot problems and sexual problems. At the same time, the GP has to 
work together with and co-ordinate the other primary care professional involved in 
the treatment of the patient (e.g., dieticians, practice nurses, podotherapist). Together 
with the other members of the multidisciplinary team the G P has to inform, educate 
and 'empower' the patient to cope with the consequences of the disorder. In addition, 
therapy should be initiated to correct possible (threatening) metabolic disturbances 
and to prevent comphcations. 
It is important to note that the majority of patients with DM2 in general practice 
are asymptomatic and feel perfectly healthy. This particularly pertains to patients who 
are diagnosed coincidentally or by case-finding. In these patients, the treatment could 
therefore be merely regarded as a form of prevention, rather than as a treatment for 
illness. Especially in preventive treatments, the 'doubt' from the old adage 'in dubio 
abstine', should be taken seriously as médicalisation is at stake. Therefore, especially in 
patients with DM2, there is a need to achieve a maximum effect through the 
application of minimal interventions. 
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In this thesis we assessed the evidence base of two interventions in the treatment and 
prevention of DM2: diet and alpha-glucosidase inhibitors. In the first part of this 
thesis, the evidence for the usefulness of dietary treatment was assessed. We focused 
on dietary patterns of patients with DM2, and on factors that determine patients' 
motivation to change their diet. In the second part of this thesis, we assessed the 
effectiveness of oral treatment with alpha-glucosidase inhibitors, in the treatment and 
prevention of DM2. 
Table 1.1. Risk factors for developing type 2 diabetes mellitus (8) 
• A positive family history of type 2 diabetes 
• Hypertension 
• Kxisung cardiovascular disease 
• Disorders of lipid metabolism 
• Hindu, Turkish, Moroccan or Surinam descent 
• Overweight 
• History of gestational diabetes 
Diet in type 2 diabetes mellitus 
The evidence base for diet therapy in DM2 
Diet and other life-style measures are traditionally seen as the cornerstone in the 
treatment of DM2 (7). The guidelines of the Dutch College of General Practitioners 
therefore recommend to refer all newly diagnosed patients to a dietician for 
individually tailored dietary advice (8). The major goals of dietary treatment are: (1) to 
reach and maintain a desirable body weight; (2) to reach and maintain optimal blood 
glucose levels, if necessary by balancing food intake with the use of oral medication or 
insulin; (3) to reduce (LDL) cholesterol levels; (4) to lower blood pressure; (5) to 
prevent or treat possible complications such as diabetic nephropathy. In order to 
achieve these goals, patients receive nutritional recommendations that are roughly in 
line with those for the general population (Table 1.2). These recommendations are 
based on a review of the Lterature and subsequent consensus meetings of experts (9, 
10). The strength of the evidence is different per recommendation and many 
questions remain unresolved. In chapter 2 we have assessed the evidence for all 
different aspects of diet therapy by means of searching and reviewing high quality 
systematic reviews. 
11 
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Table 1.2. Nutnuonal recommendauons for patients with type 2 diabetes mellitus (9) 
• Total energy intake 
O Caloric intake aimed at reducing body weight in case of overweight, 
otherwise balanced with expenditure 
• Fat 
0 Total fat intake =30% of energy intake (less in case of overweight) 
0 Saturated fat <10% of energy intake 
0 Minimization of trans fat (<1 energy%) 
O Total cholesterol <300 mg/day 
• Carbohydrates 
O >40 energy% of digestible carbohydrates per day 
• Protein 
O 10-20 energy%, in patients with micro- or macroalbuminuna: 0.8 g 
protein/kg ideal body weight 
• Fibres 
O 30-40 grams of soluble fibres per day 
Dietary habits of patients newly diagnosed with DM2 and eating behaviour as a predictor of 
short- and long-term dietary changes 
Although patients with DM2 are widely advised to adapt a healthier diet, litde is 
known on their actual diet. This is especially true for newly diagnosed patients. Only a 
few studies on fat and total energy intake in these patients have been reported. One 
study in newly diagnosed patients with DM2 showed a relatively high intake of fat, as 
compared to the recommended intake (11). A study in patients with newly diagnosed 
diabetes reported no differences in intake of fat and total energy compared to non-
diabetic subjects (12). Moreover, litde is known about the adherence to dietary 
recommendations in patients with DM2 from the moment of diagnosis. Although 
some limited success has been reported in small samples of patients with diabetes (13), 
GPs are generally pessimistic about the long term effects of dietary advise, especially 
in regards to weight loss (14-16). 
In order to improve the effectiveness of dietary treatment, studies are needed to 
assess the actual dietary habits of patients with DM2 and to determine factors that are 
relevant to their motivation to adapt and adhere to dietary changes. 
In our studies of newly diagnosed patients with DM2, we investigated dietary 
intake (e.g., intake of total energy, fat) and eating behaviour {chapter J). Eating 
behaviour results from a complex mix of biological, socio-cultural and psychological 
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mechanisms. To assess eating behaviour, we used the psychological concept of 
restrained eating and disinhibition of eating (i.e., emotional and external eating). 
Restrained eating refers to deliberately eating less in order to loose weight. Emotional 
eating is characterized by overeating triggered by mosdy negative emotions such as 
grief and anxiety. External eating pertains to situations, when people eat more than 
planned or continue to eat when one's eaten fill of, as a result of the influence of 
external factors such as the good look or smell of food. Restrained, emotional, and 
external eating can be measured using a questionnaire which has been advocated for 
use in general practice (17). 
In chapter 3.1 we assessed fat and total energy consumption m a cohort of newly 
diagnosed patients with DM2 and compared it with the general population. In 
addition, we measured changes in fat and total energy consumption shortly after 
standardized dietary consultations and after four years of usual care. In the same 
cohort we measured restrained, emotional and external eating behaviours, and we 
compared these behavioural patterns with those in the general population {chapter 3.2). 
In addition, we assessed the relation between eating behaviour and fat and total energy 
consumption at diagnosis, and the relation between eating behaviour and changes in 
fat and total energy consumption following dietary advise {chapter 3.2). 
Although restrained eating behaviour might seem a key target of dietary 
intervention in diabetes type 2, it is not unequivocal. Restrained eating is sometimes 
even described as being counterproductive. The 'restrained eating theory' states that 
patients who strive for weight reduction by eating less (restrained eating), will gain 
weight in the end, and therefore dieting might even be harmful (18). This is 
specifically important in DM2, as the importance of losing weight is one of the 
cornerstones of its treatment. Therefore, it is important that this 'dieting dilemma' is 
known to GPs, practice nurses and dieticians and is dealt with before encouraging 
people to eat less. In chapter 3.3 we addressed this 'dieting dilemma', i.e. the 
paradoxical question whether or not restrained eating is associated with weight gain. 
Alpha-glucosidase inhibitors for treatment of type 2 diabetes mellitus 
If diet and exercise alone fail to sufficiently control blood glucose levels, starting oral 
drug therapy is recommended (8). To date, six classes of oral antihyperglycermc drugs 
are available: biguamdes (metformin), sulphonylurea (e.g., tolbutamide), glinidines 
(e.g., repaglirude), thiazolidmediones (e.g., pioglitazone), dipeptidyl peptidase IV 
inhibitors (e.g., sitagliptin) and alpha-glucosidase inhibitors (e.g., acarbose) (19). 
The choice for a first-line glucose-lowering drug depends on its effectiveness, 
safety, tolerability, user-friendliness and costs. Ideally, the drug should be able to 
prevent or delay diabetes-related mortality and morbidity, without causing dangerous 
or disturbing side-effects, is easy to use and has low costs. Thus far, no drug seems to 
meet all those demands. Metformin seems to have the best track record, since it has 
been shown to reduce mortality and diabetes-related complications more effectively 
13 
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than sulphonylurea or insulin. However, these data are derived from one single study 
(20) and not confirmed in other trials (21). Metformin is contra-indicated in patients 
with impaired renal function, and a considerable proportion of patients experience 
gastro-intestinal side-effects. Sulphonylurea are the oldest available oral drugs for 
DM2 and widely used as first-line treatment. They have a clear effect on glycémie 
control, but, remarkably, beneficial effects on mortality or diabetes related morbidity 
that can directly be attributed to sulphonylurea have never been shown. Sulphonylurea 
may cause weight gain and carry the risk of (dangerous) hypoglycaemic events. 
Glimdines are short-acting insubn-secretagogues, and mainly effect post-prandial 
blood glucose levels. Data on the effects of glimdines on clinically relevant endpoints 
are still lacking. Preliminary studies on thiazolidinediones suggest beneficial effects on 
cardiovascular endpoints (22), however, this remains to be confirmed (23). Side effects 
of thiazolidinediones include weight gain and oedema. Therefore, these drugs are 
contra-indicated in patients with an increased risk for heart failure. Alpha-glucosidase 
inhibitors such as acarbose act by inhibiting the breakdown of complex carbohydrates 
m the small intestine, thereby reducing carbohydrate uptake and post-prandial blood 
glucose peaks. Because alpha-glucosidase inhibitors work solely in the gut, side effects 
are of gastro-intestinal nature and include diarrhoea, flatulence and stomachache. 
Weight gain, hypoglycaemic events or other life-threatening side-effects have not been 
observed, even at overdoses. However, rare cases of hepatic injury due to acarbose 
were described (24). In view of its safety record and the absence of weight gain, alpha-
glucosidase inhibitors might offer a safe alternative for currendy favoured oral 
treatment strategies in newly diagnosed patients with DM2, provided that alpha-
glucosidase inhibitors are at least equivalent to other drugs with respect to their effects 
on mortality, morbidity and glycémie control. 
In chapter 4.1 we report a double-blind randomized trial on the effects of acarbose 
versus tolbutamide on plasma glycated haemoglobin, fasting and post-load blood 
glucose, plasma insulin, plasma lipids, as well as their side effects. We systematically 
reviewed the literature to assess the effects of alpha-glucosidase monotherapy 
(acarbose, miglitol, voglibose) as compared to all possible other interventions (chapter 
4.2). In addition, we critically review a pubbshed meta-analysis that claims that 
acarbose reduces the incidence of myocardial infarctions (chapter 4.3. /). In response, 
the authors of this meta-analysis made comments on our systematic review. Chapter 
4.3.2 contains our reply to those comments. 
The effectiveness o f alpha-glucosidase inhibitors in patients with 
impaired glucose tolerance or impaired fasting blood glucose 
DM2 is not a clear-cut disease, but merely the result of an arbitrarily chosen point 
somewhere between the absence of insubn resistance and normal insubn secretion, 
and advanced peripheral insubn resistance and absence of insubn production. 
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Therefore, the optimal moment to start treatment is not unequivocal. Specific criteria 
have been defined for those people who have a raised post-prandial and/or fasting 
blood glucose, but who do not meet the criteria for DM2. This condition is referred 
to as 'impaired glucose tolerance' (IGT) when post-prandial blood glucose levels are 
elevated, and 'impaired fasting blood glucose' (IFBG) in case of elevated fasting blood 
glucose (criteria: Table 1.3). 
Table 1.3. Current definitions for diabetes mellitus, impaired glucose tolerance and impaired 
fasting blood glucose 

























diabetes* plus CPG 
>11.1 
OR 
FPG >7.0 on two 
occasions 
No definition 
FPG >6.1 AND 
<6.9t 
All values are venous, plasma glucose concentrations (mmol/1) 
2HPG = 2-hours Plasma Glucose, glucose concentration 2-hours after ingestion of 75 grams glucose, 
CPG = Casual Plasma Glucose, casual is defined as any time of day without regard to urne since last 
meal, FPG = Fasung Plasma Glucose, fasting is defined as no calorie intake for >8 hours 
* The classic symptoms of diabetes include polyuna, polydipsia, and unexplained weight loss 
f These criteria should be confirmed by repeat testing 'in the absence of unequivocal hyperglycemia' 
φ Excluding patients fulfilling the cntena for type 2 diabetes 
If one decides to treat this condidon, diet and exercises are an effecrive method to 
improve glucose tolerance and are recommended as first choice treatment (25). With 
life-style modifications, a reladve-risk reduction (RRR) in the progression to DM2 of 
58% may be achieved (26). Pharmacological treatment of I G T and IFBG may seem 
controversial, since it may implicate médicalisation of the non-ill. According to a 
limited number of studies, especially drugs that improve insulin sensitivity may be 
useful in IGT and IFBG. Studies have been carried out with metformin (RRR of 31%, 
endpoint DM2) (27), and rosigbtazone (RRR of 60%, combined endpoint diabetes 
and death) (28). In a large-scale multi-centre study with acarbose for patients with 
15 
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IGT, it was found that acarbose might prevent or delay DM2 (RRR of 25%) and, 
interestingly, the data also pointed at a reduction of cardiovascular events. However, it 
should be noted that this study was heavily debated because of suspected bias (29, 30). 
In this thesis we performed a systematic literature review assessing the effects of 
monotherapy with acarbose, miglitol or voglibose in subjects with IGT or IFBG with 
respect to the development of DM2, cardiovascular disease, glycémie control, serum 
lipid profile, blood pressure, body weight and side effects {chapter 5). 
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Limited evidence for effects of diet for type 2 diabetes 
from systematic reviews 
Floris A. van de Laar, Reimer P. Akkermans, Jaap J. van Binsbergen 
Radboud University Nijmegen Medical Centre, Department of General 
Practice, Nijmegen, The Netherlands 
Eur] Clin Nutr 2007;61 (8):929-937 
Chapter 2 Critical appraisal of reviews of diabetic diet 
Abstract 
Objective. Systematic reviews are an appraised method to summarize research in a 
concise and transparent way, and may enable to draw conclusions beyond the sum of 
results of individual studies. We assessed the results, quality and external validity of 
systematic reviews on diet in patients with type 2 diabetes. 
Design, Setting Subjects. We systematically searched for systematic reviews on nutritional 
interventions in patients with type 2 diabetes that used a reproducible search strategy 
in at least one major database that applied some form of quality assessment. We 
assessed quality and the external validity of the retrieved systematic reviews. 
Outcomes were defined as statistical meta-analyses or narrative results using a 
predefined and reproducible method. 
Results. Six systematic reviews met the inclusion criteria, investigating dietary 
intervenuons in general (n=3), chromium supplementation (n=l) , fish oil (n=l) or 
herbs and nutrition supplements (n=l) . Quality assessment showed minimal/minor 
flaws in four cases and major/extensive flaws in two cases. All reviews had 
insufficient data needed to judge external validity. In reviews with minimal/minor 
flaws we found beneficial effects of very-low-calorie diets and fish oil supplements. 
However, the external validity of these results could not be assessed sufficiently. 
Conclusions. Systematic reviews largely failed to produce knowledge beyond the sum of 
the original studies. Furthermore, judgment of external validity was hampered in most 
cases owing to missing data. To improve the quality and usefulness of systematic 
reviews of dietary interventions, we recommend the application of more focused 
research questions, but with broader inclusion criteria, for example, the use of 
observational studies. 
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Introduction 
Diet is an important aspect in the management of type 2 diabetes. It is directly related 
to main treatment goals such as the establishment of a (near) normal body weight, 
control of plasma lipids and hyperglycaemia, renal protection and the avoidance of 
hypoglycaemic episodes (1). In order to establish beneficial dietary changes in patients 
with type 2 diabetes, a clinician has to be informed about many aspects of diet in type 
2 diabetes, including the effects of macro- and micronutrients and food supplements. 
In addidon, it is important to know how to bring about persistent beneficial changes 
in patients' dietary habits. 
It is virtually impossible for both researcher and clinician to keep track of all 
published research in the field. Systematic reviews offer an appraised method to 
summarize all relevant studies in a concise and transparent way, and they may enable 
to draw conclusions beyond the sum of results of individual studies. In addition, 
systematic reviews may help researches to refine hypotheses, estimate sample sizes, 
and help to define future research agendas (2). 
In the last decade, systematic reviews became increasingly popular. For example, 
the Cochrane Library, a collection of regularly updated high-quality systematic 
reviews, has grown from 36 systematic reviews in 1995 to 2356 systematic reviews in 
2005 (4% of which dealt with nutrition (3)). A quick look in Pubmed (Medical Subject 
Heading 'diabetic diet') revealed more reviews (n=485) than clinical trials (n=360). 
Also, there is an increased awareness of the impact of systematic reviews for practice 
and research as can be read from different editorials in leading journals (4, 5). And, in 
an attempt to improve the uniformity and completeness of the reporting of systematic 
reviews, an evidence based guideline was developed (6). 
It is important to distinguish systematic reviews from narrative reviews: in contrast 
to narrative reviews, systematic reviews should have a clear and narrow research 
question and should be conducted by a reproducible method. Therefore, systematic 
reviews are considered a scientific exercise in itself. However, still a considerable 
amount of so-called systematic reviews, especially those sponsored by the industry or 
non-Cochrane reviews, appear to have methodological flaws (7). Moreover, studies on 
the same topic that were found to be of good quality may produce contradictor)' 
evidence (8, 9). 
In this study, we systematically searched, and critically appraised all systematic 
reviews on the topic of type 2 diabètes and diet. Our aims were to establish the 
highest levels of evidence by means of systematic reviews for different topics on diet 
and type 2 diabetes, to identify research gaps, and to analyze methodological problems 
m systematic reviews of studies in the nutrition field. 
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Methods 
Search strategy 
We searched PUBMED (which contains MEDLINE and a number of additional 
journals), EMBASE and the Cochrane Database of Abstracts of Review of Effects 
(DARE). In addition, we checked bibliographies from guidelines and known reviews, 
we contacted experts in the fields and we searched our own personal files. We used a 
combined sensitive search strategy for 'systematic reviews', 'type 2 diabetes' and 
'dietary interventions' (Appendix A). The last search was in December 2005 for 
PUBMED and DARE, and in October 2005 for EMBASE. Two independent 
reviewers (FVDL, JVB) assessed all titles and abstracts and extracted all data. 
Interrater agreement was calculated by kappa-statistics. If a study could not be 
excluded on basis of tide and/or abstract alone, we retrieved the full article for further 
assessment. 
The inclusion criteria were: (1) studies primarily aiming to review the literature, (2) 
using a reproducible search strategy, m (3) at least one major electronic database 
(MEDLINE, EMBASE or CENTRAL), (4) the main focus should be on a nutritional 
intervention in patients with type 2 diabetes (reviews that studied interventions to 
change eating habits and/or reduce body weight, and studies assessing the effects of a 
specific food composition or foodstuff (e.g., fish oil) were included) and (5) there 
should be some form of assessment of the quality of included studies. This way, 
systematic reviews were distinguished from narrative ones. 
We excluded studies in another language than English, Dutch, German, French or 
Italian. 
Oata extraction and quality assessment 
Two reviewers (FVDL, JVB) extracted independendy all data and assessed quality on a 
pre-tested data extraction form. Cases of disagreement were resolved by consensus or 
by consultation of the third reviewer (RA). We extracted the following items: 
1) General aspects: language, sponsor, and background of authors 
2) Methods / quality items: sources used, inclusion criteria, exclusion criteria and 
restrictions (language, unpubbshed studies), number of reviewers that assessed 
abstracts and extracted data, handling of missing data, method of quality 
assessment, method of investigating and handling heterogeneity (including 
heterogeneity caused by differences in setting), statistical method of meta-
analyses, method of incorporating quality items in results. External validity: 
setting (e.g., general practice, hospital), patients (e.g., duration of type 2 diabetes), 
type of intervention, length of foUow-up. 
3) Outcome assessment: outcomes were first subdivided in type of intervention 
(e.g., very-low-calorie diet, low-glycemic index diet, etc.); next we clustered the 
result per type of intervention (e.g., effect on body weight, effect on blood 
glucose). We considered the following as being an outcome from a systematic 
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review: (A) numeric data from meta-analyses with appropriate handling of 
possible heterogeneity or (B) an overall judgment of the effect of a certain 
intervention, using a predefined method, ideally taking into account quality and 
heterogeneity. A straightforward list of the results and/or conclusions of the 
included studies was not considered to be a result of a systematic review. The 
following outcomes were extracted: mortality, diabetes-related morbidity 
(cardiovascular disease, nephropathy, retinopathy, neuropathy) and quality of life, 
body weight (or body mass index), indicators for blood glucose (glycated 
hemoglobin, blood glucose, plasma insulin), risk factors for cardiovascular 
disease (plasma lipids, blood pressure), indicators for renal disease (Creatinin) and 
compliance. 
Overall quality was assessed with the Overview Quality Assessment Questionnaire 
(OQAQ), a validated tool for the critical appraisal of systematic reviews (10). The 
instrument consisted of nine questions (yes, no, cannot tell) about different aspects of 
the methodological quahty and one overall score rated from 1 (extensive flaws) to 7 
(minimal flaws). Both reviewers discussed and rated all included studies. In case of 
disagreement, a third reviewer (RA) was consulted. In addition, we assessed whether 
and how heterogeneity was assessed, and we evaluated whether and how the results of 
the quahty assessment were incorporated in the results. 
External validity is the extent to which results are applicable to other 
circumstances. It cannot be formally tested and judgment depends on study aspects 
with respect to patients, treatment regimens, settings and length of follow-up (11). 
Although, no guideline for formal assessment of external validity exists, we attempted 
to gain insight in external validity by recording whether the systematic reviews 
assessed the following characteristics of included studies: patient characteristics (age, 
sex, duration of diabetes, body weight), details of treatment regimens, setting (country, 
level of care) and length of follow-up. 
Results 
The search in PUBMED, EMBASE and DARE, resulted in 153, 1533 and 166 
records, respectively. In EMBASE, the number of records was significantly higher 
compared with other sources because the search string for 'systematic reviews' was 
made less specific owing to browser différences. The kappa for interrater agreement 
was 0.87 (95% confidence interval (CI) 0.73-1.00). We included six systematic reviews 
(Table 2.1) (12-18).Two articles referred to the same systematic review (16, 18). Ten 
other systematic reviews were initially included, but excluded after reading the full 
article: seven systematic reviews because it was unclear whether and how quality 
assessment was done (19-25) one because its focus was on both diabetic and non-
diabetic renal disease (26), one systematic review did not study the effects of diet, but 
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the impact of weight gain in patients with diabetes (27), and one systematic review 
focused on enteral nutritional support for specific subgroups of patients with diabetes 
(e.g., post-operative, slow-healing ulcers) (28). 
All other records were excluded on basis of the tide and/or abstract. We kept track 
of the reasons for exclusion for a random sample of 50 records for each database. The 
possible reasons were: (1) the study was not a systematic literature review, (2) the 
study did not focus on patients with type 2 diabetes, (3) the study did not focus on a 
dietary intervention or (4) a combination of two or three of the previously mentioned 
reasons. This yielded the following results for PUBMED: (1) 14%, (2) 14%, (3) 10%, 
(4) 62%; EMBASE: (1) 6%, (2) 0%, (3) 10%, (4) 84%; DARE: (1) 0% (DARE only 
includes systematic reviews), (2) 72%, (3) 2%, (4) 26%. 
Characteristics and quality of systematic reviews (Tables 2.1 <& 2.2) 
Of the six included systematic reviews two focused on strategies, including diet, that 
promote weight loss in patients with type 2 diabetes (13, 14). One investigated dietary 
advice in general (12), and three other studies focused on the effects of specific dietary 
interventions: the use of chromium supplements (15), fish oil supplements (16) both 
herbal remedies and dietary supplements (17). 
In all systematic reviews more than one source had been used: varying from two 
major electronic databases and reference checking (15), to searching in nine databases 
(14). The inclusion of studies in the systematic review differed widely: four of six 
reviews included only randomized studies, the other two also included non-
randomized studies (13, 17). All systematic reviews selected studies in type 2 diabetic 
patients, but in addition also studies with healthy volunteers (15,17), and patients with 
impaired glucose tolerance or type 1 diabetes were included (17). One review 
restricted inclusion to studies with obese patients with type 2 diabetes (13). Three 
reviews applied a minimum study duration for inclusion of 1 (16), 6 (12), or 12 (14) 
months. 
In all systematic reviews two investigators performed data extraction. Three 
systematic reviews reported that m case of missing data the original authors were 
contacted (12, 14, 15), but it remains unclear whether these attempts were successful. 
One systematic review reported additional data from one author (16), but it remains 
unclear whether the same effort was made for other missing data. 
Internal validity, that is, the quality of included studies, was assessed by the Jadad 
scale (12, 16, 17), by the method of Chalmers et al. (15, 29), the method 
recommended by the Cochrane Collaboration (14), or by an own, separately published 
method (13). But, even though all six systematic reviews reported some form of 
quality assessment, it was unclear in three systematic reviews how quality data were 
incorporated in the (weighing of) results (13, 15, 17). In the other three systematic 
reviews the quality data were integrated narratively (12) or by sensitivity and 
metaregression analyses (14, 16). Four systematic reviews reported methods to handle 
heterogeneity (12, 14-16), the other two did not report or perform an assessment of 
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Study Sources 
(n) 
Inclusion cntena Assessment of study quality Assessment of 
heterogeneity 
Incorporation of 







Studies: randomized controlled trials, subjects: ^18 
years, >90% with type 2 DM; interventions, dietary 
advice aimed at reducing weight or seventy of type 2 
diabetes, duration: ^ 6 months 
Studies controlled and uncontrolled studies with 
data that permitted calculation of effect sizes, 
interventions: different kinds of strategies to 
promote weight loss*; subjects: obese adults, type 2 
DM; outcomes: measure of weight loss; other same 
setung should be applied for treatment and controls 
A (high) to C (low) scale 
adapted from Jadad 
measures 
Studies: randomized controlled trials, intervenuons· Selection, attnuon and 
weight loss/control strategies with diet, physical detection bias assessed 
activity, or behavioural intervenuons*, subjects: >18 separately 
yrs, type 2 DM, duration· >12 months (follow-up); 
outcomes, weight or BMI 
Studies: randomized controlled trials, interventions: 
chromium supplementation, control placebo or 
acuve (e.g., picolinate or yeast); subjects: healthy 
people, type 2 DM, glucose intolerance^ 
Selection, attntion, 
detection bias assessed in 
pubbshed data-extraction 
form 




Assessment of (0 low - 21 Unclear 
high)· overall design, 
selection of study sample, 
specification of illness, 
descnpaon of intervenaon, 
clanty of outcome 
definitions, directness and 

















No meta-analysis for 
type 2 DM subgroup; 
narrauve 
Table 2.1 continued 
Study Sources 
(η) 
Inclusion cntena Assessment of study quality Assessment of Incorporation of Data synthesis 
heterogeneity quality in results method 
(16) 
Ο?) 
Studies* randomized controlled tnals, interventions: 
fish oil compared with placebo or vegetable oil, 
subjects- adults, type 2 DM; duration: >1 month, 
outcomes: 'clinically relevant outcome measures' 
Studies: controlled trials; interventions: herbs and 
supplements, subjects- type 1 or 2 DM, I G T or 
those specifically at nsk for diabetes, healthy 




(0 low 5 Chi















used as additional 
evidence 
Abbreviations: BMI, body mass index; DM, diabetes mellitus; IGT, impaired glucose tolerance 
* We only considered results for the dietary interventions 
f We only considered results for patients with type 2 diabetes 
Diet and alpha-glucosidase inhibition in the early treatment of type 2 diabetes mellitus 
heterogeneity (13, 17). Examples of methods used to assess heterogeneity were: Chi-
square tests (12, 15, 16), and sub-group analyses (12, 14, 16). Four systematic reviews 
accounted for assumed heterogeneity with the use of a random effects model (12, 14-
16). 
Statistical meta-analyses were presented in three systematic reviews (13,14, 16) and 
planned in two other systematic reviews but owing to low numbers of included 
studies results were presented narratively (12, 15). One review rated the evidence by 
using the US Preventive Task Force Criteria and American Diabetes Association 
Evidence Grading System for clinical recommendations (17). 
Details about external validity are summarized in Table 2.3. All but one systematic 
review reported details of treatment regimens. The setting and the duration of 
diabètes were the least frequently reported. 
Table 2.2. Methodological quality of included systemauc reviews according to Overview 
Quahty Assessment Quesuonnaire (OQAQ) (10) 
Study 
1 Were the search methods stated' 
2 Was the search reasonably comprehensive' 
3 Were the inclusion critena reported' 
4 Was bias in the selection of the studies 
avoided? 
5 Were the cntena used to assess validity 
reported? 
6 Was validity assessed using appropriate 
cntena? 
7 Were methods used to combine findings of 
studies reported? 
8 Were findings of relevant studies combined 
appropnately? 
9 Were the conclusions supported by reported 
data? 



































































Y = yes, Ν = no 
* Number of authors that searched tnals not reported. 
f Allocation concealment, method of blinding and attnnon not assessed, own developed scoring form. 
Instrument not validated 
H Overall score should be based on the answers to the first nine quesuons. We used the following 
guidelines: if the 'no' option was used on question 2, 4, 6 or 8, the review is likely to have major flaws 
(awarded with a score of 3 or less) 
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Outcomes of the systematic reviews 
Dietary advice in general. One systematic review focused on dietary advice in general for 
patients with type 2 diabetes (12). Eighteen studies were included, but nine of these 
compared dietary advice with dietary advice and exercise or behavioural interventions. 
The nine studies on dietary intervendons were sub-divided in three comparison 
groups: an ADA exchange diet versus a reduced fat diet (two studies), a low-fat diet 
versus a moderate fat or low-carbohydrate diet (five studies) and very-low-calorie diet 
versus low-calorie diet (two studies). Statistical meta-analyses could not be performed 
owing to the low number of studies, heterogeneity and low quality of included studies, 
thus no conclusions were drawn. 




Duration of diabetes 
Bodv weight or BMI 
Details of treatment regimens 
Setung· Country 
Care level (e.g., primary care) 













































Information about characteristics of included studies are reported adequately (+) if the information is 
reducible to individual included studies; (-) = not reported 
Diet for losing or controlling body weight. In two systematic reviews, diet for the purpose of 
Controlling or losing weight was being studied as a part of a broader research question 
that also included other interventions for controlling weight (e.g., exercise). A 
systematic review published in 1996 included 89 studies of which, 40% involved 
dietary interventions (13), 72% of includes studies were non-experimental (one-group 
pre-post-test design). In the main meta-analysis, all dietary approaches were 
considered together and the lengths of the interventions ranged from 'immediate' 
outcomes to more than 1 year. Dietary interventions (ADA reduced calorie, very-low-
calorie diet, protein sparing modified fast diet) lowered body weight by approximately 
9 kg (20 lb) and reduced glycated haemoglobin by 2.7%. 
Another systematic review of more recent date investigated dietary and behavioural 
interventions to reduce body weight. Twenty-two studies were eligible for inclusion in 
the meta-analyses. However, pooled results for diet-only studies were sparse. A meta-
analysis of two studies compared very-low-calorie diet with low-calorie diets (14), this 
resulted in a decrease in body weight of 3 kg (95% CI 0.5 to 6.4) in favour of the very-
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low-calone diet. In an additional meta-analyses, the effects of treatment in individual 
study arms (i.e. pre-test value considered control, post-test value intervention), the 
effect of 'usual care' was a decrease of 2 kg in body weight (95% CI 0.6 to 3.5) and 
low calorie diet resulted in a decrease of 3.7 kg (95% CI 2.3 to 5.1). Details for 5 out 
of 8 items necessary to assess external validity were missing (Table 2.3). 
Effects of supplements. Althuis et al. reviewed the effect of chromium supplements on 
glucose and insulin concentration (15). Only four of the included studies were 
performed in patients with type 2 diabetes. Duration ranged from 8 to 24 weeks and 
the dosage of chromium ranged from 10.8 μg in yeast to 1000 μg chromium 
piccolinate. N o meta-analyses in this subgroup were performed. N o overall result of 
the systematic review in the type 2 diabetes subgroup was given, as the results of the 
individual studies were inconclusive. 
Farmer et al. performed a systematic review on the efficacy of fish oil 
supplementation in patients with type 2 diabetes mellitus. Eighteen studies were 
included in the review. The dosage of fish oil ranged from 1.1 to 5.2 grams 
eicosapentaenoic acid and 0.3 to 4.8 grams docosahexaenoic acid, and the control 
interventions were placebo tablets or vegetable oil. The duration of studies ranged 
from 3 to 24 weeks. In meta-analyses, the use of fish oil resulted in a statistically 
significant decrease in triglycerides of 0.56 mmol/1 (14 trials, 95% CI 0.40-0.71) and a 
statistically significant increase of LDL-cholesterol of 0.24 mmol/1 (11 trials, 95% CI 
0.05 to 0.43). N o statistically significant effects were found for glycated haemoglobin, 
fasting glucose, total- and HDL-cholesterol and body weight. 
Finally, Yeh et al. reported results of a systematic review on the effects of herbs 
and dietary supplements (17). They included 108 trials with 26 different substances 
that were subdivided in three main groups: single herbs, combination herbs and 
vitamin/mineral supplements. N o statistical meta-analyses were performed. Instead, 
evidence was rated by using two different sets of criteria as mentioned before. 
Whether the summarized trials of one certain compound was awarded the highest 
level of evidence (level I, level A), did not depend on the quality of the trials. Nor was 
a 'level 1 ' label a guarantee for a clear outcome. For example, the conclusions for the 
substance Cocania indica (ivy gourd) was that 'the potential role of Coccinia indica 
warrants further study', which was awarded with the highest level of evidence (I, A). 
This way, 'preliminary' or 'suggestive' evidence for, or 'potential effects' on glycémie 
control were found for ginseng, fenugreek, nopal (a cactus species), gymnema sylvestre, 
momordica charantia, aloe vera, traditional Chinese medicine and vanadium formulas were 
found. In addition, 'preliminary' evidence for no effect was found for bauhinia forficate, 
myrda uniflora and combination formulas in Native American medicine. Inconclusive 
results were reported for ivy gourd, garlic species, holy basil, fig leaf, milk thisde, 
combination formulas in Tibetan medicine, chromium, magnesium, L-Carnitine and 
alpha-lipoic acid. Results for studies with type 1 and type 2 diabetic patients were 
considered together; however only four studies were done in type 1 diabetic patients. 
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Discussion 
Our review of systematic reviews of diet in patients with type 2 diabetes showed that 
most systematic reviews resulted in inconclusive findings, and if a statistically 
significant finding was reported, interpretation was difficult because data necessary to 
assess external validity were mostly lacking. Therefore, to assess the value of 
nutritional interventions in type 2 diabetes, systematic reviews are currently not 
helpful. A 'technical review' such as pubbshed by the American Diabetes Association 
(1) may provide a comprehensive overview of the evidence for the different topics in 
dietary treatment of type 2 diabetes, but it should be noted that such a narrative 
approach is susceptible for many sources of bias. 
Previous studies attempted to review systematic reviews and meta-analyses in the 
fields of asthma (7), back and neck pain (8, 30, 31), analgesia and anaesthesia (9, 32), 
emergency medicine (33) and surger)' (34). With no exception, those studies discussed 
the (predominandy low) quality of systematic reviews. The applicability of the results 
for practice was not a topic and none of those studies assessed external validity. We 
are not aware of any comparable study in the field of nutrition. 
The results of our exercise have been influenced by factors on three different 
levels. First, the approach of a systematic overview of systematic reviews has its own 
strengths and limitations. Second, outcomes are directly influenced by the 
methodological quality of the included systematic reviews. And finally, the results are 
influenced in an indirect way by the studies included in the systematic reviews. 
Strengths and limitations of a review of systematic reviews 
Because no clear-cut guidelines for the systematic evaluation of systematic reviews 
exist, we roughly followed similar methodology as in normal systematic reviews. This 
means that we tried to reduce selection and detection bias by rigorous methods in 
defining in- and exclusion criteria, searching of studies, extracting data, quality 
assessment and combining results. We experienced problems in the assessment of 
quality, external validity and method of reporting and combining outcomes. With 
respect to quality assessment, we used the O Q A Q , to date the only validated 
instrument to rate quality of systematic reviews. In addition we assessed two other 
important aspects of quality, namely the method of heterogeneity assessment and the 
method of incorporating quality aspects in the results. The fact that the O Q A Q fails 
to rate those aspects is a drawback of the instrument. Our results showed that the 
method of incorporation of quality in the results is unclear in three out of seven cases, 
confirming previous findings that there is substantial room for improvement 
regarding the incorporation of quality data in the results (35, 36). The assessment of 
external validity was the second problem we encountered. This is an underexposed 
topic in the appraisal of systematic reviews (37). As there are no accepted guidelines 
on how external validity of systematic reviews should be assessed, we used a self-
developed approach. We found that data necessary to assess external validity is mostly 
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missing, and this hampers the judgment of generalizability of the results. Finally, we 
had difficulties in establishing the outcomes. Systematic reviews are original research 
in itself, and should therefore add new informadon to what is already known. We 
decided a prion that results from statistical meta-analyses or overall judgment of 
effectiveness reached by predefined methods should be considered outcomes of a 
systematic review. Doing so, we only found clear outcomes in the systematic review 
on fish oil supplements (16). The other systematic reviews yielded no outcomes (12, 
15) or very limited outcomes of which the external validity remained largely unclear 
(13,14,17). 
Quality of included reviews 
Overall quality according to the O Q A Q was good: five out of seven systematic 
reviews had minor to minimal flaws. The two studies with low scores on the O Q A Q 
(13, 17) both failed on the issues of heterogeneity assessment and incorporation of 
quality in the results, whereas among the other systematic reviews only one study 
failed on the issue of incorporating quality (15). The relatively high scores for quality 
can for a large extent be explained by the inclusion criteria we applied. We decided a 
priori, that only systemadc reviews that reported to have searched in at least one major 
database, and that had done a quality assessment were included. Therefore, all 
systematic reviews automatically scored 'yes' in three out of rune questions in the 
OQAQ. 
Despite those overall good quality scores, it is quite remarkable that the results are 
mostly inconclusive. One reason might be in the so-called 'stainless steel' law of 
systematic reviews, that is, the more rigorous the review, the less evidence that an 
intervention will be effective (38). 
Another reason for the inconclusive results might be that, except for the reviews 
on fish oil and chromium supplementation, reviews had broad instead of focused 
research questions resulting in a post hoc division in treatment groups (12-14, 17). A 
more optimal approach in, for example the systematic review on herbs (17), would be 
that each herb would be investigated in a single systematic review. Only that way, 
sufficient detail and transparence can be achieved. 
Quanhty and quality of studies included in the systematic renews 
It is very difficult to conclude about the quantity and quality of primary studies from 
an overview of systematic reviews. The number of studies that actually exists, and the 
method and rigorousness of the selection method determine the quantity of primary 
studies in systematic reviews. All studies scored 'yes' on the question whether search 
strategies were reasonably comprehensive. So differences in numbers of included 
studies will be largely determined by differences in inclusion criteria. The two reviews 
about dietary advices in general (12) and interventions aimed at reducing weight (14) 
included 18 and 22 studies respectively. This is a relatively low number of studies, 
especially when one considers the broadness of the topic. The other review on weight 
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loss interventions retrieved 89 studies (13). This difference might be explained by the 
fact that the latter review included studies of short duration and did not exclude 
uncontrolled designs. Unfortunately, this review was at high risk for bias (OQAQ 
score 2) and failed to produce data for the assessment of external validity. 
Recommendations for future research 
We conclude that currently there is only scarce evidence from systematic reviews for 
diet m patients with type 2 diabetes. However, this finding should not lead to the 
conclusion that dietary treatment is useless. After all, absence of evidence does not 
imply evidence of absence (39). To effectively assess the state of the evidence and to 
identify the needs for new primary studies, we recommend performing systematic 
reviews with more focused research questions but broader inclusion criteria, such as 
inclusion of short-term studies and the cautious use of non-randomized studies (3, 
40). 
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Appendix A 
# 1 (httpV/www.nlm.mh.gov/bsd/pubmed_subsets/sysreviews_strateg).html accessed 17-01-2005) 
(("sjstematic review*" OR "systematic literature review*" OR meta-analysis |pt] OR meta-analysis [n] OR 
metaanalysis [ti| OR meta-analyses [n] OR evidence-based medicine OR (evidence-based AND (guideline 
[tw] OR guidelines [tw] OR recommendations)) OR (evidenced-based AND (guideline [tw] OR 
guidelines |rw] OR recommendation*)) OR consensus development conference [pt] OR health planning 
guidehnes OR guideline|pt] OR Cochrane database syst rev OR acp journal club OR health technol assess 
OR evid rep technol assess summ OR evid based nurs OR evid based ment health OR clin evid) OR 
((systematic [tw] OR systematically OR critical [tw] OR (study [tiabj AND selection [aab]) OR 
(predetermined OR inclusion AND cnten* [tw]) OR exclusion cnten* OR "main outcome measures" 
OR "standard of care") AND (survey [tw] OR surveys [tw] OR overview* OR review [tw] OR reviews 
OR search* OR handsearch OR analysis [tw] OR critique [tw] OR appraisal OR (reduction AND risk 
AND (death OR recurrence))) AND (literature [tw] OR articles OR pubbcations [tw] OR publication [tw] 
OR bibliography [tw] OR bibliographies OR published OR unpublished OR citation OR citations OR 
database OR internet [tw] OR textbooks [tw] OR references OR trials OR meta-analysis [mh] OR 
(clinical [tw] AND studies) OR treatment outcome)) NOT (case report [ti] OR editoria] [a] OR editorial 
[pt] OR letter [pt] OR newspaper article [pt])) 
#2 
(("Diabetes Mellitus, Type II"[MeSH] OR "Insulin Resistance"[MeSH] OR "Metabolic Syndrome 
X"[MeSH] OR "Obesity in Diabetes" [MeSH] OR impaired glucose tolerance [TW] OR "glucose 
intolerance" [TW] OR "insulin resistance" [TW] OR "obese diabetes" [TW] OR "obesity diabetes" [TW] 
OR "obese diabetic" [TW] OR MODY [TW] OR NIDDM [TW] OR "non insulin dependent" [TW] OR 
"nonmsulin dependent" [TW] OR "non insulindependent" [TW] OR "nonmsulindependent" [TW] OR 
"non-insulin dependent" [TW] OR nomnsulinodependent [TW] OR "non insulin treated" [TW] OR 
"nonmsulin treated" [TW] OR "non insulintreated" [TW] OR "nomnsulintreated" [TW] OR "non-insulin 
treated" [TW] OR nonmsulinotreated [TW] OR ((non insulin [tw] OR nonmsulin [tw] OR type 2 [TW] 
OR type II [tw]) AND diabetes [tw]) OR type 2 DM [TW] OR type II DM [TW] OR DMNID [TW] OR 
"type II diabetes" [TW] OR "type 2 diabetes" [TW] OR "type II diabetic" [TW] OR "type 2 diabetic" 
[TW] OR diabetes type 2 [TW] OR diabetes type II [TW] OR diabetes mellitus type 2 [TW] OR diabetes 
mellitus type II [TW] OR "adult diabetes" [TW] OR "maturity onset diabetes" [TW] OR "late onset 
diabetes" [TW] OR "stable diabetes" [TW] OR "adult diabenc" [TW] OR "maturity onset diabetics" [TW] 
OR "late onset diabencs" [TWT OR "stable diabetics" [TW] OR metabolic syndrome [TW] OR syndrome 
X [TW]) NOT ("Diabetes Insipidus"[MeSH] OR "diabetes insipidus" [TW])) 
#3 
(("Diet"[MeSH] OR "Diet, Sodium-Restncted"|MeSH] OR "Diet, Protein-Restncted"[MeSH] OR "Diet, 
Fat-Restricted"[MeSH] OR "Diet, Vegetanan"[MeSH] OR "Diet Therapy"[MeSH] OR "Diet, 
Mediterranean" [MeSH] OR "Diet, Macrobiotic" [MeSH] OR "Diet, Atherogenic" [MeSH] OR "Diabetic 
Diet"[MeSH] OR "diet therapy"[Subheading] OR "Dietetics"[MeSH] OR "Nutrition Therapy"[MeSH] 
OR "Dietary Supplements"[MeSH]) OR ("diabetic diet" [TW] OR "diet therapy" [TW] OR "diet 
treatment" [TW] OR "dietary treatment" [TW] OR "dietary counseling" [TW] OR "dietary fat" [TW] OR 
"dietary fats" [TW] OR "dietary sugar" [TW] OR "dietary· sugars" [TW] OR "reducing diet" [TW] OR 
"weight management" [TW] OR fat restricted diet [TW] OR carbohydrate diet [TW] OR "carb diet" [TW] 
OR restricted diet [TW] OR glycémie diet [TW] OR dietary advice [TW] OR Mediterranean diet [TW] 
OR atherogenic diet [TW] OR vegetanan diet [TW] OR diabetic meal [TW] OR sugar diet [TW] OR 
vegetable diet [TW] OR fat diet [TW])) 
#4 #1 AND #2 AND #3 
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Abstract 
Background. Although treatment targets for the consumption of dietary fat in type 2 
diabètes are well accepted, little is known about the actual fat consumption by newly 
diagnosed patients or the dietary adjustments that they make in the following years. 
Aims. To measure fat intake in patients with type 2 diabetes in general practice at 
diagnosis, shortly after dietary consultation, and after four years. 
Research Design and Methods. This is a prospective cohort study that included 144 
Patients from 33 general practices (49% male, mean age (SD) 57.6 (8.2) years) with 
newly diagnosed type 2 diabetes mellitus. All patients were referred to a dietician and 
fat consumption (main outcome measure) was assessed at diagnosis, eight weeks and 
after four years with a 104-item food-frequency questionnaire. Reference values for fat 
consumption were obtained from an age-matched sample of a population-based 
survey. 
Results. At diagnosis, total energy intake was 10.6 MJ/day and cholesterol intake 300 
mg/day. Total fat consumption was 40.9%, saturated fatty acids 15.0%, 
monounsaturated fatty acids 14.3% and polyunsaturated fatty acids 9.2% of energy 
intake. All levels except for polyunsaturated fatty acids were significantly unfavourable 
compared with those from the general population. After eight weeks, all levels except 
saturated fatty acids, which was lower, had decreased to levels similar to those in the 
general population. After four years there was a slight increase in consumption of total 
fat and monounsaturated fatty acids but consumption of cholesterol and saturated 
fatty acids decreased further. 
Conclusions. We conclude that patients with newly diagnosed type 2 diabetes have an 
unfavourable fat consumption at diagnosis. They adapt a more desirable consumption 
shortly after diagnosis, and sustain this improved dietary behaviour after four years. 
Recommendations regarding consumption of total- and saturated fat are, in contrast 
to those for cholesterol, by far not met by patients in general practice. 
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Introduction 
The treatment of type 2 diabetes mellitus requires counselling on lifestyle 
modifications and dietary advice. Consultation with a registered dietician is advised in 
most guidelines for type 2 diabetes (1, 2). The recommended dietary advice should be 
tailored to patients' individual needs and aims. Diet therapy aims at reducing risk 
factors such as overweight and dyslipidemia. To achieve these aims, (modest) weight 
loss by reducing total energy intake and the proportion of total fat (<30% of energy 
intake) as well as a reducdon of saturated fat intake (<10% of energy intake) and 
cholesterol intake (<300 mg/day) are strongly recommended. Moreover, minimising 
trans-unsaturated fatty acid intake and a modest intake of polyunsaturated fat (—10% 
of energy intake) is advised (1). 
Although these guidelines are based on solid evidence from mostly experimental 
studies, they do not take into account the normal dietary habits from the general 
population. This might be pardy because little is known about the fat consumption by 
recently diagnosed patients with type 2 diabetes m general practice, nor about 
alterations m dietary habits after diagnosis and treatment. In the United Kingdom 
Prospective Diabetes Study, the intake of total fat in a sample of 65 patients both at 
baseline (38.2% of energy intake) and after three years (36.9% of energy intake) was 
higher than the recommended 30 to 35% of energy intake (3). Data from a Dutch 
cross-sectional study showed no significant differences between diabetic and non-
diabetic subjects regarding total energy intake or the consumption of total, saturated 
or polyunsaturated fats (4). 
The necessity for sensible treatment targets, which are rooted in the population 
that is aimed at, has been discussed before m relation to type 2 diabetes mellitus. So 
far, targets for the treatment of type 2 diabetes mellitus do not account for what is 
feasible for patients in normal daily life (5). Therefore we investigated the fat 
consumption of patients with newly diagnosed patients with type 2 diabetes in general 
practice. The development of diabetes is associated with unfavourable eating habits 
such, as high consumption of total and saturated fat (6-8). We expected that the 
amount of energy and the amount and type of dietary fat consumed by patients newly 
diagnosed with type 2 diabetes is unfavourable when compared with the intake by the 
general population. Confirmation of this hypothesis would support the above-
mentioned advice to refer all newly diagnosed patients with type 2 diabetes to a 
dietician. 
We conducted a study with the following research questions: what is the fat 
consumption of patients with newly diagnosed type 2 diabetes in Dutch general 
practice compared with reference values for the general population? What are the 
alterations in fat consumption eight weeks after the initial diagnosis and referral to a 
dietician according to the Dutch guidelines for treatment of type 2 diabètes (2) and 
what is fat consumption after four years of follow-up compared with initial 
consumption in these patients? 
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Methods 
This study was designed as a prospective cohort study. Reference values for the 
general population were obtained from the Dutch National Food Consumption 
Survey (DNFCS) 1998 (9). 
Patents and practices 
Forty-six general practitioners working in 33 general practices throughout the 
Netherlands included patients with newly diagnosed type 2 diabetes aged between 40 
and 70 years. Diabetes mellitus was defined according to the criteria estabhshed by the 
World Health Organization (10): patients were eligible for the study when they had 
complaints suggestive for diabetes mellitus and a fasting blood glucose (FBG) >6.7 
mmol/1 and <20.0 mmol/1. In patients with asymptomatic newly diagnosed diabetes, 
the FBG had to be >6.7 mmol/1 at two or more occasions. 
Treatment 
In accordance with the Dutch guidelines for the treatment of type 2 diabetes mellitus 
(2), all included patients were referred to a registered dietician. Dietary intervention 
consisted of two consultation sessions within a 4-weeks period, in which pauents 
received dietary advice concerning all aspects of medical nutritional therapy for 
diabetes, tailored to their individual needs. The dieticians were informed about 
baseline fat consumption in all patients. Otherwise, the dieticians did not receive extra 
training nor used special protocols. Patients who still had a FBG >6.7 mmol/1 after 
eight weeks were eligible for oral anti-diabetic therapy. These patients were asked to 
participate in a 30-weeks randomised controlled trial comparing acarbose with 
tolbutamide (11). After these thirty weeks, all patients received usual care by their GP. 
Measurements 
Measurements took place at diagnosis, after eight weeks, and after 4 years. The 
consumption of dietary fat was measured using a 104-item food-frequency 
questionnaire (FFQ), in which the past month is used as the reference period (12, 13). 
This questionnaire was filled out by the patient and checked for errors by the 
investigator. Values for total energy per day (MJ/day), total fat (% of energy intake), 
saturated fatty acids (% of energy intake), monounsaturated fatty acids (% of energy 
intake), polyunsaturated fatty acids (% of energy intake) and cholesterol (mg/day) 
were calculated using a computer program (VET Expresl.02, BaS Nutrition Software, 
The Netherlands) designed especially for the questionnaire. At the 4-years 
measurement, an updated version of the questionnaire was used (Wageningen 
University, The Netherlands, not published), including an updated calculation 
program (Komeet 3.0, BaS Nutrition Software, The Netherlands). 
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Body weight and height were measured without shoes and with light clothing. Data 
on medical history, co-morbidity and use of medication were obtained from the 
padent's record by the GP. Additional visits to a dietician or the use of other sources 
for dietary information were recorded with a short questionnaire. At four years 
follow-up the G P made the same assessment on medical history and co-morbidity. 
Furthermore, the G P provided information about the use of anti-diabetic and 
cholesterol-lowering medication during the interval. Central laboratories (Andreas 
Hospital Amsterdam for basebne and short term, Canisius Wilhelmina Hospital 
Nijmegen for 4-years measurements) using standard techniques and reference ranges 
measured HbAic and lipids. Glucose measurements were performed locally using a 
calibrated glucose analyser. 
Reference values 
Data from the Dutch National Food Consumption Survey 1998 (DNFCS) were used 
to serve as reference values for fat intake by the general population. The DNFCS is a 
cross-sectional study in a representative sample of the Dutch population, comprising 
6250 subjects (aged 1-97 years) using a 2-days dietary record method. To match with 
the cohort of patients with newly diagnosed diabetes, we used the proportion of 
subjects aged 40-70 years (n=2296). 
Statistical analysis 
Results are given m mean ± standard deviation (SD). For comparison between groups 
(i.e. missing / non-missing, male / female), Student's two-sample t-tests were 
performed. For comparison of results between subsequent measurements, Student's 
one-sample test was used. Additionally, a repeated measure analysis was performed to 
assess an overall time-effect. In order to correct for multiple testing, alpha was divided 
by the number of tests used. Therefore, for the T-tests P<0.0024 and for the repeated 
measure analysis P<0.0072 was considered significant. 
Ethics approval 
This study was performed in accordance with the declaration of Helsinki. The 
protocol for the 8-weeks study was approved by the Central Medical Committee for 
Studies in General Practice. The Local Ethics Committee of the University Medical 
Centre Nijmegen approved the protocol for the 4-years study. All patients gave their 
informed consent. 
Results 
The general practitioners included 144 patients with newly diagnosed type 2 diabetes. 
Baseline measurements were performed in all 144 patients; the 8-weeks measurements 
were performed in 110 of the 144 patients. 106 Patients participated in the long-term 
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follow-up (4-years measurement) after a mean of 3.9 years (SD 1,0) (Figure 3.1.1). The 
baseline characteristics of these 144 patients are displayed in Table 3.1.1. With respect 
to blood glucose and lipid profile the study population was representative for patients 
newly diagnosed with type 2 diabetes (14). Baseline results of patients who did not 
participate in the 8-weeks or 4-years evaluation did not differ significandy from results 
of the patients whose measurements were not missing (data not shown). 
Table 3.1.1. Baseline characteristics in 144 newly diagnosed patients with type 2 diabetes in 
general practice 
Male / female 
Age (years) 
Body mass index (kg/m2) 
Fasang blood glucose (mmol/1) 
HbAic (%) 
Diastolic blood pressure (mmHg) 
Systolic blood pressure (mmHg) 
Total Cholesterol (mmol/1) 
LDL Cholesterol (mmol/1) 
HDL Cholesterol (mmol/1) 
Triglycerides (mmol/1) 




































Table 3.1.2 shows the mean (SD) values for energy intake and fat consumption for 
newly diagnosed patients with type 2 diabetes at diagnosis, after 8-weeks and after 
four years. Compared to reference figures for the general population, patients had a 
higher intake of energy and fat consumpuon. The mean changes for the three possible 
intervals are shown in Table 3.1.3. At 8-weeks follow-up, we found a decrease of total 
energy intake, total fat, saturated fatty acids and monounsaturated fatty acids. 
Polyunsaturated fatty acids and the relative cholesterol intake (mg/MJ) did not change 
significantly. At 4-years consumption of total fat and monounsaturated fatty acids 
increased significandy compared to 8-weeks but remained significandy lower than at 
basehne. Consumption of cholesterol decreased significandy compared to baseline and 
8-weeks. Other values did not differ significantly from 8-weeks. The repeated measure 
analysis showed similar results with exception of the fact that the difference in 
42 
Diet and alpha-glucosidase inhibition in the early treatment of type 2 diabetes mellitus 
consumption of total fat between 8-weeks and four years was not significant. Male 
and female patients showed similar fat consumption at baseline, except for energy and 
cholesterol intake, which was higher in men. Women showed a more profound 
decrease in the consumption of total fat, monounsaturated fatty acids and saturated 
fatty acids at both 8-weeks and 4-years measurement (data not shown). When 
stratified for body weight (BMI <25, >25 and <30, >30 kg/m2), results were similar. 
In both our study at all three time-points, and in the reference figures for the general 
population, the people with BMI >30 kg/m 2 reported the lowest energy intake (data 
not shown). 
Table 3.1.4 reports the percentage of patients that meet the guidelines for fat 
consumption. The percentage of patients that met the guideline regarding saturated 
fatty acids (5:10% of energy intake) increased from 7.6% at baseline to 27.4% at 4-
years measurement. Similarly, the percentage of patients that consumed less than 7% 
of energy intake by way of saturated fatty acids increased from 0.7% to 9.4%. 
Table 3.1.2. Consumption of total energy and fat by patients newly diagnosed with type 2 
diabetes compared to reference values for the general population of similar age. All values are 
means (SD) 
Energy intake (MJ/day) 
Total fat (En%) 
Saturated fatty acids (En%) 
Monounsaturated fatty acids (En%) 
Polyunsaturated fatty acids (En%) 
Cholesterol intake (mg/day) 
Cholesterol intake (mg/MJ) 
En% = % of energy intake 
Newly diagnosed patients with 
type 2 diabetes 
Diagnosis 8-weeks 4-years 
(n=144) (n=110) (n=106) 
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Table 3.1.3. Changes in consumption of total energy and fat by patients newly diagnosed with 
type 2 diabetes: mean changes from diagnosis to 8-weeks, from diagnosis to 4-years and from 
8-weeks to 4 years. A negative value indicates a decrease in time. 
Change in mean Change in mean Change in mean 
difference difference difference 
Diagnosis - Diagnosis - 8-weeks -
8-weeks (n= 110) 4-years (n= 106) 4-years (n=86) 
Mean difference Mean difference Mean difference 
(95% CI) (95% CI) (95% CI) 
Energy intake (MJ/day) -2.2 (-2.6,-1.7) -1.8 (-2.3,-12) 0.5'(0.09,0.9) 
Total fat (En%) -5.1 (-6.6,-3.5) -3.0 (-4.8,-12) 2.5(1.1,3.9) 
Saturated fatty acids (En%) -2.4 (-3 0,-1.8) -3 1 (-3.8,-2.3) -0.5" (-1.1,0.1) 
Monounsaturated fatty acids (En%) -2.5 (-3.1,-1.8) -1 5 (-2.3,-0.6) 1.0(0.4,1.6) 
Polyunsaturated fatty acids (En%) 0.3'(-0.4, 0.9) 0.9" (0.0,1.7) 0.9" (0.0, 1.8) 
Cholesterol intake (mg/day) -63 1 (-77 8,-48.3) -99.7 (-120.0,-79.4) -33.6 (-48 3,-18.8) 
Cholesterol intake (mg/MJ) -0.3" (-1.5, 1.0) -6 2 (-7.8, -4.6) -5.6 (-7.2, -4.0) 
All values are significant (p<0 0024) except those indicated with an astensk (*). Significance tests are 
done with an alpha of 0.0024 (0.05:21) in order to account for muluple tesung; En% = % of energy 
intake 
Plasma lipids, glycémie control and body weight 
After eight weeks and two consultations with a dietician 25.7% of the patients had a 
fasting bloodglucose <6.7 mmol/1. HbAic% had decreased from 9.0 tot 7.8%, all 
plasma lipid values except for HDL-cholesterol and triglycerids had improved at 8-
weeks measurement (data not shown). After 4 years, HbAic% and plasma lipids had 
significantly improved compared to baseline and, except for triglycerides, to 8-weeks 
measurement. BMI decreased at 8-weeks measurement (29.5 to 28.3 kg/m2 , p<0.01) 
but was back at its baseline value at 4-years measurement. 
Diabetes treatment 
At 4-years measurement 19 of the 106 patients (18%) were still treated with lifestyle 
modification alone and for two patients the use of medication was not known. The 
use of cholesterol lowering medications increased from 10/144 (7%) at baseline, to 
34/106 (32%) at 4-years follow-up (unknown for 2 patients). On average, after the 
first two visits, patients visited a dietician 0.6 times per year (SD 0.9). 77% of the 
patients visited a dietician less than 1.0 times per year, 13% had between 1 and 2 
consultations, and 10% had 2 or more consultations. 
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Newly diagnosed 
patients with type 2 






8 weeks assessment 
(n=110) 
Lost to 8 weeks 
assessment 
(n=34) 
Lost to 8 weeks but 
recovered for 4 years 
assessment 
(n=20) 




5 died, 1 not suitable 
according to GP, 
2 unknown 
Lost to 4 years 
assessment 
(11=14): 
5 refused, 3 died, 
4 moved, 1 GP 
refused to cooperate, 
1 questionnaire 
illegible 
4 years assessment 
(2000-2001) 
(n=106) 
No 4 years 
assessment 
(n=38) 
Figure 3.1.1. Study flow diagram 
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Table 3.1.4. Proportion of patients newly diagnosed with type 2 diabetes at diagnosis, after 8-
weeks and after 4-years that meet recommendations for the consumption of fat. All numbers 
are percentages (%) 
Total fat 
Saturated fatty acids 
Polyunsaturated fatt\ acids 







































































* ADA 2002, f Panents with IX)L >2.6 mmol/1 may benefit from saturated fatty acids <70/o of energy 
intake and a cholesterol <200 mg/day, % No specific recommendation; En% = % of energy intake 
Discussion 
Summary and interpretation of main findings 
This study showed that patients in general practice at the moment that type 2 diabetes 
was diagnosed have an unfavourable fat intake compared to reference values for the 
general population. Shortly after the first dietary consultation, fat consumption 
decreased to levels similar to the general popudarion. After four years, consumption of 
total fat had increased again, but was sdii lower than baseline. This increase was due to 
a higher intake of both poly- and monounsaturated fatty acids. The intake of 
cholesterol was decreased at the 8-weeks assessment and decreased further after four 
years. 
The observed changes in the reported fat consumption may be due to several 
factors. First, ongoing treatment for type 2 diabetes, including education by GP's and 
dieticians, may have a sustained effect on habits. The patients included in our study 
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received usual care by their GP's, including an inidal dietary advice in two 
consultations, according to the Dutch guidelines on diabetes. Some patients got more 
consultations on their own initiative or advised by their GP. No further interventions 
or efforts were made to improve compbance with diet. Of course, from the data of 
this observational study we cannot measure the contribution of specific aspects of 
diabetes counselbng on the outcomes. But because we observed patients who received 
usual care, we feel that the presented results should be regarded as the mirumally 
achievable goals that can be reached regarding fat consumption. 
Second, food habits in the general population are not constant. In the adult general 
population in The Netherlands, consumption of total fat decreased almost 1% of 
energy intake but saturated fatty acids increased about 1% of energy intake from 1992 
to 1998 (9). In our study the decrease of total fat consumption was more profound 
and the consumption of saturated fatty acids decreased. Therefore, it is not likely that 
our main results are merely a reflection of the trend in the general population. 
Thirdly, the content of foodstuffs is not constant. Since 'light' and low-fat 
products are fashionable nowadays, manufacturers may tend to change the amount 
and sorts of fat in their products. In theory it is possible that someone who does not 
alter his consumption in terms of foodstuffs, will have a different consumption in 
terms of nutrients because the content of the foodstuffs have been changed. We have 
not identified studies in the bterature to assess the influence of this potential bias. 
Finally, the method of measuring food habits is a possible source of bias (15). All 
available instruments to measure food intake are subject to recall-bias and therefore a 
real gold standard doesn't exist. We used a semiquantitative food-frequency 
questionnaire, whereas the reference figures for the general population are based on a 
dietary record method. Therefore, the comparison of the data from patients with type 
2 diabetes with those from the general population should be interpreted with caution. 
Strengths and Imitations of this study 
The mam strengths of our study were that it provided follow-up data: a) of sufficient 
length, b) in a cohort of newly diagnosed patients with type 2 diabetes. Data that 
provides knowledge of what happens during a patients' 'career' is important because it 
is helpful for formulating feasible treatment goals; c) with a good long-term 
participant rate of 74%; d) rooted in general practice. In the Netherlands as in the UK, 
approximately 75% of patients with type 2 diabetes are treated by their GP. 
One of the drawbacks of our study was that a relatively high number of patients 
did not complete the FFQ at 8-weeks measurement, partially due to loss of motivation 
in the patients and the GP's. For the 4-years follow-up, 20 of these 34 patients could 
be included again. The possibibty of selective dropout was examined by comparing 
essential characteristics of patients with missing data at short- and 4-years follow-up. 
No significant differences were observed, thus attrition bias is less probable. Further, 
this study lacks a control-group. We emphasise that this study is not meant as an 
intervention study but as a long-term study to assess the changes under usual care. 
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The referral to a dietician is in concordance with the Dutch guidelines. After the first 
eight weeks patients were not given extra care regarding their lifestyle. Thus, diabetic 
patients as control would be unethical because in our view, we would deliberately have 
undertreated them. Aged-matched healthy volunteers as controls would have been 
helpful to estimate the secular trend for fat-consumption. 
Comparison with existing literature 
To our knowledge, only one previous study assessed fat consumption in newly 
diagnosed patients with type 2 diabetes at diagnosis and after several years (3). In a 
small sample of the UKPDS population (n=65) half of the patients compbed with 
recommendations regarding total energy intake, at three years of follow-up. The 
results of this study cannot easily be compared to the findings in the present study, 
because the types of fat were not specified. The overall decrease in total fat 
consumption is larger in our study (~3 versus 1% of energy intake in the UKPDS). 
The differences between men and women that were found in the UKPDS population 
could not be confirmed in our study 
Implications for future research and policy 
The results regarding the percentage of patients that meet with recommendations 
might be of particular interest in the development of future guidelines and treatment 
targets. The most important treatment targets are those for saturated fatty acids and 
cholesterol consumption, being <10% of energy intake and <300 mg/day 
respectively, and <7% and <200 mg/day for patients with LDL cholesterol >2.6 
mmol/1 (which is the case for most patients in our study at diagnosis). Only 27% of 
patients consumed less than 10% of saturated fatty acids measured as % of energy 
intake, and only 9% of the patients consumed less than 7% of their energy intake by 
way of saturated fatty acids. In contrast to this disappointing result 93% (<300 
mg/day) and 55% (<200 mg/day) of patients met the target for cholesterol intake. So, 
the target for the consumption of cholesterol seems to be realistic and attainable for 
this GP-population whereas the target for the consumption of saturated fatty acids is 
not. 
This study reports food-habits in terms of nutrients. We realise that in normal day 
life, patients and doctors don't talk about mono- or polyunsaturated fatty acids but 
about french fries, eggs and tomatoes instead. Future research should investigate what 
alterations in the choice of foodstuffs (beef, chicken, peanut-butter) are more likely to 
be sustained. Further, a better understanding of the characteristics of patients that 
have a very good or a very bad compliance with dietary advice might contribute to 
more effective dietary intervention strategies. 
This study might take away some of the scepticism of doctors about the feasibility 
of initiating and maintaining more favourable dietary habits. However, the very strict 
treatment targets for consumption of saturated fatty acids and total fat are not very 
realistic. To optimise the dietary treatment of type 2 diabetes any further lastingly care 
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for diet and lifestyle but also a reconsideration of treatment targets for dietary fats 
among diabetic patients remain necessary. 
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Chapter 3.2 Eating behaviour and adherence to diet in Type 2 diabetes 
Abstract 
Aims. To assess restrained, emotional and external eating behaviour in patients newly 
diagnosed with type 2 diabètes compared with the general population, and to assess 
the relationship of eating behaviour to changes in fat and energy intake. 
Methods. We assessed emotional, external, and restrained eating behaviour and 
measured fat and energy intake in a cohort of patients with newly diagnosed type 2 
diabetes. Data from a comparable sample of the general population served as 
reference figures. We calculated correlation coefficients of the three different types of 
eating behaviour at diagnosis between: (i) energy and fat intake at diagnosis and (il) 
changes in energy and fat intake between diagnosis and both 8 weeks and 4 years later. 
In addition, we used a stepwise multiple regression model with energy and fat intake 
or changes in energy and fat intake as dependent variables. 
Resu/ts. The distribution of the three types of eating behaviour was similar in patients 
with type 2 diabetes and the general population. Emotional and external eating was 
associated with increased intake of energy and fat. Conversely, restrained eating 
showed an inverse correlation with energy and fat intake. External eating, but not 
emotional eating, showed a statistically significant relation with a decrease in energy 
intake in women. We found no statistically significant correlations between eating 
behaviour (measured at diagnosis) and changes in energy and fat intake between 
diagnosis and 4 years. 
Conclusions. Patients newly diagnosed with type 2 diabetes have similar eating 
behaviour compared with the general population. At diagnosis, external eating 
behaviour and emotional eating behaviour are associated with high-energy intake and 
restrained eating behaviour with low-energy intake. Women with high scores for 
emotional eating behaviour seem to be less able to make initial dietary changes after 
being diagnosed and having received dietary advice. 
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Introduction 
In the treatment of patients with type 2 diabetes, lifestyle adjustments consisting of 
dietary improvements and increased physical exercise are the first measures to be 
taken and remain important throughout the course of the disease. However, in 
contrast to taking medication or self-monitoring of blood glucose, lifestyle changes are 
not clear-cut and are more difficult to implement and maintain (1). Therefore, it is of 
great importance that potential obstacles or supportive factors are identified to 
improve strategies to optimize dietary habits and other lifestyle factors (1, 2). 
It is evident that our food choices are more than just the product of a full 
conscious process (3). In this study, we examined eating behaviour in relation to 
energy and fat intake and subsequent changes in intake in patients newly diagnosed 
with type 2 diabetes. Van Strien et al. Distinguished three types of eaung behaviours: 
(i) emotional eating behaviour (eating more when experiencing negative emotions); (n) 
external eating behaviour (easily responding to food-related stimuli such as good 
smells or the look of attractive food); (m) restrained eating behaviour (fixed on losing 
weight) (4). These types of eating behaviour can be assessed with a short questionnaire 
which is easy to use in daily clinical practice. 
Thus far, research on eating behaviour and type 2 diabetes has focused 
predominantly on eating disorders such as bulimia or binge-eating disorder (5-7), 
while non-pathological variations of eating behaviours, which may also play a role in 
the (unsuccessful adoption of healthy dietary choices (8), have received less attention. 
However, there is evidence that, in subjects recruited from the general population, 
a combination of external and/or emotional eating is associated with higher body 
mass index (BMI) and weight gain, and that restrained eating attenuates that relation 
(9). In individuals with impaired glucose tolerance, restrained eating was significandy 
related to lower BMI, and emotional eating (external eating was not assessed or 
reported) had the opposite relation (10). We are not aware of studies investigating 
non-pathological variations of eating behaviour in patients with type 2 diabetes. 
Therefore, to better understand the role of eating behaviour in the (un) successful 
adoption of a healthy diet in patients with type 2 diabetes, we formulated the 
following research questions: (i) what is the distribution of restrained, emotional and 
external eating behaviour in patients newly diagnosed with type 2 diabetes in general 
practice, compared with reference values for the general population, (u) what is the 
relation between eating behaviour and energy and fat intake in patients with newly 
diagnosed type 2 diabetes, and (iii) what is the relation between eating behaviour and 
changes in energy and fat intake, respectively, 8 weeks and 4 years after diagnosis? 
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Methods 
This study was part of a prospective cohort study that assessed alterations in energy 
and fat intake of patients newly diagnosed with type 2 diabetes in general practice. 
Details about study design and patient flow are described elsewhere (11). 
Patients and procedures 
One hundred and forty-four patients with type 2 diabetes aged 40-70 years at the time 
of diagnosis, were recruited through 46 general practitioners (GPs) working in 33 
general practices throughout the Netherlands from 1995 to 1998 (Table 3.2.1). 
Diabetes mellitus was defined according to the World Health Organization (WHO) 
criteria (12). In accordance with the Dutch guidehnes for the treatment of type 2 
diabetes mellitus (13), all patients were referred to a registered dietician. During two 
consultation sessions in the first weeks after diagnosis, all patients received dietary 
ad\rice tailored to their individual needs and in accordance with current guidelines 
(that is, reduction of energy in case of overweight, reduction of total fat to a maximum 
of 30% energy, saturated fat to a maximum of 10% energy, and cholesterol intake to a 
maximum of 300 mg per day). Eight weeks after diagnosis, energy and fat intake were 
reassessed (n=110). On a\rerage, 4 years later, all baseline measurements were repeated 
and information about treatment and health status was obtained from the GPs 
records (n—106). During the follow-up interval, all patients received care as usual by 
their general practitioner. The baseline characteristics of patients who did not 
participate in the 8-week or 4-year evaluation did not differ significantly from those of 
the participants (data not shown). 
Most patients lived with a partner (87.2%) and the educational level was low as 
67.4% had primary or basic vocational education only. The blood glucose and lipid 
profile of the study population was representative for patients with newly diagnosed 
type 2 diabetes (14). 
Measurements 
Energy and fat intake were measured at diagnosis, after 8 weeks and after 4 years by a 
validated 104-item food-frequency questionnaire (FFQ) (15, 16) with a reference 
period of 1 month to measure fat intake. This list was completed by the patients and 
checked for errors by the investigator (FvdL). The mean intake for total energy 
(kj/day), total fat (% energy), saturated fat (% energy), and cholesterol (mg/day) were 
calculated using a computer program (VET Expres 1.02, BaS Nutrition Software, 
Arnhem, The Netherlands). To account for possible changes in the composition and 
availability of foodstuffs, we used an updated version of the questionnaire for the 4-
year measurement (Wageningen University, The Netherlands, unpublished data, 1997), 
including an updated calculation program (Komeet 3.0, BaS Nutrition Software). 
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Table 3.2.1. Baseline characteristics in 144 newly diagnosed patients with type 2 diabetes in 
general practice 
η Mean SD 
Male / female 
Age (years) 
Body mass index (kg/m2) 
Fasting blood glucose (mmol/1) 
HbAic (%) 
Diastolic blood pressure (mmHg) 
Systolic blood pressure (mmHg) 
Total Cholesterol (mmol/1) 
LDL Cholesterol (mmol/1) 













* Median; f Range 





















Eating behaviour was assessed at diagnosis and after 4 years with the validated 
Dutch Earing Behaviour Questionnaire (DEBQ) (4). This is a 33-item questionnaire 
that contains three scales measuring emotional eating behaviour (13 questions, e.g., 
' D o you have the desire to eat when you are worried?'), external eating behaviour (10 
questions, e.g., 'If food smells and looks good, do you eat more than usual?") and 
restrained eaung behaviour (10 questions, e.g., 'If you have put on weight, do you eat 
less than you usually do?"). All items were rated on a five-point scale ranging from 1 
(seldom) to 5 (very often) and by dividing the total score by the number of valid 
answers, the overall score per type of eating behaviour was calculated (range 1-5). 
Internal reliability coefficients (Cronbach's a) were 0.95 for the emotional eating scale, 
0.81 for the external eating scale and 0.95 for the restraint scale in a sample of non-
obese women. Factor analysis of the current data reproduced the same factor 
structure as in the initial validation study (4). 
Reference figures for the general population 
Eating behaviour in the general population was assessed in a sample from the Dutch 
National Food Consumption Survey (DNFCS) 1998 (17). The D N F C S was 
conducted by a market research institute experienced in nation wide surveys, in close 
cooperation with a steering committee of experts in food consumption studies. Taken 
from an existing panel, 2564 households participated in the study. This panel 
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consisted of a stratified probability sample of non-institutionalised households living 
in the Netherlands. Institutionalised subjects, households whose head housekeeper 
was aged 75 or over, and households whose members could not speak Dutch were 
not included. A total of 6250 persons, aged 1-97 years, participated in the study. 
Response rate was 70.5% at the household level and 68.6% at the individual level. An 
additional questionnaire, which included the Dutch Eating Behaviour Questionnaire 
(4), was submitted to a subpopulation of the third DNFCS. In total, 2270 subjects 
(response rate 82%) completed the additional questionnaire: 1449 women principally 
responsible for domestic affairs (aged 19 years and over), 246 young people (13-22 
years) and 575 men of 22 years and older. We used a random sample with a similar age 
range (40-70 years, n=1083, mean age 52.4 years ± 8.6, mean BMI 25.6 kg/m2 ± 4.3, 
71.2% female) from this subpopulation to compare their eating behaviour with the 
cohort of patients with newly diagnosed type 2 diabetes. 
Statistical analysis 
Results are given as means ± standard deviation. For comparison of results between 
diagnosis and 4-year measurements, the Student's one-sample t-test was used and, for 
comparisons between the general population and the group of patients with diabetes 
at diagnosis, Student's two-sample t-test was used. In order to account for multiple 
testing, we considered a lower than usual P-value (P <0.01) as statistically significant. 
We calculated correlation coefficients between the three different types of eating 
behaviour and energy and fat intake at diagnosis, and between eating behaviour and 
the changes in energy and fat intake (changes between diagnosis and both 8 weeks and 
4 years later). In addition, we studied the three types of eating behaviour in a stepwise 
multivariate regression model. For the dependent variables, we used energy 
percentages of total fat, saturated fat and cholesterol intake (mg/day and mg/MJ) 
because those values reflect the most important dietary aims for optimizing fat intake 
in patients with type 2 diabetes. We also used energy intake (MJ/day) as a dependent 
variable, because most patients with type 2 diabetes are overweight and reduction of 
energy intake is recommended in most cases. 
Ethics approval 
This study was performed in accordance with the declaration of Helsinki. The 
protocol for the short-term study was approved by the Central Medical Committee for 
Studies in General Practice. The Local Ethics Committee (Radboud University 
Nijmegen Medical Centre) approved the protocol for the long-term study. 
Results 
At diagnosis, energy intake was 10.6 ± 3.4 MJ/day, mean intake of total fat was 40.9 ± 
7.3, saturated fat 15.0 ± 2.8% energy and cholesterol intake 301 ± 1 2 3 mg/day. From 
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diagnosis to the 8-week measurement, energy intake (change=-2.2 MJ/day, T(109)— 
9.59, P<0.0001), intake of total fat (change=-5.1% energy, T(109)=-6.52, P < 0.0001), 
saturated fat (change=-2.4% energy, T(109)=-7.94, P<0.0001) and total cholesterol 
intake (change=-63 mg/day, T(109)=-8.49, P<0.0001) significandy decreased. 
Significant decreases were also found from diagnosis to the 4-year measurement: 
energy intake (change=-1.8 MJ/day, T(106)=-6.37, P<0.0001), intake of total fat 
(change=-3.0% energy, T(106)=-3.26, P=0.0015), saturated fat (change=-3.1% 
energy, T(106)=-8.31, P<0.0001) and total cholesterol intake (change=-100 mg/day, 
T(106)=-9.74,P<0.0001) (11). 
Eating behaviour of patients with type 2 diabetes and the general population 
The scores for emotional, external and restrained eating behaviour at diagnosis, both 
from patients with diabetes and the general population, are presented in Table 3.2.2. 
Pearson correlation coefficients between restrained and emotional eating were: 0.28 
(P<0.05, females) and 0.34 (P<0.05, males); between restrained and external eaung: 
0.23 (NS, females) and 0.18 (NS, males); and between emotional and external eating: 
0.55 (P<0.01, females) and 0.60 (P<0.01, males). 
Values for all three types of eating behaviour in the general population were similar 
to those in the group of newly diagnosed patients. 
In the 4-year assessment, the mean values for external eating behaviour decreased 
significandy and for restrained eating behaviour increased significantly. Emotional 
eating beha\'iour did not change. 
Eating behaviour and energy and fat intake at diagnosis (Table 3.2.3) 
All statistically significant (P<0.05) correlation coefficients between eating behaviour 
and energy and fat intake at diagnosis had a positive value for external and emotional 
eating behaviour and a negative value for restrained eating behaviour in both sexes. 
This means that higher scores on external and emotional eating behaviour were 
associated with higher energy and fat intake and higher scores on restrained eating 
behaviour with lower energy and fat intake. 
In women, both external and emotional eating behaviour were correlated with 
higher energy intake at diagnosis, and restrained eating correlated with lower energy 
intake. In the stepwise multivariate regression analysis, external eating (partial 
R2=0.31, slope=2409 kj/day more intake per 1 point higher score on external eating, 
P<0.0001) and restrained eating (partial R2=0.06, slope=-808 KJ/day/score point, 
P=0.02) were entered in the final model (R2 whole model 0.37). External eating was 
correlated with higher intake of saturated fat (partial R2=0.08, slope 1.2% 
energy/score point, P=0.02) and restrained eating with lower saturated fat intake 
(partial R2=0.07, s lope=-0.9% energy/score point, P=0.02) (R2 whole model 0.15). 
Restrained eating was correlated with decreased intake of total fat (R2=0.13, slope=— 
3.3% energy/score point, P=0.002). 
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In men, a higher score on external eating was correlated with higher levels of 
energy intake, and restrained eating was significandy correlated with lower energy 
intake at diagnosis. In the stepwise multivariate analysis, external eating (partial 
R2=0.11, slope=2065 KJ/day/score point, P=0.008) and restrained eating (partial 
R2=0.12, slope=-1434 KJ/day/score point, P=0.003) were entered in the final model 
(R2 whole model 0.23) for energy intake. Both emotional and external eating 
correlated significantly with cholesterol intake at diagnosis. However, when the 
relative (mg/MJ) instead of the total intake (mg/day) of cholesterol was used, no 
significant results were found. 
Table 3.2.2. Eating behaviour of patients newly diagnosed with type 2 diabetes and after 4 






































2 1 (0 8) 
2.4 (0.6) 
2.8 (0.9) 
*Number of patients may be slightly lower in subscores as a result of missing items. 
Student's one-sample t-test for comparison 4-year measurement with diagnosis: f P<0.01, £ P<0.001. 
Student's two-sample t-test for comparison general population and pauents with type 2 diabetes at 
diagnosis· no significant differences. 
Eating behamour and change in energy and fat intake (Table 3.2.4) 
In women, external eating predicted a significant decrease in energy intake from 
diagnosis to 8 weeks (R2=0.21, slope=1486 KJ/day/score point, P=0.0005) but not 
from diagnosis to 4 years (R2=0.05, slope 954 KJ/day/score point, P=0.09). In 
contrast, emotional eating behaviour showed no significant correlation coefficients for 
changes in energy or fat. In men no significant results were found. 
Discussion 
Summary and interpretation of main findings 
In this study, we found that patients with newly diagnosed type 2 diabetes have similar 
eating behaviours compared with the general population. Eating behaviour seemed to 
be related more to the quantity (energy) of food, than to the quality (% energy of fat). 
Both external and emotional eating behaviour showed a positive relationship with 
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energy intake at diagnosis. An inverse relation was found for restrained eating With 
respect to change in energy and fat intake, we found that external eating predicted a 
decrease in energy intake in women, whereas emotional eating was not related to 
change in energy intake Therefore, we conclude that women with a high score on 
external eating are, in contrast to those with high scores for emotional eating, to a 
larger extent susceptible to initial dietary changes. 
Table 3.2.3. Results from a bivanate correlation analysis (P-value) of eaüng behaviour and 
energy and fat intake of male and female panents with type 2 diabetes at diagnosis 
Energy Total fat Saturated fat Cholesterol 
Men (n=64) 
Emotional eaüng 0 23(0 06) 0 23(0 07) 019(0 13) 0 29(0 02)* 
External eating 0 33 (0 008)* 0 08 (0 51) 0 05 (0 67) 0 33 (0 007)* 
Restrained eating -0 27 (0 03)' 0 04 (0 70) 0 14 (0 29) -0 19 (0 11) 
Women (n—72) 
Emotional eating 0 36(0 002)* 0 07(0 55) 010(0 42) 0 18(013) 
External eating 0 56(<0 0001)* 015(0 21) 0 29(0 02)* 0 32(0 006)* 
Restrained eaüng -0 28 (0 02)* 0 35 (0 002)' 0 28 (0 02)* -0 12 (0 32) 
*Significant values 
The question arises how these differences in 'effects' of emotional and external 
eating should be explained, especially as both eating behaviours are correlated. The 
finding of a significant correlation between emotional and external eanng is not new, 
having being reported in the original validation study (4). The question arises whether 
they are distinct or overlapping constructs. Although emotional and external eating 
often coexists, it is assumed that they should be conceived as independent constructs 
The main reason for this is that the pathogenesis of both excessive emotional and 
external eating is essentially different. The concept of emotional eating is derived from 
psychosomatic theory. It implies that, whereas the normal reaction to emotional 
distress is an increased feeling of satiety, subjects with high scores for emotional eaüng 
respond with hunger. The concept of 'external eating' is derived from externality 
theory. In a similar way to psychosomatic theory, externality theory posits that 
disturbed eaüng behaviour is comparatively unresponsive to internal physiological 
signs. However, in contrast to emphasis placed on poor interoceptive awareness of 
physiological signals accompanying emotions, externality theory focuses on the 
external food environment as a determinant of eating behaviour. However, previous 
experimental studies showed that emotionality and food cues operated conjointly to 
elicit food consumption (18). 
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female padents with type 2 diabetes between three different rime points (diagnosis, 8 weeks, 4 years) 
Diagnosis — 8 weeks Diagnosis - 4 years 
Energy Total fat Saturated fat Cholesterol 
(kj/day) (% energy) (% energy) (mg/day) 
Energy Total fat Saturated fat Cholesterol 

















0.17 (0.23) 0.09 (0.54) 
0.06 (0.66) 0.00 (0.97) 




-0.09 (0.49) 0.04 (0.77) 0.21 (0.12) 
0.08(0.59) 0.18(0.18) 0.33(0.02)* 









0.15(0.33) 0.09(0.53) 0.16(0.30) 
-0.11(0.44) 0.06(0.71) 0.13(0.37) 
-0.01 (0.96) -0.04 (0.78) -0.01 (0.94) 
0.04 (0.75) 0.10 (0.45) 0.03 (0.84) 
0.06(0.67) 0.12(0.37) 0.14(0.29) 
-0.11(0.41) 0.03(0.85) -0.02(0.91) 
A positive correlation coefficient indicates a decrease of fat or energy 
*Significant values 
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As to the question why emotional eating predicted no decrease in energy intake, in 
contrast to external eating, evidence is accumulating that this type of eating behaviour 
is more resistant to therapy (19). Emotional eating is associated with disturbed 
psychological functioning that hampers a successful adoption of a healthy diet after 
dietary advice alone. Previous research showed that emotional eating is associated with 
alexithymia (difficulty in describing or recognizing one's own emotions) (20), 
impulsivity (21) and depression (22). For external eating such relationships have hardly 
been investigated. However, recent research from our university (unpublished data) 
showed no correlations between external eating and both alexithymia and depression, 
and only a very small correlation with impulsivity. Further, there is evidence that 
emotional eating, in contrast to external eating, is related to a deficit in brain-
dopamine (23), and this deficit may make individuals more receptive to the reinforcing 
value of food (24). In the present study no specific intervention had been directed to 
alexithymia, impulsivity or depression. This might explain the unfavourable outcomes 
for paflents with high scores on emotional eating. 
Our findings, that restrained eating is correlated with lower energy intake and that 
emotional eating is correlated with higher energy intake, corresponds with findings in 
subjects with impaired glucose tolerance, in which a higher BMI was correlated with 
low scores for restrained eating and high scores for emotional eating (10). We have 
also partly confirmed the findings from another study in healthy women (9) as we 
found that 'disinhibition' (i.e. a combination of external and emotional eating) was 
associated with higher energy intake. However, the relation between disinhibition and 
long-term weight gain could not be confirmed as we found no significant relationships 
between eating behaviour and changes between diagnosis and 4-year dietary intake. 
The associations between restrained eating and lower energy intake seem logical. 
The essence of restrained eating is losing weight by reducing caloric intake. However, 
literature is equivocal on this issue. It has been suggested that people with high scores 
on scales for restrained eating behaviour are at increased risk for weight gain and 
bulimia, and this has even led to the suggestion that dieting (i.e. restrained eating) 
should be discouraged (25). Alternatively, it has been argued that a tendency toward 
overeating, i.e. emotional and or external eating, may cause increased food intake and 
weight gain (26, 27). The conflicting results could be explained by the use of 'impure' 
questionnaires for restrained eating in which behaviours that explain loss of control 
over eating are included (e.g., 'do you eat sensibly in front of others and splurge 
alone?") (28). In the DEBQ, a 'pure' restrained scale is combined with two possible 
explanations for 'loss of control': external and emotional eating behaviour. Thus, our 
study underlines the theory that restrained eating behaviour itself does not lead to 
increased food intake and that 'loss of control' may be explained by other factors such 
as emotional or external eating. 
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Strengths and weaknesses of this study 
One of the main strengths of this study is that it included patients at the time of 
diagnosis with type 2 diabetes, a severe and chronic disease. The period shortly after 
diagnosis is of special importance and might set trends for later. At diagnosis, the 
motivation of patients to change their lifestyle is probably high. This may be pardy as 
a result of the 'shock' of the diagnosis, and partly the possibility that patients have not 
become disappointed as a result of previous failure to change behaviour. The results 
from this study may contribute to the development of effective strategies to stimulate 
and maintain beneficial lifestyles in a crucial phase of the disease. 
We calculated changes in energy and fat intake by using a validated food frequency 
questionnaire at three different time points instead of asking patients whether or not 
they think they have changed their diet. Such a longitudinal design gave the 
opportunity to study changes in behaviour over time. 
Weaknesses of this study that should be recognised are the method of assessment 
of food intake and eating behaviour. Patients with high scores for restrained eating 
behaviour might have underreported food intake. A clue for this assumption could be 
found in our previous observation that especially overweight people (patients with 
diabetes and in population) reported less energy intake (11). 
Another problem is that it remains impossible to distinguish pathological eating 
behaviour from the normal range of eating behaviours. The finding that patients with 
diabetes do not differ with respect to eating behaviour from the general population 
underlines the fact that we do not deal with eating 'abnormalities' but with a trait 
instead. Further, the different types of eating behaviour cannot be defined within a 
single patient and scores for the different types of eating belmdour exist 
simultaneously. For these reasons, we did not aim to categorise patients into a single 
predominant eating behaviour. Therefore the results should be seen as explorative 
instead of 'hypothesis-testing' and should give direction to further research. 
Our study did not have a control group. However, our main goals were not to 
assess changes in eating behaviour over time, or to assess the effect of an intervention 
directed to eating behaviour. Instead, our main objective was to assess the relation of 
eating behaviour with energy and fat intake at diagnosis and with subsequent changes 
in intake after short- and long-term follow-up. 
Implications for policy and future research 
In daily practice, the D E B Q could be of help for the G P or dietician to identify 
patients that are less likely to adhere to dietary recommendations. Women with high 
scores on emotional eating might need special attention, because emotional eating is 
associated with high-energy intake and (in contrast to external eating) emotional eating 
was not predictive for beneficial changes in dietary intake. For these patients, routinely 
dietary advice, aimed at informing and educating the patient, might be insufficient or 
even contraindicated. After all, 'failing' dietary adherence is not without risk as it 
might induce feelings of incompetence in the patient and as a consequence reduce 
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self-efficacy. Thus, patients with high scores on emotional eating behaviour might be 
better off with a psychological intervention (e.g., cognitive therapy) in addition to 
regular advice. As mentioned above, cut-off scores have yet to be determined for 
patients with severely problematic emotional eating behaviour. For the time being, 
dieticians could use the data presented in this study as a reference. Further research 
should aim at evaluating tailored approaches that take into account a patient's eating 
behaviour. 
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Chapter 3.3 Dieting dilemma in patients with type 2 diabetes 
Abstract 
Objective. To examine whether dieting - restriction of food intake for the purpose of 
weight control — suppresses or promotes excessive food intake and weight gain. 
Design. A 4-year follow-up study of a dietary intervention in a sample of 97 patients 
with newly diagnosed type 2 diabetes. 
Main Outcome Measures. Weight gain, change in body mass index (measured weight in 
kilograms divided by measured height squared), and intake of energy, as measured 
with a food frequency questionnaire were assessed in relation to dietary restraint and 
tendency to overeat (emotionally or externally induced overeating), as assessed with 
the Dutch Eating Behaviour Questionnaire. 
'Results. Tendency to overeat at diagnoses and not dietary restraint was associated with 
weight gain and intake of energy 4 years after diagnosis. 
Conclusion. These findings suggest that the success of a dietary intervention can be 
predicted by a subject's tendency toward overeating. The possibility of matched 
treatment of obesity is discussed on the basis of the distinction between patients with 
low versus a high tendency to overeat. 
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Introduction 
Dieting, or the restriction of food intake for the purpose of weight control: Does it 
suppress or promote excessive food intake and weight gain? This question has been 
called the dieting dilemma (1). Studies on the effects of dieting show contradictor}' 
findings. Some experimental and prospective studies that have measured self-reported 
dieting tendencies suggest that dieting is associated with excessive food intake, bulimic 
pathology and weight gain (2-4). Because these findings suggest that dieting may be 
worse than the disease (overweight and obesity), it has been advocated that the best 
treatment for overweight is to stop dieting and simply accept one's "natural" heavy 
weight (5, 6). Other experimental studies, however, found no link between self-
reported dietary restraint and overeating (7, 8). Also, prospective intervention studies 
that have assigned people to a weight loss diet show contradictor)' results (9). Further, 
dieters with successful maintenance of lost body weight have been reported (10-12), 
and actual caloric deprivation was even found to reduce bulimic pathology (13). 
Hence, it is also possible that dieting is not the widely accepted risk factor for weight 
gain and bulimic pathology, as it was also shown to result in successful reduction of 
body weight (14). 
Much is at stake. Obesity is a prevalent disorder that might have severe medical 
consequences, such as diabetes, hypertension, cardiovascular disease and some cancers 
(15). For decades, dieting has been the treatment of choice for obesity, and without 
this treatment care providers seem to stand empty handed. So it is of utmost 
importance that the dieting dilemma is addressed. 
In the present article, we address the dieting dilemma in a cohort of patients with 
newly diagnosed type 2 diabetes in whom we may assume high motivation for weight 
loss as this is one of the main treatment targets. Therefore, all patients in the study 
had been referred to a registered dietician for a dietary intervention aimed at an 
optimization of fat consumption (i.e., reduction of total and saturated fat and 
cholesterol intake) and a reduction of calorie intake in overweight patients. This study 
assessed intake of energy and long-term changes of body weight 4 years after the 
diagnosis, in relation to the patients' dietary restraint. 
In addition to dietary restraint, the patients' tendency toward overeating was 
analyzed. It is still unresolved whether restrained eating is a cause or a consequence of 
overeating tendencies or whether they are reciprocally related (2, 16-18). In a 1-year 
follow-up study in female college students, Spoor et al. found that dietary restraint did 
not predict future bulimic pathology (uncontrollable overeating) (16). This finding is 
consistent with the outcome of Slice's highly similar study (17) but inconsistent with 
the outcome of a study involving a 2-year prospective investigation of adolescent girls 
(18). In contrast to Stice (17), however. Spoor et al. (16) did not find that bulimic 
pathology had an effect on future dietary restraint. Further, in the study by Stice et al. 
(18), apart from dieting, depressive symptoms and emotional eating were risk factors 
for the onset of binge eating. This finding suggests that there may be qualitatively 
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different pathways to binge eating and that dieting may promote overeating in only a 
subset of individuals (19). 
The precise direcdon of the relationship between dietary restraint and overeating 
tendencies is as yet unclear and may even differ for various subgroups: The fact is that 
restrained eating (an inhibition factor) is often empirically linked to overeating 
tendencies (disinhibition factors), and overeadng tendencies may therefore 
contaminate correlations between restraint, food intake, and change in body weight 
(20-22). Two different aspects of overeating are distinguished. The first aspect, 
emotional eating, is derived from the psychosomatic theory (23) and refers to the tendency to 
overeat in response to negative emotions such as anxiety or irritability. The second 
aspect, external eating, is derived from the externality theory (24) and refers to the 
tendency to overeat in response to external food related cues, such as attractive sight 
and smell of food. 
Psychosomatic theory departs from the human individual difference effect model 
of food intake in response to negative affect (25). In this model, the normal response 
to distress is loss of appetite as a result of physiological mechanisms: the inhibition of 
gastric contractions and the elevation of blood sugar (26). The abnormal response is 
stress induced (emotional) eating, and it occurs in people with a lack of interoceptive 
awareness: As a result of faulty learning experiences in early life, these persons confuse 
physiological correlates of emotional distress with hunger (27, 28). 
Externality theory, similar to psychosomatic theory, also posits that eating 
behaviour is unresponsive to internal physiological signals such as gastric motility. But 
in contrast to the emphasis placed on internal, emotional factors in psychosomatic 
theory, externality theory focuses on the external food environment as a determinant 
of eating behaviour. External eaters overeat as a result of their hyperresponsiveness to 
external food-related cues. 
In the present study, in patients with newly diagnosed type 2 diabetes, we 
examined the relation between eating behaviour, body weight change, and energy 
intake 4 years after diagnosis. In addition, we assessed possible moderating effects of 
dietary restraint and overeating tendencies. 
Methods 
Subjects and procedure 
We used data from a prospective cohort study, m which patients with newly diagnosed 
type 2 diabetes (aged 40-70 years) were included from 33 general practices throughout 
the Netherlands ^=144).' Our primary aim was to assess alterations in energy and fat 
1 Diabetes mellitus was defined according to the criteria established by the World Health Organization. 
Patients were eligible for the stud\ when they had symptoms suggestive of diabetes mellitus and a 
fasting blood glucose greater than or equal to 6.7 mmol/1 and less than 20 0 mmol/1. In patients with 
asymptomatic diabetes, the fasong blood glucose had to be greater than or equal to 6 7 mmol/1 on two 
or more occasions. 
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intake (29). Patients (n=106) answered followed-up questions 4 years after the initial 
study. Reasons for missing data on energy and fat intake were that the patients died 
(n=8), moved to an unknown address (n=4), had another reason or an unknown 
reason for not responding (n=5), or refused to fill out food frequency questionnaire 
(n=21). However, 3 of those patients still provided data on body weight and eating 
behaviour. For the present study, complete data on body weight and energy intake at 
follow up (the dependent variables in this study) were available for 46 males and 51 
females. Relevant baseline characteristics of those who did not participate at the 4-year 
follow-up did not differ significandy from the subjects whose 4-year measurements 
were not missing (Appendix A). This study was performed according to the standards 
of ethical conduct, and all patients gave written informed consent.2 
Treatment 
All patients received regular care from their general practitioner. This included a 
referral to a registered dietician just after diagnosis. In two visits with the dietician, 
individually tailored advice was given, according to current guidelines. Generally, this 
implied a reduction in energy and fat consumption. 
Measurements 
Measurements took place at diagnosis, 8 weeks after diagnosis, and 4 years after 
diagnosis. The following measurements were included. 
'Body weight and height were measured without shoes and with light clothing. In every 
practice, the same balance was used for subsequent measurements. Body mass index 
(BMI) was calculated as follows: Weight in kilograms was divided by height squared. 
To assess the fat and energy consumpnon, we used a food frequency questionnaire 
(FFQ). In this questionnaire, the frequency of consumption of 104 food items is 
scored retrospectively. The reference penod was 1 month and common festivities 
such as birthday visits and parties were considered to be part of the habitual food 
pattern. The FFQ was completed by the patient and checked for major errors by the 
investigator; if necessary, the patient was contacted for clarification. Total energy 
intake (MJ/day) and total fat (expressed as the percentage of energy intake) were 
calculated using software designed especially for the questionnaire (30). For the 4-year 
measurement, an updated version of the questionnaire was used (31), and calculations 
were done using updated software (32). In a validation study, the FFQ showed results 
similar tot those from dietary history (Pearson correlation coefficients for energy 
intake and total fat were .83 and .78, respectively (33)). The FFQ has been shown to 
2 This study was performed in accordance with the World Medical Association Declaration of Helsinki, 
Ethical Pnnciples for Medical Research Involving Human Subjects The protocol for the 8-week study 
was approved by the Central Medical Committee for Studies in General Practice. The Local Ethics 
Committee of the Radboud University Ni|megen Medical Centre approved the protocol for the 4-year 
study. 
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have good reproducibility over 2 months (Pearson correlation coefficients for energy 
intake and total fat were .97 and .87, respectively (34)). 
Dietary restraint and overeanng-tendency were measured with the Dutch Eating 
Behaviour Questionnaire (DEBQ (35, 36)). This questionnaire has a scale on 
restrained eating (e.g., "Do you try to eat less at mealtimes than you would like to 
eat?") and two separate scales on overeating tendency: emotional eating (e.g., "Do you 
have a desire to eat when you are irritated?") and external eating (e.g., "If food smell 
and looks good, do you eat more than usual?"). Each of these two aspects of 
overeating tendency corresponds with a major theory on the aetiology of overeating, 
that is psychosomatic theory (23) and externality theory (35-37). Information on their 
construct, concurrent, and prédictive validity has been published previously (36, 38, 
39).3 Cronbach's alpha coefficients of the scales as obtained at diagnosis and at follow 
up in the present study can be found in Table 3.3.1. 
Data on use of medication were derived from the patients' record and provided by the 
general practitioner. In addition, the use of anti-diabetic and cholesterol-lowering 
medication during the interval was registered. 
Physical activity was measured by another questionnaire with nine equally weighted 
yes-or-no questions. Patients were asked whether they had the following regular 
activities: playing sports, bicycling, gardening, walking, doing odd jobs, climbing stairs, 
doing household activities, doing daily food shopping, and working (either paid or 
unpaid (42)). Thus, a score ranging from 0 {no exercise) to 9 {maximum amount of exercise) 
was calculated. 
Other variables such as smoking, age, and level of education were assessed by a 
short questionnaire. 
Strategy for analyses 
First, descriptive analyses were conducted to gather information about the means, 
standard deviations, and intercorrelations of the model variables. Because of sex 
differences in life style and body composition (43), these analyses were conducted 
separately for males and females. To assess the change between scores at diagnosis 
' Suce, Fischer and Lowe (40) questioned the validity of the DEBQ restraint scale on the basis of 
outcomes of studies using unobtrusive measures for food intake, but this conclusion has been refuted 
by Van Strien, et al (39). A major problem with the study by Soce et al (40), is that food intake was 
measured only at one moment in time, and this is at variance with both the fundamentals of valid 
dietary assessment and the concept of restraint as a trait. In nutntional science, single eanng episodes 
are regarded as inappropriate for assessing chronic dietan intake: A minimum time window of 24 hours 
is normally recommended (41). Moreover, we know of at least three experimental taste-test studies 
where the positive associauon between restraint and food consumption disappeared or even became 
negative when tendency toward overeating was controlled for (7, 8, 21) In the studies bv Stice et al. 
(40), the tendency to overeat was not paroaled out of the relation between restraint and food intake. A 
problem with all validity studies is that the ob)ective measures ma\ not reflect restriction of food intake, 
that is, eating less than desired In theorv, people ma\ eat more than required (in terms of physical 
activity and body weight) and still be restrained eaters insofar as (owing to dietan restraint) the\ eat less 
than they would otherwise be inclined to eat. 
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and at the 4-year follow up, we calculated effect sizes (d) by dividing the difference 
between the means by the standard deviation at diagnosis. Effect sizes between 0.2 
and 0.5 reflect a small effect, between 0.5 and 0.8 a moderate effect, and above 0.8 a 
large effect (44). 
Next, for the whole sample, an hierarchical regression analysis was conducted to 
determine whether restrained eating, overeating tendency (emotional and external 
eating), and their interaction at diagnosis, in addition to change in restrained eating 
and overeating tendency (emotional and external eating) after 4 years, accounted for a 
significant amount of variance in BMI at 4 years, over and above that accounted for 
by BMI at diagnosis, sex, and smoking at 4 years.4 Of special interest was the 
significance of the change in explained variance associated with the variables at each 
step in the analysis. 
A similar procedure was followed in the analyses with energy intake at 4 years as 
dependent variable. However, here we corrected for sex, body weight, and physical 
activity5 by forcing these variables into the first step of the analysis. 
Unfortunately, data for smoking or physical activity were missing in 2.5% of the 
records for the 97 subjects in the main analyses. It turned out that missing values were 
randomly distributed. Litde's missing completely at random test yielded a chi-square 
of 90.246 with 71 degrees of freedom (n=97, p=.060). So missing values could be 
estimated by the expectation-maximization algorithm, which preserves correlations 
between the independent variables as well as possible (see SPSS Missing Value 
Analysis, Version 7.5). It is stressed that the dependent variables (BMI and intake of 




At diagnosis, the 46 males had a mean age of 58.7 years (SD=6.9), a me<in body 
weight of 87.1 kg (80=14.2), and a mean BMI of 28.0 kg/m2 (SD=4.0). Most patients 
were living together with a partner (87%) and 67% had primary or basic vocational 
education only. After 8 weeks, 34 men showed weight loss (M=-3.4 kg, SD=2.4) and 
5 gained weight (M=1.5 kg, SD=1.4); for 7 patients, change in weight was unknown. 
A Sulphonylurea (e.g., tolbutamide, glibenclamide) and insulin therapy may increase bod\ weight b\ 
increasing the level of circulating insulin. Other medication for Type 2 diabetes is weight neutral. 
Because there was no vanation in use of medicine in the subjects (as all subjects used either insulin or 
sulphonylurea), this variable was left out of the analysis. 
Age, level of education, physical acnviu at diagnosis or at follow up, smoking at diagnosis, or change in 
smoking did not, in preliminary analysis, affect change in BMI. Therefore, we did not control for these 
variables at Step 1. 
^ Body weight and physical activity were forced at Step 1, to account for the fact that the individual 
energy requirements depend largely on body weight and physical activity. 
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The mean weight change between diagnosis and after 4 years was a gain of 1.3 kg 
(SD=5.4). Nineteen men showed weight loss or maintenance of body weight in 
relation to their body weight at diagnosis (mean weight loss=3.3 kg, SD=3.8), and 27 
men showed weight gain in relation to their body weight at diagnosis (mean weight 
gain=4.6 kg, SD=3.7). 
At diagnosis, the 51 women had a mean age of 58.6 years (SD=8.1), a mean body 
weight of 81.9 kg (SD=17.7), and a BMI of 30.7 kg/m 2 (SD=5.6). After 8 weeks, 40 
women showed weight loss (M=—3.1 kg, SD=2.0); for 11 patients, change in weight 
was unknown. Four years after diagnosis, only a few women had maintained this 
weight loss. The mean weight change compared with weight at diagnosis was —1.1 
kilograms (SD=5.0). Thirty women showed weight loss or maintenance of body 
weight in relation to body weight at diagnosis (mean weight loss=—4.4 kg, SD=3.8), 
and 21 women showed weight gain in relation to body weight at diagnosis (mean 
weight gain=3.5 kg, SD=2.0). 
Results on energy intake, fat intake, and the three types of eating behaviour are 
shown in Tables 3.3.1 and 3.3.2. Both men and women reported lower intakes of 
energy at the 4-year follow-up, compared with their intakes at diagnosis: For men, 
/(45)=4.544, /><.000, ^=-0.607; for women, 450)=4.650 ) p <.000, ^=-0.555. In men, 
there were no differences in total fat intake, /(45)=1.398 ns, (i=-0.302, whereas in 
women a lower total fat intake was reported, /(50)=3.646, p<.000, i/=-0.564. Further, 
for both the men and women, the change in bodyweight at the 4-year follow-up 
compared with diagnosis was not significant: For men, /(44) =-1.600, ns, ii=0.103; for 
women, /(50)=1.517, ns, d——0.071. In both men and women, an increase in restrained 
eating was found: For men, /(45)=3.061, p<M5, ^=0.465; for women, <50)=3.989, 
p<.000, d=0.488. In men, scores on external and emotional eating did not change: For 
external eadng, t(45)=-1.375, ns, </=-0.164; for emotional eating, /(45)=1.041, ns, 
d=0.119. In women, scores on external eating showed a statistically significant 
decrease, ΐ(50)=-2.091,^=.042, </=-0.200, whereas scores on emotional eating did not 
change, /(SO)=.822, ns, rf=0.106. 
Correlanons between model variables 
The correlation matrix and the Cronbach's alphas of the three types of eating 
behaviour at diagnosis and at 4 years, is shown in Table 3.3.1. In Table 3.3.2, the 
correlation matrix and the Cronbach's alphas of eating behaviour, and energy and fat 
consumpdon and BMI are shown. 
For each of the three types of eating behaviour, high and statistically significant 
test-retest correlations were found, ranging from .51 to .68 m men and from .61 to .73 
in women. So it seems that assessment of eating behaviour, particularly when this 
involves emotional or external eating, pertains a trait like construct with fair temporal 
stability rather than a temporary state. In both men and women, emotional and 
external eating were sigmficandy correlated at diagnosis and after 4-year follow-up. 
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In men, there were no significant correlations between any of the types of eating 
behaviour and intake of energy or fat. However, when we controlled for body weight 
and physical activity in partial correlation analyses, the correlation between restrained 
eating and energy intake at diagnosis became borderline significant, Λ=—.304, ρ—.Οβ, 
and the correlation between restrained eating at follow-up and intake of fat became 
significant, r=-.360,^>=.024. The correlation between external eating and energy intake 
at follow-up became borderline significant, 7=304, ƒ>=.060. 
In women, both types of eating behaviour at diagnosis were significantly correlated 
with energy intake at diagnosis. Emotional eating at diagnosis was also associated with 
energy intake at the 4-year follow up. Further, there were significant negative 
correlations between restrained eating and fat intake at diagnosis and between 
restrained eating and fat intake at the 4-year follow up. 
Table 3.3.1. Pearson Correlation Coefficients, Descriptive Statistics and Cronbach's Alpha of 
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Hierarchical regression analyses 
BMI at 4 years. Change in restrained, emotional and external eating (the significant 
increase in explained variance associated with restrained, emotional, and external 
eating at follow-up over and above restrained, emotional and external eating at 
diagnosis) did not significandy explain variations in BMI at 4 years. Also, none of the 
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interaction terms between restrained eating and emotional eating and restrained eating 
and external eating were significant, so only the outcomes of the first three steps of 
the regression analyses are reported here (Table 3.3.3). Only tendency toward 
overeating (emotional and external eating, Step 3) at diagnosis led to a significant 
increase in explained variance of BMI 4 years after diagnosis, beyond that accounted 
by sex, BMI at diagnosis, smoking and use of medicine, Fchangt (2, 90)=3.841,/>=.025. 
Table 3.3.2. Pearson Correlation Coefficients and Descriptive Statistics of the Three Types of 
Eating Behaviour, Intake of Energy, and Total Fat at Baseline and at 4 years, and of Body 

































































1 76 (1 89) 
* p<.05; ** p< 01 
••Baseline; ''Four-year follow-up 
Intake of energ). Only tendency toward overeating at diagnosis (emotional and 
external eating, Step 3) led to a significant increase in explained variance of intake of 
energy 4 years after diagnosis, Fchange (2, 90) =3.330, />=.040. When simultaneously 
entered into the model, neither emotional nor external eating was significantly 
associated with intake of energy at 4 years (see Table 3.3.4). Additional analyses 
showed that emotional eating sigmficandy explained variance in energy intake at 
follow-up when entered into the model without external eating, FchanRe (2, 90)=4.184, 
/>=.044. Similarly, external eating significandy explained variance in energy intake at 
follow-up when entered into the model without emotional eating, Fchange (2, 
90)=5.067, p—.Q21. This suggests that the overlapping variance of emotional and 
external eating is significandy associated with intake of energy at follow-up, although 
the types of eating behaviour separately only explained a small amount of variance 
(4%). 
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Table 3.3.3. Hierarchical Multiple Regression Analyses with Body Mass Index (BMI) at 4 
Years After Diagnosis in 97 Patients With type 2 Diabetes 
BMI 
Step 1 .98** 
BMI at diagnosis .92** 
Sex -.01 
Smoking at 4-years .08* 
Step 2 .00 
Restrained eating at diagnosis -.03 
Step 3 .01* 
Emodonal earing at diagnosis -.08 
External eating at diagnosis .115* 
•p<.05, ·*ρ<.0001 
"Betas in the last step 
Table 3.3.4. Hierarchical Multiple Regression Analyses With Energy Intake at 4 Years After 
Diagnosis in 97 Patients With type 2 Diabetes 
FJnergy intake 
ß» AR2 
Step 1 .06 
Sex -.276* 
Body weight at follow up -.109 
Physical activity at follow up -.028 
Step 2 .00 
Restrained earing at diagnosis -.148 
Step 3 .06* 
Emotional eating at diagnosis .160 
External eating at diagnosis .189 
*p<.05 
"Betas in the last step 
Discussion 
Four years after diagnosis of type 2 diabetes, all patients showed lower mean intakes 
of energy per day in comparison to their intakes at diagnosis. The women also showed 
lower mean intakes of total fat (as a percentage of energy). Yet, although most patients 
showed weight loss immediately after the dietary consultations, about half of the 
patients ended up weighing even more at the 4-year follow-up then they did at 
diagnosis. Although this result is in close correspondence with most follow-up results 
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of weight loss programs (45), it is a rather undesirable outcome of the treatment of 
type 2 diabetes (46). This raises the question of how this weight gain can be explained, 
especially in the view of the reported lower energy intake and higher levels of dietary 
restraint. First, it is recognized that lowering energy intake does not unequivocally lead 
to weight loss. Restrained eating, for instance, may alter metabolic functioning in the 
direction of anabolism (47-50). Increased metabohc efficiency in response to repeated 
efforts at dieting may increase the difficulty of losing weight and may even cause 
weight gain in the long run (2). Indeed, it may be necessary for dietary restraint to 
increase over time if one is to lose weight in the long run (51, 52). Other explanations 
of altered metabolism or weight gain might be in the use of anti-diabetic medication 
with weight gaining properties or in the secular trend that has shown an increase m 
body weight over the last decades. 
Second, the level of dietary restraint does not seem to be a plausible explanation 
for the weight gain either, because in the analysis no relationship was found between 
restrained eating behaviour and change in BMI at diagnosis or at follow-up, even 
when this relation was corrected for variables such as smoking. Increased metabolic 
efficiency may correspond, however, with the observation that dietary restraint, 
despite its increase, also was not related to weight loss. In this line of thought, the 
increase in dietary restraint may have been insufficient to counteract any anabolism to 
achieve the outcome of weight loss. 
Third, a candidate for explaining weight gain is tendency toward overeating that 
seems so frequendy associated with restricted eating. In the present study, support for 
this possibility was obtained by the finding that tendency toward overeating at 
diagnosis (emodonal and external eating) explained a significant (although small) 
amount of variance in BMI change, a finding substantiated by the positive 
relationships between tendency toward overeating and intake of energy at the 4-year 
follow-up. 
The suggestion that the weight gain in this study could be best explained by the 
tendency toward overeating is in line with other studies where the tendency toward 
overeating was found to be a better predictor of food consumption than was restraint 
(7, 8, 21, 22, 53). Although this finding seems a tautology at first sight, it is not in light 
of the dieting dilemma, because it suggests that the dieting dilemma could be resolved 
when the question Should we put a moratorium on dieting, yes or no, was 
reformulated into the question Who can be expected to have a good response to a 
dietary intervention and who should be treated differently? 
Towards matched treatment of patients with type 2 diabetes 
The present results fit well with research that suggests that the success of a dietary 
intervention may be predicted by a subject's tendency toward overeating (54, 55). This 
opens the possibility that the long-term effect of dietary consultations - for example, 
for patients with type 2 diabetes — may be enhanced by matching specific treatments 
to specific patients (56-58). Matched treatment may be based on a distinction between 
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type 2 diabetes patients with potentially good responses to dietary advises and those 
padents who do not have such positive responses. Patients with a low tendency 
toward overeadng (emodonal and/or external eating) may be expected to have good 
responses to the dietary consultadons. It has been shown in an experimental setting 
that persons with a low tendency to overeat were not tempted to overeat when faced 
with delicious ice cream, or appetizing cookies (7, 8, 21). Moreover, they may be more 
likely to have a stable body weight in real life (59-62). Patients with a tendency to 
overeating (emotional and/or external eating) are less likely to benefit from dietary 
advice unless their overeating tendency is addressed. In their case, treatment should 
additionally target their overeating tendency (56): their sensitivity to food cues (in the 
case of external eating) or their low interoceptive awareness (in the case of emotionally 
induced overeating (36, 63)). 
Umitanons and strengths 
A possible drawback of the study was the method of measuring food intake, which 
may have been subject to recall bias. However, it must be noted that all available 
instruments to measure food intake are subject to this bias and, therefore, a real gold 
standard does not exist. A drawback of record keeping or self-monitoring is its 
reactivity: For this precise reason, this method is a vital component of behaviour 
modification and treatment (64). A serious drawback of the unobtrusive measures that 
Sdce, Fisher & Lowe (40) used in their validation study of measures for dietary 
restraint was that food intake was only assessed at one moment in time, and this is at 
variance with the fundamentals of valid dietary assessment, where a minimum time 
window of 24 hours is required (39, 41). 
The small number of subjects may have affected the power of the study. 
Nevertheless, its strength is that the results all pointed at the same direction. The main 
strengths of our study were that it provided follow-up data (a) of sufficient length; (b) 
in a cohort of patients newly diagnosed with type 2 diabetes (subjects in whom we 
may assume high motivation for weight loss); (c) with satisfactory long-term 
participation rate; and (d) that were rooted in general practice, which means that the 
results correspond with normal daily life rather than with an experimental setting. A 
further strength of the study is that body weight and height, which were central to the 
outcome variable BMI change, were not based on self-reports but had been actually 
measured. 
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Appendix A 
Descriptive statistics at baseline of dropouts versus subjects 










































































Is acarbose equivalent to tolbutamide as first 
treatment for newly diagnosed type 2 diabetes in 
general practice? A randomised controlled trial 
Fions A. van de Laar,1 Peter L.B.J. Lucassen,' Jaco Kemp,2 Eloy H. van de 
Lisdonk,' Chris van Weel,1 Guy E.H.M. Kutten' 
1 Radboud University Nijmegen Medical Centre, Department of General 
Practice, Nijmegen, The Netherlands; 2 Quinales ClinData, Bloemfontein, 
South Afnca; 3 Julius Centre for Health Sciences and Primary Care, Utrecht, 
The Netherlands 
Diabetes Res Clin Pract 2004;63(1):57-65 
Chapter 4.1 Acarbose versus tolbutamide for type 2 diabetes 
Abstract 
We performed a double blind randomised controlled trial in General Practice to assess 
equivalence between tolbutamide and acarbose with respect to the effect on mean 
HbAic in newly diagnosed patients with type 2 diabetes. Secondary objectives were to 
compare the effects of both treatments on fasting and post-load blood glucose and 
insulin levels, lipids, and adverse events. Patients were randomised to receive acarbose, 
dosed step-wise to a maximum of 100 mg three times daily (n=48) or Tolbutamide, 
similarly dosed to a maximum of 2000 mg in three doses (n=48). The two treatments 
were considered equivalent if the two-sided 90% confidence interval (CI) for the 
difference in mean HbAic levels was within the range -0 .4% to 0.4%. Results were 
analysed on an intention-to-treat, per-protocol and on worst-case basis. Both agents 
reduced the HbAic percentage and fasting blood glucose levels. The difference in 
mean decrease of HbAic was 0.6% in favour of tolbutamide (90% CI 0.3,0.9; 95% CI 
0.2,1.0). A worst-case analysis, assuming no change in HbAk for dropouts, yielded a 
difference in mean decrease of 0.9% (90% CI 0.6,1.2) in favour of tolbutamide. The 
difference in mean decrease of fasting blood glucose was 1.0 mmol/1 in favour of 
tolbutamide (95% CI 0.3,1.7). There were no significant differences in post-load blood 
glucose, fasting and post-load insulin levels, or lipids. In the acarbose group 
significandy more patients (15 versus 3) discontinued therapy because of adverse 
effects, mosdy of gastrointestinal origin. We conclude that the results of this study 
favour tolbutamide over acarbose as first treatment for patients with newly diagnosed 
type 2 diabetes. 
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Introduction 
Currendy, sulfonylureas are the most frequendy used and recommended medication 
for type 2 diabetes in general pracdce. The Dutch guidelines for general practitioners 
are the most explicit (1), recommending as first choice a sulfonylurea in non-obese 
patients, when diet therapy has failed. Metformin is the first choice in obese patients, 
and if neither is sufficient alone, the two should be combined. Acarbose is indicated if 
the combination of both sulfonylurea and metformin fails, or in case of 
contraindicadons to, or adverse effects from tolbutamide or metformin. In contrast to 
other guidelines (2), the Dutch guidelines do not recommend the use of more than 
two different blood glucose lowering agents. 
Worldwide, most expenence has been gained with tolbutamide, a first-generation 
sulfonylurea. The results of the controversial University Group Diabetes Program, in 
which increased cardiovascular morbidity was associated with the use of tolbutamide, 
are now not considered of clinical importance (3). Tolbutamide causes relatively few 
hypoglycaemic events compared to other sulfonylureas and there is no convincing 
evidence that second-generation sulfonylureas are to be preferred over tolbutamide 
(4)· 
Acarbose, an inhibitor of alpha-glucosidase of the small intestine brush border, has 
a beneficial effect on postprandial bloodglucose and HbAic levels. It is well 
established in placebo-controlled trials as both first-line treatment (5) and as an 
adjunct to other oral agents (6, 7). An additional advantage of acarbose may be a 
beneficial effect on hyperinsulinaemia, a risk factor for cardiovascular disease (8). 
In view of its capacity to lower postprandial blood glucose and insulin levels, 
acarbose might be the preferred first-line agent, provided that its glucose-lowering 
potential equals that of the sulfonylureas. 
The results of studies comparing the glucose-lowering capacities of acarbose and a 
sulfonylurea are contradictory. Two trials showed a 0.4% advantage for the 
sulfonylurea in decreasing HbAic levels (p=0.03 (9) and p=0.068 (10)), one showed a 
0.2% (p=0.07) advantage for acarbose (11), and two more showed no difference at all 
(p-value not reported) (12, 13). None of these studies were designed as equivalence 
trials. In addition, postprandial insulin levels were measured in three of these studies, 
and acarbose treatment resulted in statistically sigmficandy lower levels compared to 
sulfonylurea (9-11). None of these studies was earned out in a primary care setting or 
in newly diagnosed diabetic patients. 
Because of these contradictory results, we conducted a study in newly diagnosed 
type 2 diabetic patients in primary care to asses equivalence in the capacity of lowering 
HbAk levels between acarbose and tolbutamide. Secondary objectives were to 
compare the effects of both treatments on fasting and post-load blood glucose and 
insulin levels, plasma lipids, and tolerability. 
87 
Chapter 4.1 Acarbose versus tolbutamide for type 2 diabetes 
Methods 
Patient selection 
The study took place from April 1995 to July 1998. Forty-six general practitioners 
working in general practices spread throughout the Netherlands recruited patients. 
Not all physicians participated for the entire period of three years. The physicians 
were asked to select patients either with complaints suggestive of diabetes mellitus and 
a capillar}' fasting blood glucose (FBG) >6.7 mmol/1 or patients in whom a raised 
blood glucose level was found coincidentally. For patients without symptoms more 
than one abnormal fasting blood glucose was needed (14). 
Padents were eligible for the trial if their FBG levels were between 6.7-20.0 
mmol/1 after an 8-week dietary treatment period (see below), and they met the 
following criteria: age between 40 and 70 years; and sufficient understanding of 
spoken Dutch to follow instructions. 
Exclusion criteria were: any significant disease or condition likely to prevent 
patients from completing the study; uncorrected endocrine disturbances; pregnancy or 
breastfeeding; women of childbearing age not using contraceptives; diseases with 
abnormal gut motility or altered absorption of nutrients, or use of medications for 
such conditions; use of systemic glucocorticoids; hypersensitivity or other 
contraindications to acarbose or tolbutamide; habitual use of drugs or an alcohol 
intake >10 units daily; lactose intolerance; participation in another experimental study; 
serum cholesterol >10 mmol/1 or a serum triglyceride >4 mmol/1; use of lipid 
lowering agents containing ionic-substitution resins (e.g. colestipol); aspartate 
aminotransferase (AST) >50 U/l, alanine aminotransferase (ALT) >50 U/l, Gamma 
G T >150 U/l; creatinine >150 μπιοΐ/ΐ; myocardial infarction within the last 6 months. 
All patients gave their written informed consent and the study protocol was 
approved by a central review board on medical ethics and was conducted in 
accordance with the Declaration of Helsinki. 
Study Design 
All selected patients entered an 8-week dietary treatment period. Dietary advice 
tailored to individual food habits and to serum levels of HbAic and lipids was given by 
a registered dietician. This was given at two visits and followed current 
recommendations for type 2 diabetes mellitus. All patients who still had a FBG 
between 6.7 and 20 mmol/1 at the end of the diet phase were randomised into the 
tolbutamide or the acarbose group. During the 30 weeks trial period patients visited 
their general practitioner seven times. At each visit the FBG was measured, and 
compliance, concomitant diseases or medication, and adverse events were checked. 
Post-load glucose, fasting and post-load insulin, lipids, and liver and kidney functions 
were measured one week before randomisation and in week 29. HbAk was measured 
before randomisation and in weeks 22 and 29. 
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In the first 6 weeks after randomisadon patients received an individually titrated 
step-up dose of tolbutamide or acarbose. As long as the FBG exceeded 6.7 mmol/1 
the physician increased the dosage of the double-blind medication at two, four and/or 
six weeks. The maximum dosage schedule at week 0, 2, 4 and 6 was for acarbose 
(milligrams, morning - afternoon - evening): 50 - 0 — 0, 50 - 0 - 50, 50 - 50 — 50 and 
1 0 0 - 1 0 0 - 1 0 0 respectively. Similarly, for tolbutamide the scheme was 500 - 0 - 0 , 
500 - 0 - 500, 500 - 500 - 500 and 1000 - 500 - 500 respectively. Otherwise 
medication dosage was continued to the end of the trial. If FBG was >20 mmol/1 at 
the end of the sixth trial week patients were excluded from the study. 
Randomisation and blinding 
Patients entering the trial received a code provided by a computer program generating 
random numbers at the trial centre. Each code corresponded to one of the treatments. 
The clinical quality assurance manager kept the allocation schedule in a central study 
file not accessible to the participating general practitioners. The code was sent to the 
general practitioner in a sealed radio-opaque envelope that was only to be broken in 
case of a medical emergency. At the end of the study the envelope had to be returned 
unopened. 
Because of the different sizes of the actual tablets it was necessary to use the so-
called 'double dummy' technique to ensure blinding. All patients received two sets of 
pills, apparendy acarbose and tolbutamide, but only one set contained an active 
substance. 
Measurements 
Post-load blood samples for glucose and insulin were taken one hour after ingestion 
of 75 g glucose in 300 ml water. Patients were instructed to take the morning study 
medication after the test was completed. We chose the option of the post-load glucose 
test, using it as a measure of seventy of the insulin-resistance syndrome. Insulin was 
measured by a radioimmunoassay technique (Pharmacia, Uppsala, Sweden). HbAi c 
measurements were done by HPLC (Perkin Elmer, series 4, reference range 4.5-6.0%, 
assay DCCT aligned). For cholesterol and HDL-cholesterol estimation the C H O D -
PAP method on Hitachi 717 (Boehnnger Mannheim, Almere, The Netherlands) was 
used, and for triglycerides the Pendochrom triglycend GPO-PAP method on the 
same machine. Fasting and one-hour post-load glucose measurements were 
performed on the spot using a calibrated glucometer for capillary samples. Reference 
ranges for the safety parameters were: AST 8-32 U/1, ALT 8-32 U/1, Gamma G T 8-28 
U/1 and creatinine 56-125 μιηοΐ/ΐ (females) and 39-103 μπιοΐ/ΐ (males). Drug 
compliance was checked by pill counting, and adverse effects were assessed by history 
taking and, if necessary, physical examination. 
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Statistical analysis 
The number of participants was calculated by the formula for the power of the two-
sample t-test for equivalence (15). Given a beta value of 20%, the formula yielded a 
sample size of 70 patients per treatment group. 
The efficacy analysis was performed on an intention-to-treat (ITT) basis and as a 
per-protocol analysis (PP). ITT analysis included all randomised patients, including 
those who were included in the trial in error, those with low compliance, and patients 
whose data were missing. Missing data were handled according to the last-
observadon-carned-forward principle. Padents without baseline or without both post-
baseline HbAic measurements were excluded from ITT analysis. In the event of 
significant differences in drop-out rates, a worst-case-analysis was carried out 
assuming that HbAic values for drop-outs did not change from baseline values. The 
PP analysis included all patients who completed the protocol without any violation. 
Analysis for safety was carried out for all patients who received at least one dose of 
the study medication. 
The primary efficacy measure was defined as the decrease in HbAic levels at the 
end of treatment, analysed by means of covariance (ANCOVA) with the baseline 
values as covanates. Therapeutic equivalence was assumed if the two-sided 90% 
confidence interval for the difference in mean HbAic levels between the two 
treatments was entirely within the range from -0 .4% to 0.4%. In addition a second 
analysis was performed assessing the difference in proportion of patients with a 
reduction of HbAk >0.8%, taking this difference as a cut-off level for successful 
treatment. The decrease of 0.8% was based on expected effects of both agents as 
described in a recent literature overview (16). 
Secondary efficacy measures were the fasting and one-hour post-load blood 
glucose levels; fasting and one-hour post-load insulin levels; total cholesterol, 
triglycerides, and HDL-cholesterol; and adverse events. Glucose, insulin, and lipid 
levels in the two treatment groups were also compared, by means of analysis of 
covariance, with baseline values as covanates. For each measure the 95% confidence 
interval for the difference in mean level was computed. 
Differences in the occurrence of adverse events were assessed by the Cochrane-
Mantel-Haenszel-chi-square test. 
In the case of withdrawals before week 22, no post-baseline HbAk measurements 
were available. Therefore, to estimate the possible influence of withdrawal on trial 
results, we analysed fasting blood glucose levels in all randomised patients. Missing 
values were handled according to the last-observaoon-carried-forward principle. 
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Results 
Patientflow 
We recruited 144 subjects with newly diagnosed type 2 diabetes. Forty-eight patients 
did not enter randomisation because of the following reasons: FBG <6.7 mmol/1 
(n=33), high liver enzymes (n=5), consent withdrawn (n=6), FBG >20 mmol/1 (n=l) , 
protocol violation (n=l) , falsely included (n=2). Of 96 patients that were eligible for 
randomisation, 48 were randomised to acarbose and 48 to tolbutamide (Figure 4.1.1). 
In the acarbose group, 15 padents discontinued the study due to side effects: 
gastrointestinal adverse events like flatulence, diarrhoea, abdominal pain or nausea 
(n=13), headache (n=l) , not reported (n=l) . One patient discondnued for other, 
unknown, reasons. In the tolbutamide group five patients discontinued, three because 
of respectively eructation, nausea and flatulence. For two patients the reason was not 
known. The difference between the two groups was statistically significant (p=0.007). 
Due to protocol deviations we excluded for the PP analysis six patients in the 
acarbose group (insufficient data on compliance n=2, myocardial infarction n = l , 
single FBG <6.7 mmol/1 before randomisation n = l , low compliance and duodenal 
ulcer n = l , breast carcinoma n= l ) , and five patients in the tolbutamide group 
(insufficient data on compliance n = l , myocardial infarction n = l , cholecystitis and 
pancreatitis n = l , randomisation code broken n=2). There were no significant 
differences in baseline characteristics between the groups (Table 4.1.1). 
In the acarbose group, 5, 4, 7, and 17 patients used 50, 100, 150 and 300 mg of 
acarbose respectively in the tolbutamide group, 8, 8, 7, and 20 patients used 500, 1000, 
1500, and 2000 mg respectively. 
Efficacy 
In both groups the primary efficacy measure, HbAic percentage, decreased 
significantly. The decrease of HbAk levels was more pronounced with tolbutamide 
than with acarbose. The calculated difference in mean decrease was 0.6% (90% CI 
0.3,0.9, 95% CI 0.2,1.0) (Table 4.1.2). By definition, equivalence would have been 
established if the confidence interval of the difference in mean decrease in HbAk 
concentration was between -0 .4% and 0.4%. Thus, these results do not demonstrate 
equivalence between acarbose and tolbutamide. However, equivalence cannot be ruled 
out on the basis of these results, as 0.4%, the predefined lower limit of equivalence, 
lies within the confidence interval. 
The worst-case-analysis, assuming no change in HbAk for dropouts, yielded a 
difference of 0.9% (90% CI 0.6,1.2) between acarbose and tolbutamide in favour of 
tolbutamide. The proportion of patients with a reduction of HbAic >0.8% was 17/48 
(35.4%) in the acarbose group and 35/48 (72.9%) in the tolbutamide group. Drop-
outs were considered to have a reduction <0.8%. This difference was statistically 
significant (p<0.001). 
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Sex (male/female) 
Mean age (years) 
BMI (kg/m2) 
HbAic (%) 
Fasting blood glucose (mmol/1) 
Glucose 1 hour post-load (mmol/1) 
Fasting insulin (pmol/1) 
Insulin 1 hour post-load (pmol/1) 
Triglyceride (mmol/1) 
Total cholesterol (mmol/1) 
LDL cholesterol (mmol/1) 

















































































Randomized: (n=96): All randomized patients who took study medication 
Intenuon-to-treat group (n=75): AU randomized pauents with at least one post-baseline HbAu measurement 
Per-protocol group (n=64): All randomized pauents who completed the protocol without any violations 
Values are mean (standard deviation) 
T a b l e 4.1.2. Secondary efficacy measures . ITT analysis (n—75) 
Acarbose Tolbutamide 
Baseline Endpoint Change (n; SD, 95% CI) Baseline Endpoint Change (n, SD, 95% CI) Point 95% CI 
(SD) (SD) (SD) (SD) Esnmatet 
HbA,c(%) 7.9(1.7) 6.8(1.3) -1.1 (32; 1.0;-1.4,-0.7) 8.2(1.7) 6.4(1.0) -1.8(43,13,-2.2,-1.4) 0.57 
FBG (mmol/1) 9.8(2.5) 8.3(2.5) -1 5 (32; 2.1; -2.2,-0.7) 10.3(2.8) 7.4(1.7) -2.9 (43; 2.6;-3.7,-2.1) 115 
B G 1 hour Post- 18.1(4.1) 16.9 (3.7) -1 2 (29,3.9;-2.7,0.3) 18.8(3.9) 16 4(3.4) -2.2 (41; 2.8;-3.0,-1.3) 0 7 
load (mmol/1) 
Fasting insulin 139 5(59 3) 134.8(56.8) -4.7(28,56.0,-26.4,17.0) 154.9(107.8) 151.7(123 2) -3.2 (35,96.1;-36.2,29.9) -6.0 
(pmol/1) 
Insulin 1 hour Post- 385.4(192.3) 392.9(208 7) 7.5 (25; 136.5;-48.9,63 8) 494 3(324.1) 520.7(301.2) 26.4 (35; 282 2,-70.5,123.4) -61.5 
load (pmol/1) 
Tnglycendes 2.5(2.5) 2.2(1.2) -0.3 (28; 1.6;-0.9,0.3) 2.7(2.4) 2.4(1.9) -0 4 (39; 21;-1.0,0 3) -0.1 
(mmol/1) 
Total cholesterol 5.5(0.9) 5 7(1.0) 0.1(28,0.5,-0.1,0.3) 6.0(1.1) 6 0 (12 ) 0.0(39,0.7,-0.2,0.2) 0.1 
(mmol/1) 
LDL-Cholesterol 3.5(0.6) 3.6(0.8) 0.1 (27,0.4;-0.1,0.3) 3.8(10) 3.7(0.8) -0.1 (38; 0.7,-0 3,0.2) 0.1 
(mmol/1) 
HDL-Cholesterol 1.0(0.2) 1.1(0.3) 0.1(28,0 2,0.0,0.2) 1-1(3 1) 1.2(0.3) 0.1 (38; 0.4; 0.0,0.2) -01 
(mmol/1) 
f Calculated by Analysis of Covanance (ANCOVA) with basebne values as covanates 
* 90% CI, 95% CI 0 2,1 0 
Values are mean (standard deviation) 
0 3,0 9· 
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a Patients with at least one post-baseline HbA|c measurement 
b Patients who completed the protocol without deviauons 
Figure 4.1.1. Study design and patient flow 
Except for fasting blood glucose, all secondary measures of efficacy, including 
post-load insulin levels, did not differ significandy. The results from analysis on a PP 
basis did not differ from the results of the ITT analysis (data not displayed). 
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To estimate the effect of premature withdrawals, the mean difference in FBG 
levels in all randomised padents was calculated. The point estimate (acarbose-
tolbutamide) was 1.01 mmol/1 (0.29,1.73). This result was similar to that of the ITT 
and PP analysis. 
Safety and adverse drug reactions 
Of the 96 patients who received at least one dose of the study medication, 22 (46%) 
patients in the acarbose treatment group and 12 (25%) patients in the tolbutamide 
treatment group reported 39 and 27 drug-related adverse events, respectively. The 
most frequendy occurring drug-related adverse events were flatulence, diarrhoea, and 
abdominal pain or nausea. Except for the expected higher rate of flatulence in the 
acarbose treatment group (acarbose 27%; tolbutamide 2%), the two treatment groups 
had similar profiles of drug-related adverse events. There were no hypoglycaermc 
events reported in both treatment groups. 
N o patients had to be excluded due to FBG >20 mmol/1 during the treatment 
period. 
Discussion 
Equivalence between acarbose and tolbutamide could not be established in this trial. 
Rather, this trial provides evidence that, when taking all aspects of treatment and side 
effects into account, the effects of acarbose are inferior. The result of the worst-case 
analysis and the more pronounced reduction of FBG values among tolbutamide users 
underpin this. 
Further, this study shows no difference in post-load insulin levels and a statistically 
and clinically significant difference in adverse effects in favour of tolbutamide. 
With respect to the primary efficacy measure the results of this study are in line 
with the results of Comff (9) and Salman (10). Statistical significance, however, was 
only established in the study of Coniff et al., which was also the only trial with 
tolbutamide as the sulphonylurea. The studies that report no differences or an 
advantage for acarbose were performed earher and all conducted by the same group 
(11-13). 
We found no differences in post-load insulin levels. This was surprising because 
such evidence as is available indicates an advantage for acarbose (9-11). This 
conflicting result might be because we did not conduct full meal tolerance tests, but 
instead we measured post-load insulin after ingestion of 75 g glucose, without 
previous ingestion of the study medication. Because acarbose does not affect the 
absorption of simple carbohydrates like glucose, ingestion of acarbose prior to a 
glucose tolerance test would not have influenced the normal insulin rise. We also 
found no evidence that treatment with acarbose offers advantages over tolbutamide 
with respect to glucose tolerance, fasting insulin levels, and insulin response. 
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In contrast to previous studies, adverse effects were a major cause for 
discontinuation, especially in the acarbose group. One of the reasons for this 
remarkable discrepancy might be the increase in dosage from 150 to 300 mg, which 
could be too rapid. Also, the setting of the study may have been contributed to the 
large number of dropouts. Comparable studies were performed in hospitals or 
specialised diabetes centres with more opportunities to monitor and motivate 
participating patients. The general practitioners who treated patients in our study 
probably had only limited time to motivate patients who experienced adverse 
gastrointestinal effects. Although the high number of withdrawals is disappointing for 
the investigators, it demonstrates everyday practice and is therefore a valuable 
outcome, which hampers the long-term treatment of at least one in every three 
patients. By calculating the outcome for fasting blood glucose in all randomised 
patients we showed that it is unlikely that these withdrawals affected the primary 
endpoint. 
We could not achieve the number of patients required by the power calculation. 
To estimate the influence of insufficient power, we recalculated the difference in mean 
HbAic using 70 patients per treatment group, assuming the same statistical 
distribution. This resulted in a 90% confidence interval of 0.3,0.8. Thus, even if the 
patient numbers called for by the power calculation had been met, a statistically 
significant outcome was not sure. This was also true for the secondary efficacy 
measures. 
Because about 75% of all type 2 diabetic patients in the Netherlands are treated by 
general practitioners, our findings represent the main patient population treated for 
diabetes mellitus. To our knowledge there is no previous study conducted in a similar 
setting: this makes comparison with other reports insecure. The literature does not 
provide unequivocal results that allow drawing unambiguous conclusions. 
Nevertheless, this study may be a guide to judging the usefullness of acarbose in 
general practice by its true merits. 
To conclude, we found no evidence to challenge the current pohcy of giving a 
sulfonylurea as the first treatment of choice for type 2 diabetes in general practice. The 
relatively low cost of sulphonylureas compared to acarbose together with a favourable 
safety profile, underlines this policy. Acarbose remains a rational alternative, however, 
when a sulfonylurea fails, or as an addition to other drug therapy. 
For a definite answer to our primary question, we strongly recommend a meta-
analysis of our results together with those of previous studies. 
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Chapter 4.2 Alpha-glucosidase inhibitors for type 2 diabetes 
Abstract 
Objective. To review the effects of monotherapy with alpha-glucosidase inhibitors 
(AGIs) for patient with type 2 diabetes, with respect to mortality, morbidity, glycémie 
control, insulin levels, plasma lipids, body weight and side effects. 
Methods. We systematically searched the Cochrane Central register of Controlled Trials, 
MEDLINE, EMBASE, Current Contents, LILACS, databases of ongoing trials, 
reference lists and we contacted experts and manufacturers. Inclusion criteria were 
randomized controlled trials of at least 12-weeks duration, AGI monotherapy 
compared with any intervendon, and one of the following outcome measures: 
mortality, morbidity, GHb, blood glucose, lipids, insulin levels, body weight, or side 
effects. Two independent reviewers assessed all abstracts, extracted all data, and 
assessed quality. We contacted all authors for data clarification. Continuous data were 
expressed as weighted mean différences and analyzed with a random-effects model. 
Possible influences of study characteristics and quality were assessed in sensitivity and 
meta-regression analyses. 
Results. Forty-one studies were included in the review (acarbose 30, miglitol 7, 
voglibose 1, and combined 3), and heterogeneity was limited. We found no evidence 
for an effect on mortality or morbidity. Compared with placebo, AGIs had a 
beneficial effect on G H b (acarbose -0.77%, miglitol -0.68%), fasting and postload 
blood glucose and postload insulin. With acarbose dosages higher than 50 mg t.i.d., 
the effect on G H b was the same, but the occurrence of side effects increased. 
Acarbose decreased the BMI by 0.17 kg/m2 (95% CI 0.08 to 0.26). None of the AGIs 
had an effect on plasma lipids. Compared with sulphonylurea, AGIs seemed inferior 
with respect to glycémie control, but they reduced fasting and posdoad insulin levels. 
For comparisons with other agents, little data were available. 
Conclusions. We found no evidence for an effect on mortality or morbidity. AGIs have 
clear beneficial effects on glycémie control and postload insulin levels but not on 
plasma lipids. There is no need for dosages higher than 50 mg acarbose t.i.d. 
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mtim mightol - ^ J ^ S è vogliboseÎPH^JESiJ-^ α-ΙΒ^ϋ^ϋίΦΐϋίϋΟ«! 
¥ . / l ¥ * W ^ ^ t : $ , ^ ^ $ . ife^MMM^fêiRito psi p^^ffi 
5ftÎ$fÎ^JWWMÔtlÎie^ffl. IHfcMi:gâ-0 8%[95%CI (-0 9 to 
-0 7) ], ïg-kÉLM -1.1 mmol/L [ 95%CI ( -1 4 to -0 9) ], JsfcfäELfä -2 3 
iiimol/L[95% CI (-2.7to-1.9) ], M-£$iMXÎMLmÙtf)îfM^Mm 
im* mxìjsftmmmykW; ìmmfà&imÉLmmm$.mm& 
Ì Ì^*J^»^ in^^#Jg | f t^zKYA-24.8 pmoVL [ 95% CI ( -43.3 to 
-6.3) ]|5$fàflJ-133.2pmol/L[95%CI ( -184.5 to -81.8) ] , ìa&W^ìfe 
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Introduction 
Alpha-glucosidase inhibitors (AGIs: acarbose, miglitol, voghbose) are widely used in 
the treatment of patients with type 2 diabetes. AGIs delay the absorption of 
carbohydrates from the small intestine and thus have a lowering effect on postprandial 
blood glucose and insulin levels. 
In modern medicine, the efficacy of an intervention should be investigated in well-
designed randomized trials. Results from the trials should be collected in a high quality 
systematic review, if possible with a meta-analysis. And finally, the evidence should 
have its repercussions on practice guidelines. 
How does this apply for AGIs? Recommendations on when to use AGIs and the 
evidence used for these recommendations appear to be different in various guidelines. 
For example, the guideline by the European Diabetes Policy Group (1) and a 
consensus statement by the American Diabetes Association (2) are not very specific. 
They mention the possible use of AGIs as first-line agent or in combination with 
other antihyperglycemic drugs, but they don't offer a more precise judgment, and 
literature references are not given. The Dutch guidelines are more explicit about the 
use of AGIs. They advise using acarbose only when other agents are contraindicated, 
and references are provided with this advice (3). The guidelines of the Royal College 
of General Practitioners in the U.K. reach similar recommendation as the Dutch. 
These guidelines are based on a systematic review of the literature. For AGIs the 
advice is based on one review article and 17 additional trials, with acarbose both as 
monotherapy and as additional therapy (4). 
In recent years literature reviews focused exclusively on acarbose or miglitol. 
Voghbose has not been subject to a literature review. It is difficult to value the results 
of these reviews because all have methodological weaknesses: no description of search 
strategy and inclusion criteria (5-7), no report of search results (5-9), and either lack or 
have an unclear quality assessment of the included studies (5-9). In general, all reviews 
reported beneficial effects on glycémie control. One review reported results from a 
meta-analysis by calculating the mean effect from 13 trials with acarbose (GHb -
0.90%, fasting blood glucose —1.3 mmol/1, postprandial blood glucose -3.0 mmol/1) 
(7). Although generally assumed, the existence of a dose dependency of the effect 
could not be concluded from these reviews. 
A review on the effect of oral antihyperglycemic agents on serum lipids in patients 
with type 2 diabetes found beneficial effects of acarbose on HDL and LDL 
cholesterol and a decreasing effect of voglibose on triglycerides (10). However, a 
meta-analysis was not performed. Another study of very recent date concluded from a 
meta-analysis of seven trials that acarbose reduces the incidence of myocardial 
infarctions in patients with type 2 diabetes (11). However, this study was subject to 
publication bias, heterogeneity, detection bias and confounding (12). 
We conducted a systematic literature review and meta-analyses within the framework 
of the Metabolic and Endocrine Disorders Review Group of the Cochrane 
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Collaboration Our main research focused on the effects of AGIs versus placebo (or 
any other intervention) with respect to: 1) mortality and (diabetes-related) morbidity; 
2) glycémie control, plasma lipids, insulin levels, and body weight; and 3) side effects. 
Methods 
We searched the Cochrane Central register of Controlled Trials (CENTRAL), 
MEDLINE, EMBASE, Current Contents, LILACS, reference lists of reviews on the 
topic, and we contacted manufacturers and experts for additional (unpublished) trials. 
In addition, we searched databases of ongoing trials on the Internet. The last 
systematic search was in December 2003 for Current Contents and April 2003 for the 
other databases. 
For MEDLINE, we combined the search strategies for "type 2 diabetes mellitus" 
and "randomized controlled trials" that we adapted from the Review Group (13) and 
combined these with a combination of the Medical Subject Headings key word 
"acarbose" and all different spellings for AGIs and their brand names. This strategy 
had to be slighdy adapted for EMBASE and Current Contents, making the search 
more sensitive. For the other databases we searched with the words for AGIs only, 
because these databases already included controlled trials only (CENTRAL, databases 
of ongoing trials) or because its browser didn't allow complex searches (LILACS). 
Studies had to meet five inclusion criteria: 1) inclusion of patients with type 2 
diabetes that received no other antidiabetic medication (when both patients with and 
without additional antidiabetic medication were included, the results for the latter 
(sub)group should be well presented); 2) a duration of at least 12 weeks; 3) 
intervention with an AGI; 4) random allocation to the comparison groups; 5) at least 
one of the following outcome measures: mortahty, morbidity, quality of life, glycémie 
control, insulin or C-peptide levels, lipids, body weight, or adverse effects. 
When a study could not be excluded on basis of tide or abstract alone, it was 
included and retrieved for further scrutiny. Two independent reviewers read all titles 
and abstracts. Interrater agreement was calculated by kappa statistics. 
Data extraction and quality assessment 
The same two independent reviewers extracted all data and assessed quality. For data-
extraction we used an adapted version of a form provided by the Review Group. We 
extracted the following aspects: general items (e.g., setting, sponsoring, ethical 
approval), design (parallel or cross-over, method of randomization, blinding), 
participants (e.g., diagnostic criteria, inclusion and exclusion critena), interventions 
(e.g., dietary reinforcement, dosage schedules), basebne characteristics (e.g., age, sex, 
GHb), and outcomes (e.g., occurrence of mortality, changes in blood glucose and 
measures of variance). We attempted to contact authors in the case of missing 
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information or uncertainties. If necessary, we also extracted data from graphical 
figures. 
Differences in opinion between the reviewers were resolved by consensus, by 
referring back to the original data, or by consulting a third reviewer in case of 
persisting disagreement. 
We assessed and scored the following quality items being adequate or 
inadequate/unclear (14, 15): randomization and allocation concealment (referring to 
selection bias), blinding (performance bias) and handling of drop-outs (attrition bias). 
For studies that had morbidity or quality of bfe as main endpoints, the method of 
blinding outcome assessment was also assessed (detection bias). 
Data analysis 
Available data of sufficient quality were summarized statistically and used for meta­
analyses. We first divided the data into all possible comparisons (e.g., acarbose versus 
placebo, vogbbose versus sulphonylurea) and then subdivided them into all possible 
outcomes (e.g., death, glycated hemoglobin). Finally, within the outcomes we made 
subgroups for the different dosages. Outcomes were calculated per subgroup and for 
all subgroups together. 
Dichotomous data were expressed as odds ratios and continuous data as weighted 
mean differences; the overall results were calculated with the random effects model. 
The measures of effect for all continuous variables were the differences from baseline 
to endpoint. When the SDs for these differences were missing, we first contacted the 
authors for these additional data. If these data were not provided we calculated the SD 
of the difference with the following formula (14): 
oL^paireddifference '· ^^L'pre-m.atmermal i ieJ" ~'~ ^oL/post treatmentvaluej" Ζ Χ Γ X O.L/prc-treatment\alue X 
aUpost-rreatmentvalue) · 
We used a conservative correlation coefficient (r) of 0.4. 
Heterogeneity was assessed by a visual inspection of the forest plots first. In 
addition, we used Ζ score and Chi square statistics. We also used funnel plots to test 
for possible small study bias. Sensitivity analyses were performed to investigate the 
possible influence of the predefined quality criteria (14, 15), language of publication, 
country, source of funding and statistical model (random versus fixed effects models). 
Further, we performed subgroup and meta-regression analyses for baseline GHb, 
mean age, sex, duration of diabetes, duration of intervention, use of a step-up dosage 
schedule, and use of a fixed dose versus an individually titrated scheme. 
We used Revman 4.2.3 (2003, The Cochrane Collaboration, Oxford, U.K.) for all 
analyses, except for meta-regression analyses, which were done with in SAS proc 
Mixed (version 8.0). 
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1491 records (ode and/or abstract) found in 
CENTRAL, MEDLINE, EMBASE, LILACS, Current 
Contents, send by experts, manufacturers and found by 
hand searching , 
1268 records excluded on basis of tide 
and/or abstract 
223 records initially included 
139 double records 
84 references initially included and retneved 
for further review 
15 excluded after reading full article 
69 references finally included 
' 
28 references to multiple or double 
publications 
41 studies included 
Figure 4.2.1. Study flow diagram 
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Results 
Interrater kappa for agreement on inclusion read by the two reviewers was 0.74 (95% 
CI 0.67 to 0.81). All differences in opinion were resolved by consensus. We included 
41 studies in the systematic review (Figure 4.2.1) (16-56). Fifteen studies were 
excluded after reading the full article. Eleven studies investigated the use of AGI in 
addition to other antidiabetic therapy, and there was no clear report of a diet-only 
subgroup (57-67). Two studies had a duration less than 12 weeks (68, 69), one study 
was not randomized (70) and one study included patients with impaired glucose 
tolerance (71). In addition, we found three trials in registers of ongoing trials (72-74), 
but we were not able to obtain pubbshed or unpublished reports. 
The main study characteristics are listed in Table 4.2.1. All but three studies (33, 
36, 38) showed one or more deficiencies or insufficient reporting of the main quality 
criteria. Pharmaceutical companies sponsored 33 studies, 2 studies were sponsored by 
another fund, 1 study was not sponsored, and possible sponsoring was unclear for 5 
studies. We attempted to contact all authors for data clarification, which led to 
additional data for 22 studies. 
Effects on mortality and morbidity 
Three studies reported mortality and found no differences between treatment groups 
(24, 37, 40). The trial performed within the United Kingdom Prospective Diabetes 
Study (UKPDS) reported prospectively collected data concerning "any diabetes-
related endpoint" and microvascular disease. The relative risks for acarbose compared 
with placebo were 1.00 (95% CI 0.81 to 1.23) and 0.91 (95% CI 0.61 to 1.35), 
respectively. Another study with miglitol found statistically significant less 
cardiovascular events in the miglitol-treated patients than in patients treated with 
glyburide (17 vs. 29%), but these outcomes were derived from the safety data and not 
collected in a well defined and prospective way (40). 
Meta-analyses 
Most data for meta-analyses were available from studies with acarbose. The main 
overall results are summarized in Table 4.2.2. 
Glycémie control 
Compared with placebo acarbose decreased G H b by 0.77% (95% CI 0.64 to 0.90) 
(Appendix A) and miglitol by 0.68% (95% CI 0.44 to 0.93), respectively. For 
voglibose, only one study was available, which yielded a difference of 0.47% in favour 
of voglibose (95% CI 0.31 to 0.63) (43). With respect to GHb, we found no evidence 
for a dose dependency for acarbose in the range from 50 mg t.i.d. to 300 mg d.d.. The 
106 
Diet and alpha-glucosidase inhibition in the early treatment of type 2 diabetes mellitus 
subgroup analyses for acarbose 50 mg, 100 mg, 200 mg and 300 mg t.i.d. showed a 
decrease in G H b of 0.90%, 0.76%, 0.77% and 0.78% respectively (Appendix A). In 
contrast, for miglitol such a dose dependency seemed to be present; miglitol 25 mg, 50 
mg, 100 mg and 200 mg t.i.d. decreased G H b by 0.46, 0.58, 0.79 and 1.26%, 
respecdvely. However, the results from this meta-analysis are based on seven 
comparisons, of which four were derived from one (multi-arm) trial (28). 
In the subgroup analysis and meta-regression analyses, we found a tendency 
towards a larger effect on G H b of acarbose at higher baseline levels for GHb. The 
subgroup analyses for studies with baseline G H b <7%, 7-9% and > 9 % yielded a 
decrease in G H b of 0.56% (95% CI 0.36 to 0.76), 0.78% (95% CI 0.63 to 0.93) and 
0.93 (95% CI 0.53 to 1.33), respectively. In the meta-regression analysis with effect on 
G H b as dependent and baseline G H b as independent variable, we found a regression 
coefficient o f -0 .12 (95% CI -0.26 to 0.03), indicating an extra 0.12% G H b decrease 
for every 1% higher baseline GHb. 
The subgroup-analysis for study duration yielded that long-term studies (more than 
24 weeks) showed less effect on GHb. The decrease in G H b for studies with a 
duration of less than 24 weeks, equal to 24 weeks and more than 24 weeks was 0.77 
(95% CI 0.61 to 0.93), 0.82 (95% CI 0.63 to 1.01), and 0.53 (95% CI 0.20 to 0.87) 
respectively. This was mosdy due to the data from the UKPDS study (duration 156 
weeks) in which a decrease of only 0.19% on G H b was found (95% CI —0.29 to 0.67) 
(37). 
In the subgroup and meta-regression analyses, we also found that the application 
of a fixed dosage scheme and the absence of a step-up dosage scheme, increased the 
effect on glycémie control, but also increased the occurrence of side effects (data not 
shown). 
For acarbose fasting blood glucose decreased by 1.09 mmol/1 (28 comparisons; 
95% CI 0.83 to 1.36), for miglitol by 0.52 mmol/1 (2 comparisons; 95% CI 0.16 to 
0.88), and for vogUbose by 0.60 mmol/1 (1 comparison; 95% CI 0.23 to 0.9η. One 
hour posdoad glucose decreased by 2.32 mmol/1 (acarbose; 22 comparisons; 95% CI 
1.92 to 2.73), 2.70 mmol/1 (miglitol; 2 comparisons' 95% CI -0.14 to 5.54) and 2.40 
mmol/1 (voglibose; 1 comparison; 95% CI 1.83 to 2.97). In contrast to the outcome 
for G H b , acarbose showed a dose-dependent decrease of posdoad glucose. Acarbose 
50 mg, 100 mg, 200 mg, and 300 mg t.i.d. reduced posdoad glucose by 1.63, 2.26, 
2.78, and 3.62 mmol/1, respectively (Appendix B). 
Data from studies that compared AGI with other blood glucose lowering 
interventions were scarce. Pooling of results was only possible for the comparison 
acarbose with sulphonylurea. The overall comparison of acarbose with sulphonylurea 
yielded a non-significant advantage for sulphonylurea with respect to overall G H b of 
0.38% (Appendix C). However, seven of the studies in the meta-analyses used unequal 
comparators, because they compared a fixed dose of acarbose with individually 
adjusted dosages of sulphonylurea (24, 30, 35, 44, 47, 49) or a usual dose of acarbose 
with a very low dose of glibenclamide (32). The results for the subgroup "acarbose 
100 mg versus glibenclamide 3.5 mg" were not consistent with the other comparisons. 
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T a b l e 4.2.1. Charactenst ics of 41 r a n d o m i z e d control led trials of at least 12 weeks durat ion, c o m p a r i n g A G I s with any o t h e r intervent ion 
o 
D-










5 B. Interventions 
(16) Germany, G P 
(17) Scodand, O P 
(18) Spain, O P 
(19) United Kingdom, GP 
(20) Asia, O P 
(21) Canada, O P 
(22) Canada, OP 
(23) USA, O P 
(24) USA, O P 
(25) USA, O P 
(26) Russia, O P 
(27) Switzerland, O P 

































































































AC A 100mgt.i.d., PLA 
ACA max. 200-100-200 mg (decreased with 
intolerance), PLA 
ACA100mgt.i.d., PLA 
ACA 50 mg t.i.d., ACA 100 mg 11 d , PLA 
ACA100mgt.i .d.,PLA 
ACA max 200 mg t.i.d. (utrated), PLA 
MIG 100 mg t.i.d., metformin 500 mg t.i.d., PLA, 
(combination of MIG and metformin) 
ACA max 300 mg t.i.d (titrated), PLA 
ACA 200 mg t.i.d., tolbutamide max 1000 mg t.i.d. 
(titrated), PLA, (combination ACA and tolbutamide) 
ACA 100 mg t.i.d., ACA 200 mg t.i d., ACA 300 mg 
t.i.d., PLA 
ACA 100 mg t i d , PLA 
ACA 50 mg b.i.d., PLA 
MIG 25 mg t.i d , MIG 50 mg 11 d , MIG 100 mg t.i.d., 
MIG 200 mg t.i.d., PLA 
Table 4.2.1 continued 
(29) Europe, O P 
(30) N o blinding, Germany, OP 
(31) Cross-over study, Italy, O P 
(32) Germany, OP 
(33) Germany, OP 
(34) Cross-over, Germany, O P 
(35) Single-blind (for gbbenclamide), 
Germany, OP 
(36) Single-blind (for metformin), Germany, 
O P 
(37) England, OP 
(38) Germany/France/Spain, O P 
(39) Japan, OP 
(40) USA, O P 
(41) USA, O P 
(42) USA, O P 
(43) Japan, setting unclear 
(44) Single-blind (for glibenclamide), O P 
(45) Canada, OP 



































































































































































ACA 25 mg u.d., ACA 50 mg t.i.d., ACA 100 mg 11 d., 
ACA 200 mg 11 d , PLA 
ACA 100 mg t.i d , gbbenclamide max 3 5 mg t.i d. 
(titrated) 
ACA 100 mg t i d , PLA 
ACA 100 mg 11 d , gbbenclamide 1 mg 11 d , PLA 
ACA 100 mg t id., PLA 
ACA 200 mg b ι d., MIG 200 mg b ι d , gbbenclamide 
7 mg q d. 
ACA 100 mg t.i d., gbbenclamide max 3.5 mg 11 d 
(titrated) 
ACA 100 mg t.i d., metformin 850 mg b.i.d., PLA 
ACA 100 mg 11 d (decreased in case of intolerance), 
PLA 
ACA 100 mg 11 d (decreased in case of intolerance), 
nategbnide 120 mg 11 d. 
ACAlOOmgt.i.d., PLA 
MIG 25 mg t i.d., MIG 50 mg 11 d , glybunde max 20 
mg q d. (Utrated), PLA 
MIG max. 200 mg t.i.d. (decreased in case of 
intolerance), PLA 
MIG 100 mg 11 d (decreased in case of intolerance), 
PLA 
MIG 50 mg t.i.d , VOG 0 2 mg t.i d , PLA 
ACA 100 mg 11 d , gbbenclamide max 3.5 mg t.i d 
(titrated), PLA 
ACA max l O O m g t i d (utrated), PLA 
MIG 100 mg t.i.d., gbbenclamide mg b ι d ( + 1 PLA) 
Table 4.2.1 continued 
(47) N o blinding, Germany, G P 
(48) Europe, setting unclear 
(49) N o blinding, Turkey, O P 
(50) Italy, O P 
(51) New-Zealand/Australia, O P 
(52) Europe, OP 
(53) N o blinding, Germany, O P 
(54) N o blinding, Japan, O P 
(55) The Netherlands, G P 
(56) China, O P 
24 Α Β - Β 76 57 5 N D 27.7 ACA 100 mg t.i.d, glibenclamide max. 10.5 mg in 2 
dose (titrated) 
24 Β Β Β Β 603 N D N D N D ACA 100 mg t.i.d., MIG 50 mg t.i.d.,MIG 100 mg 
t.i.d., PLA 
24 A A - Β 72 54.4| 42.1φ 53.6φ ACA max. 100 mg t.i.d (may be reduced), gliclazide 80 
mg b i d (in general, max. dose not recommended) 
16 Α Β Β Β 84 55.81 35.9φ 51 5φ ACA 50 mg ti.d., ACA 100 mg u.d., PLA 
16 Β A A Β 105 56.5 36 23.5 ACA 100 mg ( t.i.d.) (decreased in case of intolerance), 
PLA 
24 Β Β A Β 201 58.7φ 42φ N D MIG 100 mg 11d.,glibenclamide 3.5 mgq.d. (or b i d . 
when hypoglycemia was unacceptable) 
24 Α Β - Β 72 59.5φ 60): N D ACA 100 mg 11 d., glibenclamide max. 3.5 mg 
(titrated) 
12 Β Β - Β 36 50.5 28φ 0 V O G 0.3 mg t.i.d., glybunde 1.25 mg q.d., diet therapy 
30 A A A Β 96 58 6 48 0 ACA max. 100 mg t.i.d. (titrated), tolbutamide max 
2000 mg in 3 doses (titrated) 
24 Β Β Β A 77 49 3 48 49.8 ACA 100 mg t i.d., PLA *Except when indicated, all studies were parallel and double blind, f A, adequate, B, inadequate, unclear. φΑΙΙ values except these are based on all randomized patients. 
§subgroup of patients treated with diet only. | | Based on proportion of patients in analysis, number of patients randomized m diet-only group not reported 
ACA, acarbose; GP, general pracuce; MIG, miglitol; N D , N o available data; OP, outpatient; PLA, placebo, VOG, voglibose 
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This discrepancy remained unexplained. Leaving this subgroup out of the meta-
analysis yielded an overall effect of 0.63% (95% CI 0.26 to 1.00) in favour of 
sulphonylurea. In the same comparison, outcomes for the meta-analyses for fasdng 
and 1-h posdoad blood glucose were 0.69 mmol/1 in favour of sulphonylurea (95% CI 
0.16 to 1.23) and 0.10 mmol/1 in favour of acarbose (95% CI -0.43 to 0.22) (37). 
Insulin levels 
Compared to placebo, acarbose had no effect on fasting insulin levels and a lowering 
effect on 1-h posdoad insulin levels of 40.8 pmol/1 (95% CI 21.0 to 50.6). For mightol 
and voglibose, only a limited number of comparisons were available, and no 
statistically significant effects were found (Table 4.2.2). 
Compared with sulphonylurea, acarbose had a statistically significant decreasing 
effect on fasting insulin of 24.8 pmol/1 (7 comparisons; 486 participants, 95% CI 6.3 
to 43.3) and 1-h posdoad insulin of 133.2 pmol/1 (7 comparisons; 483 participants, 
95% CI 81.8 to 184.5) (Table 4.2.2). 
Plasma lipids 
Meta-analyses were only possible for studies with acarbose. We found a small effect of 
-0.09 mmol/1 for acarbose on triglycerides that was borderline statistically significant 
(95% CI -0.18 to 0.00; p=0.06). The effect on triglycerides became smaller and lost 
statistical significance in the sensitivity analysis excluding studies with inadequate 
randomization and the analyses excluding studies with high total and selective dropout 
rates. No other effects on other lipids were found. 
Body weight 
We found that acarbose had a statistically significant decreasing effect on BMI of 0.17, 
but the effect on the outcome "body weight" was not statistically significant (Table 
4.2.2). We found no beneficial effects on body weight for acarbose compared with 
sulphonylurea. 
Adverse events 
We used the total number of patients that experienced at least one adverse event. 
Most studies reported that gastrointestinal events occurred most frequendy. But for 
most reports, the definitions were insufficiendy similar to be used for meta-analysis. 
Compared with placebo, patients treated with acarbose had significandy more side 
effects (OR 3.37; RR 1.43) (Table 4.2.2). There was a dose-dependent increase in 
adverse events in the range 25-200 mg t.i.d. This relationship was even more clear 
when the subgroup of studies that applied a fixed dose (in contrast to an individually 
titrated dose) was analyzed (ORs of 1.95, 4.12, 6.97, and 8.31 for 50,100, 200, and 300 
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Table 4.2.2. Results of overall meta-analysis for the companson of acarbose and miglitol versus placebo and sulphonylurea 
Outcome 
G H b (%) 
Fasting blood glucose 
(mmol/1) 
1-h posdoad blood 
glucose (mmol/1) 
Fasting insulin (pmol/1) 






LDL cholesterol (mmol/1) 
Triglycerides (mmc 
Body weight (kg) 
BMI (kg/m-1) 
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-0.43, 0 22 
-43 3, 6 3 
-184.5,-81.8 
-0 23, 0 05 
















































Continuous data are expressed as weighted mean differences; occurrence of side effects is expressed as odds 
*Number of comparisons (comp), participants (part), f A negative value indicates an advantage for acarbose 
rano Results are calculated with a random effects model, 
or migbtol. N D , N o available data 
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mg acarbose T ID respectively). Results for miglitol were similar (OR 4.01) (Table 
4.2.2). 
Sensitivity analyses were performed for the comparison acarbose versus placebo only. 
As for the other comparisons, the number of included studies was too low. In the 
sensitivity analyses, we found very few statistically significant results. Studies with 
inadequate or unclear randomization showed, in contrast to studies with adequate 
randomization, a statistically significant beneficial effect on total cholesterol: —0.25 
(95% CI -0.47 to -0.03) vs. 0.04 (95% CI -0.06 to 0.14). Studies with a high dropout 
rate showed no statistically significant effect on posdoad insulin levels. Non-Pluropean 
studies showed a more profound effect on posdoad glucose levels. Repeating the 
analyses with a fixed effects model yielded a statisdcally significant decrease in fasting 
insulin and body weight. 
Discussion 
In this systematic review of 41 randomized studies on the efficacy of AGIs, we have 
found no evidence for a beneficial effect on morbidity or mortality. In meta-analyses 
we found statistically significant effects on G H b and fasting blood glucose (acarbose 
and miglitol), posdoad glucose and insulin levels, and BMI (acarbose). The effect on 
G H b was more profound in studies with higher baseline values for GHb, and we 
found evidence that this effect was less in studies that lasted longer than 6 months. 
We found no effects on fasting insulin levels and lipids and only minor effects on 
body weight. There was no increase in effect on G H b for acarbose dosages higher 
than 50 mg t.i.d. In general, most evidence and best results were found for acarbose. 
Comparisons with other drugs were limited and mostly hampered by unequal 
comparators. 
With respect to the effect on glycémie control, the results from our review are 
roughly m line with previous reviews. But there are significant differences and 
additional findings. First, we found evidence for a dose-dependent effect on fasting 
and postload blood glucose but not for GHb. This remarkable finding might be 
explained by a lower compliance of patients that received higher dosages. After all, 
occurrence of side effects increased with higher dosages, and the effect of a lower 
compliance will probably hardly affect fasting and posdoad blood glucose as patients 
will not "forget" their medication before a study visit. Secondly, we could not find an 
effect on plasma lipids in a meta-analysis. However, the conclusions from previous 
reviews were not based on a meta-analysis but on the results from single studies. 
Third, we could not confirm the optimistic view on side effects in the previous 
reviews. Although, due to differences in reporting, we were only able to perform a 
meta-analysis for the occurrence of "all adverse events", it was obvious from all 
reports that gastro-intestinal events (flatulence, diarrhoea, stomach-ache) were the 
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most frequent occurring. Finally, we could not affirm the optimistic view about the 
efficacy of AGIs compared with other agents. Only for the comparison acarbose 
versus sulphonylurea were sufficient data available, and these comparisons point in 
the direction of inferior effects on glycémie control and side effects but a clear 
superior effect on fasting and postload insulin levels 
This systematic review included a high number of trials. Because of the strict 
inclusion criteria, studies were similar with respect to key items: all were randomized, 
included patients with type 2 diabetes, and applied AGI monotherapy. Heterogeneity 
by other crucial factors such as comparison drug and different dosages was addressed 
by using different (sub)groups for the meta-analyses. The residual heterogeneity 
seamed to be limited in this review, because visual inspection of the forest plots of the 
main outcomes showed consistent outcomes. Further sensitivity, subgroup, and meta-
regression analyses for a number of possible confounders, including quality items, 
only yielded few significant results. AGIs given as a fixed dose and without a step-up 
scheme have the largest positive effect on G H b but also a worsening effect on side 
effects. 
One of the main limitations of our study was that not all data in the original studies 
were available in a way appropriate for a meta-analysis. This was especially striking for 
one study of long duration and with a high number of participants; data from this trial 
could not be used because the main outcome measure was the time until patients with 
good control on diet alone needed additional medication (19). At least 33 studies were 
sponsored by a pharmaceutical company. Research funded by pharmaceutical 
companies is more likely to produce results favouring the tested drug, which is mosdy 
due to publication bias or inappropriate comparators (75). The risk for publication 
bias is limited since we have done every possible effort to find published and 
unpubbshed studies. However, inappropriate comparators were obvious in the studies 
comparing acarbose with sulphonylurea. 
Clinical applicability and implications for research 
The place of AGIs in the treatment of patients with type 2 diabetes cannot be 
determined from the results of this review alone. Developers of guidelines should 
weigh the best available evidence, preferably from high quality systematic reviews, 
evaluating other drugs in the first line treatment of diabetes. The exact place for AGIs 
also depends on the priorities in diabetes treatment. For example: how important is a 
reduction of (post-load) insulin levels? 
Studies with AGI monotherapy investigating surrogate endpoints such as G H b or 
insulin levels are redundant. Therefore, future research should aim at assessing effects 
on endpoints that are direcdy relevant to patients, such as mortahty or morbidity, 
instead of focusing on surrogate parameters. At least, such endpoints should be 
included in all trials with patients with chronic diseases. Even if the study is 
underpowered for such an endpoint, such data might be useful for a meta-analysis. 
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Appendix C 
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N o evidence for a reduction of myocardial infarctions by 
acarbose 
With great interest we read the article of Hanefeld et al., in which a meta-analysis of 
seven randomised controlled trials was presented. This meta-analysis compared 
acarbose with placebo in patients with type 2 diabetes with respect to the incidence of 
cardiovascular events (1). The conclusion that acarbose can prevent myocardial 
infarctions surprised us because, currendy finishing a Cochrane systematic review on 
the topic (2), we found only scarce outcomes regarding diabetes-related morbidity so 
far Moreover, we were very disappointed that the design and conduct of this study 
was not critically discussed at all, even more so because they suggest major flaws that 
seriously undermine the conclusions. 
The criteria for the selection of these seven long-term randomised controlled trials 
are not cleaii". Studies that are included in meta-analyses should be the result of an 
extensive and systematic search strategy. Failing to do so could result in selection bias, 
affecting the outcome sigmficandy, usually in the direction of the desired outcome (3). 
Also, the results from the largest included study were never pubbshed as a journal 
article and thus not subject to the peer-review process, and two studies were not 
pubbshed at all. The inclusion of unpubbshed studies is a virtue, but the reasons why a 
study has not been pubbshed should be made clear because this might reflect 
methodological flaws or conflicting interests. 
Heterogeneity should not be investigated solely by statistical methods, but firstly 
with a visual inspection of the main study characteristics of each mal. In this meta-
analysis cbnical heterogeneity is obvious. For example, different kinds of co-
interventions were used. We also have concerns about the way the main outcome data 
were collected and handled The authors use the so-called safety data from the original 
studies, an idea that is creative in a fashion. However, safety-data were not collected 
following the rigorous methods as required m controUed trials. 
Possible other causes for a reduction of myocardial infarctions should be 
investigated carefully. First, it should be made clear which study contributes most to 
the results. This might lead to possible other factors related to study design that also 
might explain the results. Secondly, special attention should be paid to the possible 
contribution in each study of additional medication and bfestyle factors. And thirdly, 
the data should be analysed accounting for the intervention that was actually received. 
Since the authors used data from the safety group, an unknown number of patients 
did not actually use acarbose. Usually, dropouts receive some other form of anti-
diabetic treatment and thus it cannot be excluded that the measured effect on 
cardiovascular events is merely the result of anti-diabetic treatment in general, rather 
than the effect of acarbose. Finally, we wonder if the outcome 'any cardiovascular 
event' would still be significant if myocardial infarctions were excluded. If so, the 
conclusion that acarbose has shown preventive effects on 'any cardiovascular event' is 
not logical. 
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In summary, this meta-analysis is subject to publication bias, heterogeneity, 
detection bias and confounding factors. The conclusion that there is evidence for a 
reduction of myocardial infarctions by acarbose is not justified. 
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Meta-analysis of long-tetm studies to assess the effect of 
acarbose on cardiovascular risk reduction — scientifically 
credible: Reply 
The authors criticised our meta-analysis of seven long-term studies to assess the effect 
of acarbose on cardiovascular risk reduction. Two different approaches are generally 
accepted as standard procedures for meta-analyses (1). These are systematic literature 
reviews or meta-analyses of all randomised controlled trials. Our meta-analysis is 
based on the latter approach. As clearly stated in our article, data from all randomised, 
double-blind, placebo-controlled cbnical trials with a minimum treatment duration of 
52 weeks were included. The source was the Bayer Acarbose clinical database. As a 
consequence, pubbcation and selection bias (regarded as substantial risks in the 
situation of systematic literature review) (2) can be excluded. 
Whilst it is true that two studies included in the analyses were not formally 
pubbshed and therefore not subject to peer review, both studies were part of the New 
Drug Appbcation for acarbose. Although we highly respect the quabty and rigour of 
the science journal peer review procedure, we doubt that the drug approval process is 
any less strict (3). The study by Bachmann et al., has in the meanwhile recently been 
pubbshed. 
We agree with Dr. van de Laar et al., that heterogeneity should not be investigated 
by statistical testing alone. We consider only heterogeneity in the treatment effect to 
be problematic for statistical analysis (in accordance with CPMP). Some deviations 
concerning other characteristics could be seen as an advantage for increasing its 
generalisation and external vabdity (2, 4). This said, co-intervention was balanced 
between acarbose and placebo because of the randomisation. It should be mentioned 
that in addition to formal statistical testing, graphical and descriptive methods were 
also employed to confirm homogeneity of treatment effect. 
The use of individual patient data has the advantage of enabbng a common 
outcome variable to be defined across studies (4). Therefore it seems straightforward 
to use safety data to define an outcome based on cardiovascular events. Indeed, we are 
surprised to note the concerns of Dr. van de Laar et al., regarding the safety data 
collection procedure. As a matter of fact, in cbnical trials performed according to 
Good Clinical Practice the occurrence of adverse events is monitored carefully and 
recorded in detail during the trial. 
We would like to point out that in the Cox Proportional Hazards model, patients 
contribute only for the time that they are observed under treatment and only to the 
corresponding treatment group. Moreover, not only the actual number of events 
under treatment and placebo contribute to the analysis, but also the event free times in 
both groups. 
Finally, the 'any cardiovascular event' outcome is indeed still significant, even after 
exclusion of myocardial infarction from the cardiovascular events (HR=0.69, 95% CI: 
0.50-0.95). 
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In summary, our meta-analysis was conducted based on scientifically sound and 
credible principles. Thus the data pubbshed in the European Heart Journal suggest 
that acarbose, in addition to its effect on glycémie control, could have a beneficial 
effect on cardiovascular complications in patients with established type 2 diabetes. 
These results are in line with the beneficial effect of acarbose on cardiovascular 
events, as found in the STOP-NIDDM trial (5). 
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Alpha-Glucosidase Inhibitors for Patients With Type 2 
Diabetes: Response to Van de Laar et al. 
The authors of the Cochrane systematic review carefully analyzed all available studies 
that fulfilled the criteria of randomized clinical trials of at least 12 weeks' duration (1). 
With the exception of one study (2), all registered mortality and morbidity as 
secondary objectives. Glycémie control was the primary7 objective in 40 of 41 of these 
trials. Thus, the major legitimate conclusion of this careful analysis was that "AGIs 
[Alpha-glucosidase inhibitors] have clear beneficial effects on glycémie control" 
mainly through their dose-dependent effect on postprandial hyperglycemia. 
However, the authors also state as one of their main conclusions that they "found 
no evidence for an effect on mortality or morbidity." Although this statement may be 
mathematically correct, it is misleading as it purports to be based on a solid analysis of 
the data from the 41 studies. This is not the case in their meta-analysis. Most of the 
selected trials had a treatment period of <24 weeks; many were of 3-month duration 
only and were therefore not designed and powered to investigate hard clinical end 
points such as morbidity or mortality. This is well reflected by the fact that, as 
reported by the authors, information on morbidity or mortality could only be retrieved 
in 3 of the 41 trials. While one study showed a significant treatment effect regarding 
cardiovascular events, the others presented only general statements without providing 
any detail. It is well known that sample sizes of individual clinical trials are often too 
small to detect clinically important effects reliably and that this is one of the reasons 
why meta-analysis is employed (3, 4). However, hard end points such as cardiovascular 
mortality are going to be very rare in short-term duration studies unless compensated 
for by a huge population sample. Therefore, including short-term duration studies in 
their meta-analysis dilutes the cases of cardiovascular mortality. That biases the 
interpretation of the data analyzed. 
The MERIA (MEta-analysis of Risk Improvement under Acarbose) analysis of 
seven placebo-controlled, long-term, randomized studies examining the effect of 
acarbose on cardiovascular-related mortality and morbidity showed a reduction of 
cardiovascular events in patients with type 2 diabetes (5). This analysis is based on all 
available acarbose studies with a minimum treatment duration of 52 weeks from a 
database including individual patient data. Because of this, publication and selection 
bias were already ruled out, as discussed m the response (6) to the criticism raised by 
van de Laar and Lucassen. Unfortunately, the same criticism voiced previously is 
repeated in their meta-analysis without taking the detailed response into consideration. 
In summary, the MERIA analysis showed a beneficial effect on cardiovascular 
compbeations in patients with established type 2 diabetes, a finding which is in 
accordance with the results from the STOP-NIDDM trial in subjects with impaired 
glucose tolerance (7). 
We fully agree with the authors' statement that prospective trials with the primary 
objective of investigating cardiovascular events and mortality are required to confirm 
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the beneficial effect of acarbose on cardiovascular events in these high-risk 
populations. However, the combined data from the STOP-NIDDM trial and the 
MERIA meta-analysis are highly suggestive of the preventive effects of acarbose on 
cardiovascular complications in subjects with glucose intolerance. 
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Alpha-glucosidase Inhibitors for Patients With Type 2 
Diabetes: Response to Hanefeld et al. 
Hanefeld et al. (1) assert that the conclusion ("no evidence for an effect on mortality 
or morbidity") from our systematic review on the effects of alpha-glucosidase 
inhibitors (AGIs) for patients with type 2 diabetes was biased. Furthermore, they 
claim to have found evidence for such an effect based on their own meta-analysis. We 
disagree with both statements. 
First, we would like to underline that the solid basis of our results is a systematic 
review and that meta-analyses were only applied when this was methodologically 
sound. The extensive search for all possible trials investigating AGI monotherapy 
yielded only one study with prospectively collected data on morbidity or mortality (2), 
so a meta-analysis could not be done with these end points; therefore, we concluded 
that no evidence for an effect on mortality and morbidity could be found (which is 
essentially different from "evidence for no effect"). In the above-mentioned study, it 
was reported that for the entire treatment group (AGIs given both as monotherapy 
and as additional therapy), no effects of acarbose on cardiovascular end points were 
found. 
This makes it quite remarkable that this particular study (2) was not included in the 
MERIA (MEta-analysis of Risk Improvement under Acarbose) study (3). Hanefeld et 
al. assert that this meta-analysis shows a beneficial effect of acarbose on the 
occurrence of myocardial infarctions. If it had been included in the MERIA study, it 
would have been the study with the second longest duration, it would have nearby 
doubled the number of patients, and it would have been the only study with a sound 
method of collecting end points. This points to the fact that the sole use of a 
manufacturer's database is not a reliable method for the selection of studies for a 
meta-analysis and that an extensive systematic review is necessary to reduce the risk of 
selection bias. 
Other differences between the conclusions of MERIA and our Cochrane review 
can be explained by differences in inclusion and methodological robustness. Three of 
the seven studies in MERIA were also included in our Cochrane review, but no 
reliable data on cardiovascular outcomes could be obtained. The four other 
publications were excluded from our review, mainly because no data on AGI 
monotherapy were available or accessible. Moreover, it should be noted that there was 
no quality assessment of the studies included in MERIA. Other serious concerns 
about the MERIA study were expressed in our previous letter and remain largely 
unresolved (4). 
In conclusion, there is currendy no evidence for an effect on cardiovascular 
morbidity and mortality of monotherapy with AGIs in patients with type 2 diabetes. 
In the near future, indirect evidence may be derived from another Cochrane review on 
the effects of AGIs for patients with glucose intolerance (5). We are pleased that the 
authors of the main studies in this field already have assured their cooperation. 
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Abstract 
Background. Alpha-glucosidase inhibitors (AGIs) reduce blood glucose levels and may 
thus prevent type 2 diabetes and cardiovascular disease in patients with impaired 
glucose tolerance. These possible effects, and the effects on quality of life, plasma 
lipids and body weight, have never been investigated in a systematic literature review 
and meta-analysis. 
Objectives. To assess the effects of alpha-glucosidase inhibitors in patients with 
impaired glucose tolerance (IGT) or impaired fasting blood glucose (IFBG), or both. 
Search strategy. We searched The Cochrane Library (Clinical Trials database, formerly 
known as CENTRAL), PUBMED, EMBASE, Web of Science, LILACS, databases of 
ongoing trials, reference lists of relevant reviews, and we contacted experts and 
manufacturers. Date of last search was February 2006. 
Selection criteria. Randomised controlled trials of at least one-year duration in patients 
with IGT or IFBG, or both, comparing AGI monotherapy with any other 
intervendon. 
Data collection and analysis. Two reviewers read all abstracts, assessed quality and 
extracted data independendy. Discrepancies were resolved by consensus or by the 
judgement of a third reviewer. 
Main results. We included five trials (2360 pardcipants), all investigating acarbose, that 
included patients with IGT or patients 'at increased risk for diabètes' (n=l) . Study 
duradon was one, three (n=2), five and six years. One study was at low risk of bias 
and four studies at high risk of bias. Except for the outcome incidence of type 2 
diabetes in acarbose versus no treatment (two studies), meta-analyses were not 
possible. Data from the study at low risk of bias suggests that acarbose decreases the 
occurrence of type 2 diabetes (NNT=I0) , cardiovascular events (NNT=50, based on 
47 events, study not inidally powered for this outcome), post-load blood glucose (—0.6 
mmol/1, 95% CI -1.0 to -0.3) and body mass index (-0.3 kg/m2 , 95% CI -0.5 to -
0.1). N o stadstically significant effects were observed on mortality, other morbidity, 
glycated haemoglobin, fasting blood glucose, lipids and blood pressure. The effects on 
the incidence of type 2 diabetes were confirmed in two studies at high risk of bias (OR 
0.2, 95% CI 0.1 to 0.6). Adverse effects were mostly of gastro-intestinal origin (OR 
3.5, 95% CI 2.7 to 4.4). 
Conclusions. There is evidence that acarbose reduces the incidence of type 2 diabetes in 
patients with IGT. However, it is unclear whether this should be seen as prevention, 
delay or masking of diabetes. Acarbose may prevent the occurrence of cardiovascular 
events, but this finding needs to be confirmed in more studies. 
138 
Diet and alpha-glucosidase inhibition in the early treatment of type 2 diabetes mellitus 
Introduction 
Impaired glucose tolerance (IGT) and impaired fasting blood glucose (IFBG) are 
generally recognised as an expression of abnormal glucose homeostasis that is not 
severe enough to meet the criteria for type 2 diabetes mellitus (DM2). The term IGT 
was introduced in 1979. In the past IGT has been called a 'pre-state' of diabètes or 
'prediabetes'. The term IFBG (sometimes referred to as impaired fasting glycaemia) 
has been introduced much later (2). IGT and IFBG represent different 
pathophysiological mechanisms: IGT is seen as a characteristic of peripheral insulin 
resistance and IFBG is seen as an expression of raised hepatic glucose output and a 
defect in early insulin secretion. On the other hand, there are many similarities, as 
both IGT and IFBG are associated with an increased risk of diabetes and the 
development of (diabetes related) complications such as cardiovascular disease (3). 
Currendy, the criteria for IGT and IFBG are as follows (plasma venous glucose 
concentrations). IGT: fasting blood glucose <7.0 mmol/1 and 2-hours post-load 
blood glucose 7.8-11.0 mmol/1; IFBG: fasting blood glucose 6.1-6.9 mmol/1 (2-hours 
post-load blood glucose <7.8 mmol/1, if measured) (4, 5). In 2003, the ADA 
recommended to change these criteria to 5.6-6.9 mmol/1 (6). 
IGT and IFBG cause no symptoms and the condition should be seen as a risk 
factor more than a disease itself. It is closely related to other risk factors of type 2 
diabetes such as obesity and overweight, unfavourable dietary habits and a shortage of 
exercise. People with IGT or IFBG are at increased risk of developing DM2 and 
cardiovascular disease (even before the onset of diabetes). Thus, the question arises 
whether an intervention in patients with IGT or IFBG could prevent the development 
of DM2 and cardiovascular complications. Lifestyle interventions consisting of 
exercise or diet, or both, showed that the incidence of diabetes might be reduced 
(relative risk reduction) in up to 58% of cases (7-9). In addition, pharmacological 
interventions have been investigated in patients with IGT. Especially drugs that claim 
to intervene with insulin resistance seem appropriate: biguamdes (metformin: 
decreases hepatic glucose output and increases insulin action) (7), thiazolidinediones 
(rosiglitazone, pioglitazone: increase insulin sensitivity by increasing glucose utilization 
in muscle and liver) (10) and alpha-glucosidase inhibitors (see further). 
Alpha-glucosidase inhibitors 
Alpha-glucosidase inhibitors (AGIs) are reversible inhibitors of alpha-glucosidase, an 
enzyme present in the brush border of the small intestine. Currendy, three AGIs exist: 
acarbose, miglitol and voglibose. Emigbtate, a fourth AGI, is currendy not available 
on the market. AGIs delay absorption of complex carbohydrates and thus inhibit 
postprandial glucose peaks and consequendy lower postprandial insulin levels. In the 
treatment of DM2, AGIs have been proven to have beneficial effects on glycaemic 
control and post-load insulin levels but there is no evidence for a reduction of 
mortality or morbidity (11). 
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Potendal side-effects are of special importance in the use of medication in persons 
with IGT or IFBG for two reasons. First, IGT and IFBG are asymptomatic, so 
people will, in contrast to potential side-effects, not notice any direct benefits from the 
medication. Second, because of the chronic and long-lasting character of IGT and 
IFBG, medication will have to be used for a long period of time. Therefore, long-term 
safety is very important. AGIs cause unfavourable dose-dependent side-effects, mosdy 
flatulence and other gastro-intestinal side-effects, when compared to placebo or 
sulphonylurea. But there is no evidence for long-term detrimental effects of AGIs 
(11). 
Existing évidence 
More recentiy, AGIs have been put into a new light as a result of a study on the 
efficacy of acarbose in patients with IGT (12, 13). This study showed that acarbose 
could prevent or delay the development of IGT into DM2. Moreover, it showed a 
reduced risk of cardiovascular disease and hypertension in the acarbose treated group. 
However, the conclusions of this study are heavily debated (14-16). We have found no 
systematic review that focuses exclusively on the efficacy of AGIs for patients with 
IGT or IFBG. 
Objectives 
To assess the effects of alpha-glucosidase inhibitors for people with impaired glucose 
tolerance or impaired fasting blood glucose. 
Methods 
Criteria for considering studies for this review 
Types of studies 
We included randomised controlled trials with a minimum duration of one year. 
Because the common adverse effects of AGIs make true blinding difficult, both 
blinded and non-blinded studies were included. Studies pubbshed in any language and 
all identified trials, published or unpubbshed, were investigated. 
Types ofpartidpants 
Patients referred to as having a prediabedc state, i.e. IGT or IFBG, or both, existing 
or newly diagnosed. Changes in diagnostic criteria, both for IGT or IFBG, or both, or 
diabetes mellitus type 2 (1-5, 17, 18) may have produced variabibty in the clinical 
characteristics of the patients included as well as in the results obtained. We planned 
to explore these differences in a sensitivity analysis. 
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Types of interventions 
Monotherapy with AGIs (acarbose, miglitol or voglibose) compared with: 
1. Placebo; 
2. A non-pharmacological intervention (for example: diet therapy, exercise); 
3. Biguamdes (for example, metformin); 
4. Thiazolidinediones (for example, pioglitazone); 
5. Sulphonylurea (for example, glibenclamide); 
6. Meglitinide (for example, nateglinide); 
7. Any other pharmacological intervention. 
Types of outcome measures 
Primary outcomes 
1. Incidence of DM2: diagnosed with criteria prevailing at the time of the 
diagnosis (1, 2, 4, 5, 17,18); 
2. Morbidity related to impaired glucose metabolism, the metabolic syndrome or 
DM2: vascular complications (angina pectoris, myocardial infarction, stroke, 
peripheral vascular disease, amputation), neuropathy, retinopathy, 
nephropathy, erectile dysfunction, and hyperosmolar nonketotic dysregulation; 
3. Mortahty: Total mortality, mortality related to impaired glucose metabolism, 
the metabolic syndrome or DM2 (death from myocardial infarction, stroke, 
renal disease, or sudden death, death from hyperosmolar nonketotic coma); 
Secondary ou tcomes 
4. Glycaemic control: glycated haemoglobin levels, fasting and post-load blood 
glucose levels; 
5. Plasma lipids (triglycerides, total-, high-density lipoprotein (HDL)- and low-
density lipoprotein (LDL)-cholesterol); 
6. Blood pressure: diastolic and systolic blood pressure; 
7. Fasting and post-load insulin and C-peptide levels; 
8. Body weight (or body mass index); 
9. Adverse effects (e.g. diarrhoea, stomachache, flatulence); 
10. Quality of life, assessed with a validated instrument; 
11. Costs; 
Specific patient covariates, effect modifiers, confounders 
12. Compliance. 
Timing of outcome assessment (length of intervention) 
We assessed a possible influence of treatment duration in a sensitivity analysis. 
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Search strategy for identißcation of studies 
Electronic searches 
We used the following sources for the identification of trials: 
• The Cochrane Librar)' (2006, issue 1); 
• PUBMED (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi) (contains 
MEDLINE and a number of additional life science journals, 1966 - February 
2006); 
• EMBASE (1974 - October 2005); 
• LILACS (www.bireme.br/bvs/I/ibd.htm) from 1986 to March 2006; 
• Web of Science (contains: Science Citation Index Expanded 1945 - February 
2006; Social Sciences Citation Index 1956 - February 2006; Arts and 
Humanities Citation Index 1975 - February 2006). 
Databases of ongoing trials (latest access March 2006): 
• Current Controlled Trials (http://www.controlled-trials.com - with links to 
other databases of ongoing trials); 
• UK National Research Register (http://www.update-
software.com/National/nrr-frame.html); 
• USA - CenterWatch Clinical Trials Listing Service 
(http://www.CenterWatch.com/); 
• USA - National Insututes of Health (http://clinicalstudies.info.nih.gov/); 
• Dutch Trial Register (Nederlands Trial Register) (http://www.trialregister.nl/). 
The described search strategy (see below) was used for PUBMED. For use with 
EMBASE and Web of Science the strategy was slighdy adapted because these 
databases have different interfaces. The necessary changes in the search string were 
done in such a way that the search became more sensitive (i.e. yields a higher number 
of 'hits'). In The Cochrane Library, LILACS and the databases of ongoing trials we 
searched with the various text words for the AGIs and their brand names. 
Search strategy 
We combined three different search strategies (see: Appendix A): 
1. for alpha-glucosidase inhibitors we used a strategy used for a recent systematic 
review on AGIs (11); 
2. for controlled trials we used a sensitive validated search strategy (19); 
3. for IGT and IFBG we developed a search strategy combining keywords 
(MeSH headings) and text words. We extensively tested it by running the 
search and subsequendy investigated whether known key-studies were not 
included, we then adjusted the model unni we didn't find any relevant study 
that was not found by the search string. 
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Handsearching 
We searched reference lists of relevant trials and AGI reviews and selected possible 
references that were already in our own files. 
Other search strategies 
Authors of relevant identified studies and other experts were contacted by mail in 
order to obtain additional references, unpublished trials, and ongoing trials or to 
obtain missing data not reported in the original trials. Similarly, manufacturers and 
patent holders (Bayer AG, Sanofi-Synthelabo, Pfizer, Takeda) were contacted in order 
to retrieve information on AGIs trials, published and unpublished. 
Methods reviewing process 
Selection of studies 
Two reviewers (FVDL and PL) independently checked the titles, abstract sections and 
keywords of every record retrieved. Full articles were retrieved for further assessment 
when the information given suggested that the study: (1) included patients with IGT 
or IFBG; (2) compared AGIs with placebo or any other control; (3) assessed one or 
more relevant predefined clinical outcomes; (4) used random allocation to the 
comparison groups. In case of any doubt regarding these criteria from the information 
given by the title and abstract, the full article was retrieved for clarification. Interrater 
agreement for study selection was assessed using the kappa statistic (20). A third party 
(EVDL) resolved differences in opinions between the two reviewers. If resolving 
disagreement was not possible, the article was added to those 'awaiting assessment' 
and the authors were contacted for clarification. If no clarification was provided, we 
planned to consult the review group editorial base. 
Quality assessment of trials 
The two reviewers (FVDL and PL) assessed each trial independently. Possible 
disagreement was resolved with consensus, or with consultation of a third reviewer 
(EVDL) in case of disagreement. We assessed the following quality items: 
Minimisation of selection bias 
• Randomisation procedure: the randomisation procedure was scored 'adequate' 
if the resulting sequences were unpredictable (e.g. computer generated 
schemes, tables of random numbers, coin tossing); 
• Allocation concealment: allocation concealment was scored 'adequate' if 
participating patients and investigators could not foresee the assignment (e.g. 
by central randomisation remote from trial site, sequentially numbered and 
sealed radio-opaque envelopes). 
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Minimisation of performance bias 
• Method of blinding: bunding was scored 'adequate' if the two (or more) drugs 
/ pills were similar in size, colour and shape or when a double-dummy method 
was applied. Because of the sometimes-obvious adverse effects of AGIs, true 
blinding is difficult. For trials that reported bbnding of patients for 
medications, we also investigate whether blinding was checked (for example by 
asking patient and investigator afterwards about the medication they suspected 
to have been supplied with). 
Minimisation of attrition bias 
• Handling of drop-outs: handling of drop-outs was considered 'adequate' when 
studies reported a complete description of all patients failing to participate 
until the end of the trial and if the data were analysed on intention-to-treat 
(ITT) basis, that means with all randomised patients included; 
• Quantity of dropouts: overall dropout rate less than 15% was considered 
'adequate'; 
• Selective dropout: a difference in dropout rates between the main treatment 
groups less than 10% was considered 'adequate'. 
Minimisation of detection bias 
• Method of blinding outcome-assessment: outcome assessment was considered 
'adequate' if the outcome assessors were completely blind for the intervention. 
This item was considered less relevant for studies with laboratory data or death 
as main outcomes; 
• Method of blinding of analysis: this was considered 'adequate' if the outcome 
assessors (investigators, statisticians) were completely blind for the 
intervention up to the point that all analyses were completed. Blinding of 
analyses is to date not a common practice in the conduct of randomised trials. 
Therefore we only planned to explore possible influences of blinded analyses 
in a sensitivity analysis and we did not plan to use this item for the overall 
quality assessment. 
Following these criteria, studies were broadly subdivided into the following three 
categories using an adapted version of the Cochrane Handbook criteria: 
A. All quality criteria met (1. adequate randomisation and allocation concealment, 
2. adequate blinding, 3. adequate ITT analysis or both drop-out rate less than 
15% or selective drop-out less than 10%, or both 4. adequate bbnding 
outcome-assessment): low risk of bias. 
B. One or more quality criteria only partially met (1. inadequate randomisation or 
inadequate allocation concealment, 2. mentioning of bunding but exact 
method unclear, 3. inadequate/unclear ITT analysis but drop-out less than 
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15% or selective drop-out less than 10%, 4. mention of blinding outcome-
assessment but exact method unclear): moderate risk of bias. 
C. One or more quality criteria not met (1. inadequate randomisation and 
allocation concealment, 2. inadequate or no blinding, 3. inadequate ITT and 
drop-out rate equal to or greater than 15% and selective drop-out equal to or 
greater than 10%, 4. inadequate blinding outcome-assessment): high risk of 
bias. 
We explored the influence of individual quality criteria in a sensitivity analysis (see 
under 'sensitivity analyses'). The two reviewers discussed all quality items. In cases of 
disagreement, a third reviewer was planned to be consulted (EVDL). 
Data extraction and management 
Two reviewers extracted data on intervention and outcomes independently, using a 
pre-tested data extraction form that was adapted from a standard form provided by 
the review group. The data extraction form included the following items: 
General information: author, type of publication (including the existence of duplicate or 
multiple publications), year of publication, language, country where the study was 
conducted, setting (general practice, hospital or outpatient / rural, city, developed / 
developing world / single or multi-centre), the stated aim of the study pubbshed, 
sponsor(s), ethics approval; 
Study characteristics: parallel or cross-over, type of control groups (placebo, other 
medication etc.), existence of run-in or wash-out period, or both, description of 
possible carry-over effect (for cross-over studies), method, type and quality of 
randomisation, method and quality of allocation concealment, method and quality of 
blinding, information about handling of drop-outs, withdrawals and losses to follow-
up, numbers of and reasons for drop-out, method and quality of blinding of outcome 
assessment (if applicable), method and quality of blinding of analyses, existence of 
possible sub-groups, method of assessment of compliance; 
Participants: description of diagnostic criteria for IGT or IFBG, or both, and diabetes 
mellitus type 2, inclusion and exclusion criteria; 
Interventions: specification of possible lifestyle co-intervention, the nature, dose and 
regimen of AGI(s) and control interventions, duration of intervention and follow-up; 
Baseline characteristics and measurements: numbers of patients, sex, age, ethnicity, socio-
economic status and duration of diabetes, other risk factors for DM2 or 
macrovascular disease (familiar disposition, history of gestational diabetes, exercise, 
smoking) existence of significant differences at baseline, baseline glycated 
haemoglobin, fasting and post-load blood glucose, plasma lipids (triglycerides, total-, 
HDL- and LDL-cholesterol), height, weight and body mass index (BMI), fasting and 
post-load insulin and C-peptide (standard deviations if applicable), specifications 
(including reference ranges) of all laboratory measurements, type of post-load test, 
time between fasting and post-load measurements, centralisation of laboratory 
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measurements, assessment of health-status, definitions of health outcomes (e.g. 
myocardial infarction, heart failure, renal failure); 
Outcomes: total and disease specific deaths and morbidity, quality of life (including 
method of assessment), mean changes (standard deviation, SD) of the following 
values: glycated haemoglobin, fasting and post-load blood glucose, lipids, fasting and 
post-load insulin / C-peptide, body weight, BMI, occurrence of adverse events (total 
and gastro-intestinal), compliance, costs. 
Differences in data extraction were resolved by consensus, referring back to the 
original article. If necessary, information was sought from the authors of the original 
studies. If necessary, we also planned to extract data from graphical figures: two 
reviewers (FVDL and PL) would calculate the data independently and if both 
outcomes were not similar, a third reviewer (EVDL) would recalculate the data. A 
statistician checked all extracted data for errors, after transfer to the database. 
Data analysis 
The table of comparisons was divided in all possible comparisons first (e.g. acarbose 
versus placebo), then sub-divided into all possible outcomes (e.g. death, glycated 
haemoglobin, adverse events) and finally, within the outcome sub-groups were made 
for the different dosages. Outcomes were calculated per sub-group and for all sub-
groups together. 
Dichotomous data were expressed as relative risks (RR). We calculated the risk 
difference (RD) and we converted the RD into the number needed to treat (NNT) or 
the number needed to harm (NNH) taking into account the time of follow-up. 
Condnuous data were expressed as weighted mean differences (WMD) and an 
overall WMD was calculated. We used the differences from baseline to endpoint as 
the actual measure of effect of all continuous variables. The standard deviations of 
these differences are essential for the data to be included in the meta-analysis. If the 
standard deviaüon (SD) of the difference were not reported, we first asked the authors 
to provide these data. If the SDs were not provided we estimated the SD of the 
difference with the following formula: 
SDpaTedcLfferenc^VKSDl)2 + ( S D 2 ) 2 - 2 Χ Γ X S D l X S D z ] 
SDpaireddjffcrcnce=standard deviation of the difference (pre- / post-treatment) 
SDi=Standard deviation of the pre-treatment value, SDz^Standard deviadon of the 
post-treatment value, r=correlation coefficient. We used a conservative correlation 
coefficient of 0.4. 
Overall results were calculated based on the random effects model. Heterogeneity was 
statistically tested by using the Ζ score and the Chi2 statistic with significance set at 
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P<0.10. Quantificadon of the effect of heterogeneity was assessed by means of I2, 
ranging from 0-100% including its 95% confidence interval (21). I2 demonstrates the 
percentage of total variation across studies due to heterogeneity and was used to judge 
the consistency of evidence. Possible sources of heterogeneity were (planned to be) 
assessed by subgroup, sensitivity and meta-regression analyses as described below. 
The analyses were done with Review Manager (RevMan 4.2). 
Subgroup analyses 
We planned to invesügate main outcome measures by subgroup analyses in order to 
explore differences in effect as follows: 
1. Glycated haemoglobin level at baseline (subdivided into groups, based on 
data); 
2. Age (subdivided into groups, based on data); 
3. Gender (subdivided into groups, based on data); 
4. Body mass index (BMI) (subdivided into groups, based on data); 
5. Different kinds of lifestyle co-interventions used (i.e. dietary advice, exercise, 
help with smoking cessadon, combined intervendons); 
6. Duration of intervendon (subdivided into groups, based on data); 
7. Use of an individually titrated versus fixed dose of AGI; 
8. Use of a step-up dose versus administering the full dose immediately. 
Sensitivity analyses 
We planned to perform sensitivity analyses for a number of factors by comparing the 
results of the meta-analysis for studies with and without certain characterisdcs. Data 
from a minimum of five studies had to be available for both groups to be considered. 
The following factors were planned to be investigated: 
1. Comparing published and unpubhshed studies; 
2. Comparing studies with and without (or with unknown) quality characterisdcs: 
adequate randomisation, adequate allocation concealment, adequate method of 
blinding, adequate ITT analyses, adequate blinding of outcome-assessment (if 
applicable), adequate method of blinding of analyses. Further, comparing 
studies with an overall drop-out rate of more than or equal to 15% and less 
than 15%, differences in drop-out rates less than 10% and more than or equal 
to 10% between the main treatment groups. In addition, the overall score for 
quality based on the Cochrane criteria was used (studies with score A and Β 
compared to studies with Q ; 
3. Repeadng the analyses excluding trials using the following filters: diagnostic 
criteria (patients with IGT / IFBG / both), language of publication, source of 
funding (industry versus other or no sponsoring) or country; 
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4. Repeating the analyses using different measures of effect size (relative risk, risk 
difference) and different statistical models (fixed and random effects models); 
5. Repeating the analyses excluding large studies or studies with a long duration 
(based on data) to establish how much they dominate the results; 
6. Repeating the analyses excluding studies in which other risk factors for the 
development of DM2 or macrovascular disease were not equally distributed 
between treatment groups. 
Meta-regression analyses 
We planned to use meta-regression analyses (in SAS proc MIXED, version 8.0) to 
explore the influence of characteristics of study population and study design on the 
outcomes. We planned to examine all dependent variables for which sufficient studies 
are available; the minimal number of studies would need to be 10 to gain sufficient 
power. The independent variables were similar to the pre-defined sub-groups. The 
weight of each trial would be equal to the inverse sum of the within trial variance and 
the residual between trial variance, in order to perform a random effects analysis. 
Assessment of small study bias 
Small study bias was planned to be tested by using the funnel plot or other corrective 
analytical methods depending on the number of clinical trials included in the 
systematic review (22-24). 
Results 
Descrìption of studies 
Trials identified (see Figure 5.1) 
PUBMED: 224 records were retrieved and assessed on basis of tide or abstract, or 
both (until March 22nd 2006), 13 records were initially included for further reading 
and 12 were included in the final review. 
EMBASE: 551 records were retrieved and assessed on basis of tide or abstract, or 
both (until October 21st 2005), 20 records were initially included for further reading 
and 19 were included in the final review. 
Cochrane Library: 432 records were retrieved and assessed on basis of tide or abstract, 
or both (issue 1 2006), 10 records were initially included for further reading. All of 
those records remained included in the final review. 
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1489 records (tide and/or abstract) found in 
CENTRAL, PUBMED, EMBASE, Lilacs, Web of 
Science, databases of ongoing tnals, send by experts, 
manufacturers and found by handsearching , 
1409 records excluded on basis of tide 
and/or abstract 
81 records initially included 
37 double records 
44 references initially included and retneved 
for further review 
4 references (3 studies) excluded after 
reading full article 
40 references finally included 
' 
33 references to multiple or double 
publications 
7 studies included: 5 finished, 2 ongoing 
Figure 5.1. Study flow diagram 
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Web of Science: 117 records were retrieved and assessed on basis of tide or abstract, 
or both (until February 7th 2006); eight records were initially included for further 
reading. All of those records remained included in the final review. 
LILACS: 95 records were retrieved and assessed on basis of tide or abstract, or both 
(until February 7th 2006). None of these references were initially included. 
Experts: We obtained two references by corresponding with experts or authors. One 
of those references referred to a study that was included in the final review (25). 
Manufacturers: Bayer is the developer of acarbose and miglitol and Takeda the 
developer of voglibose. Sanofi-Synthelabo is patent holder of miglitol. Bayer send us 
four references, four were initially included and three were finally included in the 
review. Takeda and Sanofi did not reply to our letters. 
Handsearchmg (checking references of existing reviews, browsing on the Internet, 
posters on congress etc.): Twenty-one references found by handsearching seemed 
possibly interesting based on tide or abstract, or both. Nineteen references were finally 
included. 
Databases for ongoing trials: we retrieved 43 records, four of which were initially 
included (last search March 22nd 2006). Thus far, we did not receive any 
(un)published data that gave cause to exclude those studies for the review. Two of 
those studies were finished by the time of retrieval (26, 27) and two other studies were 
started in 2005 and will be completed in 2009 (28) and 2013 (29) (Table 5.1). 
Interrater agreement 
Interrater kappa for agreement on inclusion, calculated on basis of the first 1210 tides 
or abstracts, or both, read by the two reviewers (FVDL and PL) was 0.77 (95% 
confidence interval 0.65 to 0.90). All differences in opinion were resolved by 
consensus. 
Missing data 
We contacted all authors for data clarification and missing data. This was successful 
for one study (12). The corresponding author of the DAISI study (27) sent us the full 
statistical report with the restriction that we were not allowed to use the data before 
their manuscript was accepted for publication. The authors of the EDIT (26) study 
promised us to sent more details once their manuscript was m the galley-proof stage. 
For the other two studies the authors did not reply to our letters and mails (30, 31). 
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Cardiac Events in 
Patients With 
Myocardial Infarction 





Pauents with IGT Acarbose versus Primär)· outcomes: 1 cardiovascular mortality; 2 April 2005, 
and old standard diet and hospitalisation due to cardiovascular events; last follow-up 
myocardial exercise treatment Secondar)' outcomes: 1 all cause mortality, 2 April 2009 
infarction. hospitalisation due to coronary artery disease; 3 
progression of IGT to diabetes, 4 development or 
detenoration of either hypertension or 
hyperlipidaemia, 5 detenoraaon of renal function, 6 
hospitalisation due to cerebrovascular disease; 7 
hospitalisation due to heart failure 
Patients with Acarbose versus Pnmary outcome cardiovascular event free survival May 2005; last 
abnormal glucose standard lifestyle time. Secondar}' outcomes: 1 conversion of abnormal follow-up 
tolerance and modification glucose tolerance to type 2 diabetes, 2 all cause of April 2013 
coronary artery death, 3 occurrence of every cardiovascular event, 4 
disease occurrence of in-stent restenosis, 5 regression of 
intimai plus medial complex of the carotid artery; 6 
change in fasting, 2-hour blood glucose and insulin 
level; 7 change in homeostasis model assessment of 
insulin resistance; 8 change in HbAlc; 9 change in 
lipid profile 
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Excluded studies 
Three studies were initially included but excluded after reading the full ardcle. Two 
studies turned out to be not randomised (32, 33) and one study included patients with 
DM2 (34). 
Included studies 
Five studies with 2360 participants, described in 36 articles, abstracts or web sites were 
finally included in the review. Data and information from the STOP-NIDDM study 
was obtained from 26 references (12, 13, 16, 35-57), for the DAISI study from two 
references (27, 58), for the EDIT study from eight references (25, 26, 59-64), and for 
the studies from Fang et al. (30) and Wang et al. (31) one reference was available. 
Details are given in the Table 5.2. 
Publication type 
Three studies were (predominantly) published as journal articles (12, 30, 31). For the 
STOP-NIDDM study (12) we also considered correspondence and debate articles as a 
result of the main publications. The other two studies were published on a web site or 
as abstracts, or both (26, 27). 
Participants 
Three studies included patients with IGT according to the W H O criteria of 1985 (27, 
30, 31). One study included participants with IGT according to the W H O criteria of 
1999 in addition to a fasting BG >5.6 and <7.8 mmol/1 (12) and one study included 
participants at increased risk for DM2' with a fasting BG 5.5-7.7 mmol/1 (26). In the 
STOP-NIDDM study (12) patients were (mainly) recruited through screening of high-
risk patients and followed as outpatients in study-centres. In the EDIT study (26) the 
patients were 'self-referred' but the exact setting was unclear. Setting and recruitment 
for the other studies remained unclear, thus far. 
Trial design 
All studies had a parallel design. One study had a double-blind 2x2 factorial design 
(26). Two studies were blinded (12, 27) and two studies were not blinded (30, 31). All 
studies investigated acarbose as the alpha-glucosidase inhibitor and compared it to 
placebo (12, 26, 27), metformin (26, 30), diet and exercise (30) or treatment, or both 
(30, 31). Thus far, we found no completed studies with miglitol or voglibose. Study 
duration was six years (26), five years (30), three years (12, 27) and one year (31). In 
one study the treatment duration was followed by a three months wash-out period in 
which both groups were given placebo (12). In all other cases treatment duration was 
similar to the follow-up duration. 
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Study Methods Participants Interventions Outcomes Notes 
DAISI (27), Randomised 
Netherlands controlled double 
blind trial; 




EDIT (26), Randomised 
United controlled, double 
Kingdom blind, 2x2 factonal 
trial, pauents 
randomised for 
both acarbose and 
metformin versus 
placebo 
Duranon 6 years 
(treatment and 
follow-up) 
SETTING: unclear; RECRUITMENT: 
unclear; DIAGNOSIS: 2-hour post-load 
BG >8.6 mmol/1 and <11.1 mmol/1 after 
2 0 G T r s ( W H 0 1985) 
NUMBER. AGI: included 61, completed 
27, ITT 60, PP 32; C included 60, 
completed 33, ITT 58, PP 39, SEX: 'sex 
rano nearly 1:1', AGE (YEARS 
(MEDIAN))· AGI 61; C 56 
BMI: ND, GHB N D 
SETTING: unclear; RECRUITMENT: 
unclear, 'self-referred'; DIAGNOSIS: 
Patients 'at nsk' for developing diabetes, 
Fasong BG 5.5-7.7 mmol/1 
NUMBER: recruited 671, randomised 
631; SEX: 5 1 % Female, 49% Male, AGE 
(YEARS (MEAN (SD)): randomised 
pauents 52,1 (10,0), BMI (KG/M2 
(MEAN (SD)): randomised patients 28,6 
(4,5), GHB (% (MEAN (SD))· all 
randomised patients 5 9 (0 5) 
Diet: unclear 
AGI: acarbose, week 1 50 
mg OD; week 2 50 mg 
BID; week 3 - endpoint 30 
mg TID 
C: placebo, dosing 
schedule not descnbed 
Diet: unclear 
2X2 Factorial design, four 
possible treatments· 
AGI- acarbose 50 mg TID 
+ placebo TID 
CI placebo TID + 
placebo TID 
C2. metformin 500 mg 
TID + placebo TID 
C3: metformin 500 mg 
TID + acarbose 50 mg 
TID 
Incidence of type 2 
diabetes and 'conversion 
to' normal glucose 
tolerance, fasting venous 
glucose; total- and HDL-
cholesterol, tnglycendes; ß-
cell function and insulin 
sensitivity 
Progression to type 2 
diabetes, Quality of life; 
fasting BG, 'lipid profiles'; 
ß-cell function and insulin 









of ongoing studies, 
handsearching 





Sponsor· Bayer and 
Merck-Lipha 
Author contacted: 





of ongoing studies, 
handsearching, 
experts 
Table 5.2 continued 
Study Methods Participants Interventions Outcomes Notes 
Fang (30), Randomised SETTING: unclear; RECRUITMENT: 
China controlled mal, selected volunteers, details missing; 
Duration: 5 years DIAGNOSIS: IGT according to WHO 
(treatment and 1985, NUMBER: 549 volunteers 
follow-up) screened, 178 cases of IGT included· AGI 
50, Cl 40, C2 48, C3 40, analysed AGI 45, 
Cl 35, C2 44, C3 36; SEX (F/M): AGI 
22/28, Cl 18/22, C2 22/26, C3 22/18, 
AGE (YEARS (MEAN (SD)): analysed 
patients: AGI 50 (7), Cl 47 (14), C2 50 
(7), C3 49 (6), BMI (KG/M2 (MEAN 
(SD)) analysed pauents· AGI 24.9 (2.1), 
CI 24.8 (2.5), C2 25.2 (2.8), C3 25.3 (1.9); 
GHB· N D 
Diet: unclear 
AGI: acarbose 25-50 mg 
TID 




(=metformin) 125-250 mg 
TID 
C3 Diet and exercise: 
Education and dietary 
advice and exercise based 
on personal situation 
Incidence of type 2 
diabetes, fasung and 2-
hours post-prandial blood 
glucose, total cholesterol 
and tnglycendes; BMI, 





















3.3 years (SD 1 5) 
treatment penod. 
followed by a three 
months wash out 
penod 
SETTING: Outpauents, 
RECRUITMENT: screening high-nsk 
populations, particularly first degree 
relatives of diabetic patients, 
DIAGNOSIS IGT (WHO 1999)· 2 hour 
BG >7.8 and <11.1 mmol/1 and fasting 
BG >5.6 and <7.8 mmol/1, NUMBER 
randomised 1429, analysed 1368 (AGI 
682, C 686), medication discontinuation, 
AGI 230/682, C 130/686, SEX (F/M): 
analysed group AGI 353/329, C 342/344; 
AGE (YEARS (MEAN (SD)) analysed 
group: AGI 54.3 (7.9), C 54.6 (7 9), BMI 
(KG/M2 (MEAN (SD)): analysed 
pauents: AGI 31.0 (4 3), C 30.9 (4 2), 
GHB (% (MEAN (SD)): analysed 
pauents: AGI 5 24 (0.74), C 5.24 (0.78) 
Diet mstrucuons about 
weight-reducuon and 
exercise reinforced each 
visit 
AGI: acabose, from 50 mg 
(once daily) uputrated to 
100 mg TID or maximum 
tolerated dose. Mean daily 
dose 194 mg (SD 87) 
C: placebo, similarly dised 
as AGI, 'mean dally dose' 
was 238 mg (SD=) 
Mortality, incidence of 
diabetes and cardiovascular 
events, GHB, fasung and 
post-load blood glucose; 
total-, HDL and LDL-
cholesterol, tnglycendes; 
fasung and post-load 
insulin; body weight, BMI, 
diastolic and systolic blood 














Table 5.2 conhnued 
Study Methods Participants Interventions Outcomes Notes 
Wang (31), Randomised SETTING: unclear, RECRUITMENT: 
China controlled mal, unclear; DIAGNOSIS: IGT according to 
Duration: 1 year W H O 1985, NUMBER: randomised AGI 
(treatment and 31, C 30; analysed AGI 30, C 30; SEX 
foUow-up) (F/M): AGI 15/16, C 14/16; AGE 
(YEARS (MEAN (SD)). AGI 64.0 (8.7), C 
63.0 (7.0); BMI (KG/M2 (MEAN (SD)): 
AGI 22.7 (3.4), C 21 0 (3 0); GHB: N D 
Diet: 5 hours dietary 
training 
AGI: acarbose 50 mg TID 
C no treatment 
Incidence of type 2 
diabetes, adverse effects 
Sponsor: unclear 
Author contacted: 
yes, no reply 
Source: 
CENTRAL 
AGI=Alpha-glucosidase inhibitor; BG=Blood Glucose; BID=Bis In Die (twice daily); BMI=Body Mass Index; C=Control ; GHB=Glycated Hemoglobin , 
IGT=Impaired Glucose Tolerance; n T = I n t e n a o n To Treat Population, N D = N o Data, OD=once daily; O G T r = O r a l Glucose Tolerance Test, PP=Per Protocol 
Population; , n D = T e r In Die (three ornes a day) 
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Outcome measures 
All studies reported occurrence of DM2 as a primary outcome. Data on cardiovascular 
morbidity and mortahty was available for the STOP-NIDDM study (12) only. For two 
studies additional data for glycaemic control, lipids, blood pressure and body weight 
were available (12, 30). The DAISI (27) and EDIT (26) studies reported that they 
investigated a number of additional outcomes (e.g. plasma glucose, lipids) but these 
data were not accessible for us thus far. 
Methodological quality (see Table 5.3) 
With respect to selection bias only one study had both an adequate randomisation and 
allocation concealment (12). The risk of attrition bias was low in three studies. 
However, no study had adequate intention-to-treat analysis. Blinding (performance 
bias) was adequate in one study (12) and for two studies information was lacking 
about precise methods of blinding (26, 27). In one study outcomes were adequately 
assessed in a blinded fashion (12). 
The overall quality was roughly assessed on a three-point scale according to the 
Cochrane handbook: one study scored A (low risk of bias) and four studies scored C 
(high risk of bias). 
Heterogeneity 
Because not more than a maximum of two studies could be included per (statistical) 
comparison, formal testing of heterogeneity was not performed. The studies were 
reasonably homogeneous with respect to a number of important items: 
• All trials used acarbose as the alpha-glucosidase inhibitor (all with a dosage of 
50 mg TID, except for the STOP-NIDDM study (12) in which a dosage of 
100 mg TID was given); 
• All trials focused on patients with IGT (instead IFBG), except for the EDIT 
study (26) which included patients 'at risk' for developing diabetes (with a 
fasdng blood glucose 5.5-7.7 mmol/1); 
• In all trials the number of included females and males were almost similar, 
ranging from 47% females (30) to 5 1 % females (12); 
• All trials included patients with a similar age, ranging from a mean of 49.1 
years (30) to 63.5 years (31). 
The following items could cause possible heterogeneity: 
• Two studies were performed in an Asian population (30, 31). The effects of 
alpha-glucosidase inhibitors may be different from European or American 
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populations (the other trials) due to differences in amount and type of 
carbohydrate in the regular diet; 
• The mean BMI ranged from a normal BMI (31) to overweight (26, 30) or 
obesity (12). It was unknown for the DAISI study (27); 
• Baseline glycated haemoglobin was below 6.0% in two studies (12, 26), but 
unknown for the other studies; 
• In two trials, all participants received additional advice on diet and lifestyle (12, 
31) but for the other trials this information was missing. 
Effect of the intervention 
With exception of the outcome 'incidence of DM2' in the comparison 'acarbose 
versus no treatment' in which data from two studies were available (30, 31), we were 
unable to perform meta-analyses in this review because for none of the other 
comparisons data were available from more than one study. 
Acarbose versus placebo 
Three studies compared acarbose with placebo (12, 26, 27). However, only for one 
study sufficient data were available to allow statistical comparison (12). For the other 
two studies most of the data are not yet available (26, 27). 
Mortality, incidence of DM2 and cardiovascular disease 
No significant effects on total mortality and mortality due to cardiovascular causes 
were found (12). Data for the other two studies were missing (26, 27). 
Acarbose reduced the incidence of (conversion to) DM2 in the acarbose group: 
RR 0.78 (95% CI: 0.68 to 0.90), Risk difference (RD) 0.09 (95% CI 0.04 to 0.14), 
Number Needed to Treat (NNT) =10 (12). The N N T indicates that 10 patients have 
to be treated for three years with acarbose in order to prevent one case of DM2. Also, 
in the EDIT-study (26) it was reported that the use of acarbose had a preventive 
effect on the incidence of DM2: RR 0.66 (P=0.046). 
In the STOP-NIDDM study (12) a decreasing effect for acarbose on the incidence 
of cardiovascular disease as a combined endpoint (myocardial infarction, angina, 
revascularization procedures, cardiovascular death, congestive heart failure, 
cerebrovascular events and peripheral vascular disease) was found: RR 0.47 (95% CI 
0.26 to 0.86). Also, a decreasing effect on myocardial infarctions (RR 0.08 (95% CI 
0.01 to 0.64) was found. The RDs were 0.02 (95% CI 0.01 to 0.04; NNT=50) and 0.02 
(95% CI 0.01 to 0.03; NNT=50) respectively. N o significant differences in the 
inadence of angina pectoris, revascularization procedures, congestive heart failure, 
cerebrovascular events or peripheral vascular events were found. In total, 47 events 
took place in the whole study population and the study was not initially powered for 
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Table 5.3. Quahty of Studies 
Study 
DAISI (27) 
E D I T (26) 
Fang (30) 
STOP-

































































* A=adequate, B=not adequate / unclear 
Î
A=adequate, B=menaoning of bbnding but exact method unclear, C=non-bbnded, inadequate or unknown 
A=adequate, B=ITT inadequate, C=Unclear or no reported data on drop-out / loss-to-foUow-up 
+ A<15%> B>15% or unknown 
# A=difference in drop-out rate in main groups <10%, B>10% or unknown 
$ A=all quahty criteria met; B=one or more quahty cntena only partially met, C=one or more quahty criteria not met 
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this outcome. Thus far, we found no data on cardiovascular morbidity from the E D I T 
(26) and DAISI (27) studies. 
Glycaemic control 
Acarbose decreased post-load glucose by 0.61 mmol/1 (95% CI 0.27 to 0.95). No 
significant effects on glycated haemoglobin and fasting blood glucose were observed 
(12). 
In the EDIT study (26) acarbose decreased fasting blood glucose by 0.1 mmol/1 
(P=0.0043) and post-load blood glucose by 0.4 mmol/1 (P=0.0075). 
Plasma lipids 
No significant effects on lipids were found (12) or no data were available (26, 27). 
Blood pressure 
In our analysis, we found no significant effects on diastolic and systolic blood pressure 
(Comparison 1, outcomes 41 and 42). However, in one study the authors reported a 
beneficial effect on the incidence of new cases of hypertension (which was not an 
outcome in our review) (12). In the acarbose and placebo groups 78 and 115 patients 
developed hypertension respectively (hazard ratio 0.66, 95% CI 0.49-0.89). 
Hypertension was defined as a blood pressure greater than 140/90 mmHg on two 
visits or if the family physician added antihypertensive medication. It is remarkable 
that at baseline almost half of all patients were already diagnosed with hypertension 
(acarbose 357/682, placebo 345/686), but these participants were kept in the analysis 
for the development of hypertension. N o data on blood pressure was available for the 
other studies with the comparison acarbose-placebo (26, 27). 
Fasting and post-load insulin and C-peptide 
No significant effects on fasting and post-load insulin levels were found (12) or no 
data were available (26, 27). 
Body weight 
Acarbose decreased body weight by 1.2 kg (95% CI 0.5 to 1.8) and BMI by 0.3 kg/m 2 
(95% CI 0.1 to 0.5). For the other studies (26, 27), no data were available. 
Adverse events 
Acarbose caused more gastro-intestinal side effects compared to placebo: RR 1.40 
(95% CI 1.31 to 1.50) and RD 0.24 (95% CI 0.20 to 0.29; Number Needed to Harm 
(NNH) =4). For the other studies, no data were available. 
Quality of life 
We found no data for 'quality of life', although it was stated for the EDIT study (26) 
that this outcome would be measured. 
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Costs / compliance 
Resource consumption data were not systematically collected in the STOP-NIDDM 
study (12). A cost-effecuveness study was published in which the likely consumption 
of healthcare resources were estimated and used for analyses. It was reported that 
comphance was assessed by pill counting but we found no outcome data in the 
published articles. We failed to ask for those data in our correspondence with the 
authors. 
Adjustment for high discontinuation rate in the STOP-NIDDM study (12) 
One of the main criticisms on the STOP-NIDDM study (12) was that the 
discontinuation rate in the acarbose group was higher than in the placebo group 
(acarbose 3 1 % versus placebo 19%). Despite the fact that discontinuing patients 
remained in the ITT analyses, it was suggested that those patients were not followed-
up regularly every three months and thus possible occurrence of diabetes or a 
cardiovascular event was less likely to be discovered (16). 
In order to investigate the possible influence of differences in the frequency of 
follow-up, we re-analysed the data with the following adjustments: first we requested 
for the mean number of study visits for both treatment groups. Next, we divided the 
number of visits of the placebo group by the number of visits in the acarbose group. 
We used this outcome as correction factor for the number of events in the acarbose 
group (occurrence of cardiovascular morbidity and DM2). 
The authors of the STOP-NIDDM study (12) reported that the mean numbers of 
study visit in the acarbose (n=682) and in the placebo group (n=686) were 13.3 
(SD=5.4) and 14.6 (SD=4.3) respectively. The calculated correction factor was: 
14.6/13.3=1.1. The effects sizes (Odds Ratios) of the outcomes for incidence of DM2 
and occurrence of any cardiovascular disease became smaller after the correction but 
remained statistically significant. The (statistically significant) effects size for 
myocardial infarctions did not change (due to the fact that there was only one case in 
the acarbose group). The other outcomes remained statistically not significant after 
correction. 
Acarbose versus metformin 
One study investigated both agents in a 2x2 factorial design (26). From this study no 
data on the comparison acarbose versus metformin is available thus far. 
Another study directly compared acarbose with metformin (30). Acarbose showed 
a decreasing effect on post-load blood glucose compared to metformin: 1.40 mmol/1 
(95% CI 0.55 to 2.25). Metformin showed a statistically significant decreasing effect 
on total cholesterol (0.90 mmol/1, 95% CI 0.19 to 1.61) and diastolic blood pressure 
(6 mmHg, 95% CI 2.81 to 9.19) compared to acarbose. N o significant effects for 
acarbose or metformin were found for the effect on incidence of DM2, fasting blood 
glucose, triglycerides, BMI or systolic blood pressure. Data for cardiovascular events, 
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quality of life, insulin or C-peptide levels, costs, compbance or adverse events were 
not found. 
Acarbose versus diet and exemse 
One study investigated the comparison acarbose versus diet and exercise (30). In this 
study a beneficial effect of acarbose compared to diet and exercise was found on the 
incidence of DM2: RR 0.40 (95% CI: 0.17 to 0.96), Risk difference (RD) 0.20 (95% CI 
0.02 to 0.38, NNT=5) . 
Further, acarbose sigmficandy reduced fasting blood glucose (-1.37 mmol/1, 95% 
CI -0.50 to -2.24) and post-load blood glucose (-2.79 mmol/1, 95% CI -1.79 to -
3.79). Effects on total cholesterol, triglycerides, body weight and BMI were not 
statistically significant. Data for cardiovascular events, quality of life, insulin or C-
peptide levels, costs, adverse events or compliance were not found. 
Acarbose versus no treatment 
Two studies compared acarbose with no treatment (30, 31). 
Mortality, incidence of DM2 and cardiovascular disease 
The combined results of the two studies indicated that acarbose reduced the incidence 
of DM2: RR 0.31 (95% CI: 0.14 to 0.69), Risk difference (RD) 0.17 (95% CI -0.09 to 
0.43, NS). We found no data for effects on mortabty or cardiovascular morbidity. 
Glycaemic control 
One study reported data for the effects on fasting and post-load blood glucose. 
Compared to patients who were given no treatment, acarbose significantly reduced 
fasting blood glucose (-1.39 mmol/1, 95% CI -0.54 to -2.24) and post-load blood 
glucose (-4.53 mmol/1, 95% CI -3.54 to -5.52) (30). 
Plasma lipids 
One study reported data for the effects on total cholesterol and triglycerides. 
Compared to patients who were given no treatment, acarbose significantly reduced 
total cholesterol (-1.00 mmol/1, 95% CI -0.194 to -1.81) (30). 
Blood pressure 
One study reported data for the effects of acarbose on diastobc and systobc blood 
pressure: no significant effects were found (30). 
Fasting and post-load insuün and C-peptide 
No data were found for insubn or C-peptide levels. 
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Body weight 
Data were available from one study: compared to patients with no treatment acarbose 
showed a non-significant effect on BMI (-1.1 kg/m2 , 95% CI -2.2 to 0, P=0.05) (30). 
Adverse events 
One study reported data on adverse effects (31). Two patients in the acarbose group 
and no patients who received no treatment reported adverse effects. The difference 
was not statistically significant. 
Quality of life 
We found no data for effects on quality of life. 
Costs, compliance 
N o data were found for these outcomes. 
Sensitivity analyses, sub-group analyses, meta-regression analyses, small 
study bias 
Due to the low number of included studies no further analyses could be performed. 
Discussion 
Summary for main results 
In this systematic review we found evidence from one large study of high quality (12) 
that acarbose compared to placebo reduces the incidence of DM2 and myocardial 
infarctions in patients with impaired glucose tolerance. These findings could not be 
confirmed nor refuted by two other (but highly similar) studies because most data 
were not available thus far (26, 27). Two smaller studies of low quality comparing 
acarbose with no treatment or exercise, confirmed the capacity of acarbose to reduce 
the incidence of DM2. Effects on cardiovascular morbidity could not be confirmed in 
other comparisons. Moreover it should be noted that the effects on cardiovascular 
morbidity in the STOP-NIDDM study (12) were based on a limited number of events 
and the study was not initially powered for this outcome. Compared to placebo, 
acarbose induces more gastro-intestinal side-effects (NNH=4). 
Decrease in inddence of DM2 
We found evidence from several studies that acarbose reduces the incidence of DM2 
(12, 30, 31). A firm effect on the incidence of DM2 is not surprising. After all, 
acarbose has a clear effect on glycaemic control in patients with DM2 (11). Such a 
drug will have large effects on the 'incidence' of diabetes for people who are at the 
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border of fulfilling the criteria for DM2. So, the question is whether acarbose 
prevents, delays or even masks DM2. The authors of the STOP-NIDDM study (12) 
are undecided, as they sometimes speak of 'prevention' (in the tide) and sometimes of 
'delay' (in the summary) (12). Critics of the STOP-NIDDM study (12) suggested that 
acarbose masks DM2 since 15.4% of the patients on acarbose compared to 10,6% 
(placebo) converted to diabetes during a three months wash-out phase (15). 
To assess the value of acarbose with respect to the effects on the development of 
DM2, it is probably more straightforward to look at the effects on glycaemic control. 
After all, IGT refers to an intermediate state between normal glucose homeostasis and 
DM2. In the STOP-NIDDM study (12) these effects are disappointing: no significant 
effect on glycated haemoglobin and fasting blood glucose, and a small effect on post-
load blood glucose (-0.61 mmol/1, 95% CI -0.95 to -0.27) were found. Those effects 
are smaller than obtained in a Cochrane review on alpha-glucosidase inhibitors for 
patients with DM2 (11). This may be explained by the fact that in the before 
mentioned review it was found that the effects on glycaemic control were less strong 
with lower baseline values of glycaemia and longer study duration. Further, most trials 
in the Cochrane review studied post-load glucose with a full meal tolerance test, and 
not an oral glucose tolerance test (OGTT) as has been done in the STOP-NIDDM 
study (12). Acarbose has no direct effects on an O G T T as alpha-glucosidase inhibitors 
only delay the breakdown of complex polysaccharides (and not monosaccharide such 
as glucose). In this light, the decreasing effect of acarbose on a 2 hours O G T T is 
positive because it indicates a beneficial effect of insulin resistance. 
Another argument in the question whether an effect of acarbose on the incidence 
of DM2 is relevant or important, is the desirability of a drug intervention in people at 
high risk for DM2. It is well recognized that the increase in the number of patients 
with DM2 is in lifestyle factors such as a shortage of exercise and an unhealthy diet. 
Focussing on drugs as the solution of the problem may distract people from the issues 
that are truly important: eat less and exercise more. 
Finally the question arises whether true (primary) prevention of DM2 with a single 
drug is possible at all. DM2 is a very complex disease in which many 
pathophysiological mechanisms are involved (e.g. insulin sensitivity, blood pressure 
regulation). Only when one predominant mechanism would be identified, primary 
prevention by a drug targeting this mechanism would be feasible. Currently, it seems 
not likely that this will be the case for DM2 in the near future. In the mean while, drug 
interventions for IGT or IFBG should be regarded as secondary or tertiary 
prevention. 
Decrease in inddence of cardiovascular disease 
The observed beneficial effects on the occurrence of cardiovascular morbidity (12) are 
very interesting. However, these results should be interpreted with great prudence. 
This is underbned by the authors who sensibly stated that because effects on 
163 
Chapter 5 Alpha-glucosidase inhibitors for people with impaired glucose tolerance 
cardiovascular morbidity were secondar)' objectives and the number of events 
relatively small, they should be seen as hypothesis generating (53). 
Critics mentioned the skewed discontinuation rate as another explanation for the 
observed effects, other than an effect of acarbose (16). Because more patients in the 
acarbose group stopped taking their medication (mostly due to side-effects), the 
patients in the acarbose group were not followed-up as regular as the patients in the 
placebo group and could have had therefore less chance to be 'detected' in case a 
cardiovascular event had taken place. We re-analysed the data accounting for 
differences in follow-up rate and found that the odds ratios for the occurrence of any 
cardiovascular event became less strong, but remained statistically significant. 
Another explanation could be in the existence of (unknown) confounding factors. 
Clues for differences in treatment groups were reported in the cost-effectiveness sub-
study of the STOP-NIDDM trial (43). Baseline risk profiles were determined with a 
formula for the identification of high risk for DM2 (65) or cardiovascular risk (66). 
Based on these risk scores, it was stated that '... more placebo patients than acarbose-
treated patients were represented in the high-risk subgroups...'. So, patients in the 
placebo group could have had a higher a-pnori risk than patients on acarbose. 
We conclude that the observed effects of acarbose on cardiovascular disease may 
be due to a treatment effect or to (unknown) confounding factors, or both. The 
results from the ongoing studies are needed to confirm or refute the observed effects 
in the STOP-NIDDM study (28, 29). 
Effects on inddence of hypertension 
We could not confirm the beneficial effects on hypertension observed in the STOP-
N I D D M study (12), in which hypertension was studied as a clinical outcome (blood 
pressure greater than 140/90 mmHg on two or more occasions). Instead we studied 
the differences in diastolic and systolic blood pressure. These outcomes yielded no 
statistically significant effects of acarbose compared to placebo (12), and a detrimental 
effect of acarbose on diastolic blood pressure compared to metformin in one study of 
low quahty and with a low number of participants (6 mmHg (95% CI 3 to 9)) (30). 
Comparison with existing literature 
As far as we are aware of, no systematic review has been done with an exclusive focus 
on alpha-glucosidase inhibitors for people with IGT of IFBG. Nevertheless, alpha-
glucosidase inhibitors have been studied as part of a recent systematic review on all 
kind of drug therapy to delay or prevent DM2 (67). In that review two studies on 
acarbose were included: the STOP-NIDDM study (12), and a non-randomised study 
(32) (excluded for the current review). It was concluded that acarbose reduced the 
incidence of DM2 compared with placebo but that it could not definitively be 
recommended for diabetes prevention. Similar conclusions were drawn for 
metformin, troglitazone and orlistat (a weight reducing agent). Further, inconclusive 
results for a decrease in the incidence of DM2 were reported for cholesterol lowering 
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agents (fibrates and statins), antihypertensive agents and oestrogens. A systematic 
review on the efficacy of lifestyle education concluded that lifestyle education was 
clearly effective for reducing 2-hour plasma glucose (0.84 mmol/1, 95% CI 0.39 to 
1.29) and the incidence of DM2 over one year (RR 0.55, 95% CI 0.44 to 0.69), and 
should thus be recommended for patients with patients at high risk for DM2 (68). 
Strengths and limitations of the review 
One of the main strengths of this review is the ngourness and completeness of the 
search. It is remarkable that only one trial (12) was listed in the database that is mostly 
used by clinicians all over the world (PUBMED), and that the other studies were 
retrieved from less well-known databases (EMBASE or The Cochrane Librar)'), in 
databases of ongoing trials or by handsearching. Second, the a prion decision to 
include randomised trials only with a duration of at least one year ensured a 'minimum 
level' of quality. Third, we assessed many different outcomes in the review which 
enables the readers to judge by themselves what matters most for their own particular 
question. Finally, we think that the tables and figures and the extensive provision of all 
outcome data and information related to quality and heterogeneity, makes the review 
transparent. 
It is clear that the main limitations are the missing data, especially from the EDIT 
(26) and DAISI (27) studies. The authors have kindly promised their help once their 
manuscripts are accepted for publication, but it is remarkable that these important 
studies have not been accepted for publication to date (July 2007). This points to a 
possible time lag bias: a kind of reporting bias in which studies may be published 
rapidly or delayed depending on the nature and direction of the results. Of course we 
will use upcoming data from these studies, and from the studies that are still going on 
in future updates of our review. Another limitation is the external validity of the 
results. Only for one study the recruitment of the participants was clearly described. It 
is important to know how selection took place in order to be able to generalize the 
results to other clinical settings. For example, were the participants volunteers 
recruited with a newspaper advertisement (and thus highly motivated), or were they 
recruited from the files of general practitioners (and maybe less motivated). Further, 
we only found studies with acarbose as the AGI. The question whether the results 
may be extrapolated to miglitol or voglibose depends on the existence of a possible 
group effect for AGIs. The answer to this question is not known, although in the 
Cochrane review on AGIs for DM2 comparable results for acarbose and miglitol were 
obtained for most outcomes (11). 
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Reviewers' conclusions 
Implications for practice 
In patients with impaired glucose tolerance the use of acarbose reduces the incidence 
of DM2, but the effects on glycaemic control are limited. Acarbose has a possible 
effect on cardiovascular morbidity, which has to be confirmed in other studies. 
Lifestyle interventions remain the cornerstone of treatment for patients at risk for 
DM2. If physicians and patients feel that an active treatment for impaired glucose 
tolerance is needed, they should consider this evidence together with evidence for 
other interventions, especially lifestyle interventions. 
Implications for research 
First, the disclosure of the finished - but unpublished - studies is needed in order to 
confirm or refute the possible effects on cardiovascular morbidity. If the evidence 
remains inconclusive after these data have been incorporated in the systematic review, 
the results from two ongoing long-term intervention studies on the effects of alpha-
glucosidase inhibitors for patients with IGT or IFBG may be awaited. Otherwise, new 
long-term studies with a similar focus could be initiated. 
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Appendix A 
Unless otherwise stated, search terms are free text terms, MesH=Medical subject heading 
(Medline medical index term), exp=exploded MeSH, the asterisk (*) stands for any 
character(s), tw=text word, pt=publication type, sh=MeSH, ad)=ad]acent 
# 1 Alpha glucosidase inhibitors (11) 
"Acarbose"[MeSH] OR acarbos* [tw] O R bayg5421 OR bay 5421 [tw] OR glucobay [tw] OR 
precos* [tw] OR prandas* [tw] O R akarbos* [tw] OR miglitol [tw] OR glyset [tw] OR diastabol 
[tw] O R bayml099 [tw] OR bay 1099 [tw] OR voghbos* [tw] OR (basen N O T basen [au]) OR 
emiglitat* [tw] OR alpha-glucosidase inhibitor [tw] OR glucosidase inhibitor [tw] OR alpha 
glucosidase inhibitors [tw] OR glucosidase inhibitors [tw] 
# 2 Controlled trials (19) 
(Randomised controlled trial [pt] OR controlled clinical mal [pt] OR randomized controlled 
trials [mh] OR random allocation [mh] OR double-blind method [mh] OR single blind method 
[mh] OR clinical trial [pt] OR clinical trials [mh] OR (clinical trial [tw]) OR ((singl*[tw] O R 
doubl* [tw] OR trebl* [tw] OR tnpl* [tw]) A N D (mask* [tw] OR bünd* [tw])) OR (latin square 
[tw]) OK placebos [mh] OR placebo* [tw] OR random* [tw] OR research design [mh noexp] 
OR comparative stud) [mh] O R evaluation studies [mh] OR follow up studies [mh] OR 
prospective studies [mh] OR cross-over studies [mh] OR control* [tw] OR prospectiv* [tw] 
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# 3 Impaired Glucose Tolerance or Impaired Fasting Blood Glucose 
"Glucose Intolerance" [MeSH] O R "Diabetes Mellitus, Type II/prevention and 
control" [MeSH] O R "Glucose Tolerance Test" [MeSH] OR "Insulin Resistance/drug 
effects" [MeSH] OR "Metabolic Syndrome X"[MeSH] OR "impaired fasting glucose" [tw] O R 
"impaired fasting blood glucose" [tw] O R "impaired fasting bloodglucose" [tw] OR "impaired 
fasting glycaemia" [tw] O R "impaired fasung glycerma" [tw] OR impaired glucose toleran* [tw] 
OR impaired glucose stat* [tw] O R impaired glucose respons* [tw] OR impaired glucose 
control* [tw] OR IGT [tw] O R glucose intoleran* [tw] OR impaired glucose regul* [tw] OR 
impaired glucose metab* [tw] OR impaired glucose homeost* [tw] OR reduced glucose 
metabolism* [tw] OR reduced glucose toleran* [tw] OR glucose intolerant* [tw] OR glucose 
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[tw] O R mild diabet* [tw] OR insulin resistan* [tw] OR impaired insulin secret* [tw] OR 
reduced insulin secret* [tw] 
Whole search # 1 A N D # 2 A N D # 3 




Chapter 6 General discussion 
General discussion 
In this thesis we assessed the evidence base for diet and alpha-glucosidase inhibition 
in the treatment for padents with type 2 diabetes mellitus (DM2) and/or impaired 
glucose tolerance. We also focused on dietary patterns of patients with DM2, and 
eating behaviour as a predictor of success or failure in dietary treatment. In this 
chapter, the main conclusions are discussed and suggestions for future research and 
advices for (guidelines for) diabetes care are given. Finally, some reflections are made 
about this thesis in the light of primary care research. 
Diet in type 2 diabetes mellitus 
The evidence base for diet therapy in DM2: lessons from systematic reviews 
In order to assess the highest levels of evidence for diet for DM2, we reviewed all 
currendy available systematic reviews on this topic {chapter 2). Our rigorous approach, 
based on Cochrane analysis guidelines, yielded six systematic reviews. Data from these 
reviews appeared to be mosdy inconclusive. 
Four out of six reviews aimed at studying a very broad topic (e.g., all dietary 
supplements, diet in general for DM2). As a consequence many authors limited the 
inclusion to long-term randomised trials, leaving only a small number of studies on 
which conclusions are based (e.g., Moore et al. (I)), others included a large number of 
heterogeneous studies and therefore were not able to draw conclusions beyond the 
sum of the original studies with implications for daily practice (2, 3). Therefore, we 
argued that new reviews should apply a more focussed research question and at the 
same time use broader inclusion criteria (e.g., the inclusion of non-randomised trials). 
The question emerges how a systematic review on diet should ideally be done. It 
should first be recognized that it is difficult to look at 'diet' as a single intervention. 
Doctors and nurses may tend to look at diet as simply one aspect of Lfestyle, but 
eating is far more complex. Eating behaviour is inextricably bound up with its 
psychological, social, cultural and economical context (4), all of which can serve as 
confounder or effect modifier. Those factors will inevitably affect outcomes of studies 
and will also be an important obstacle when it comes to generalizing the results to 
other populations, especially when the possible confounders are not reported or 
unknown. 
To formulate a research question for a new systematic review in the field of diet 
and DM2, we made a distinction between efficacy, effectiveness and efficiency. The 
efficacy — does an intervention bring about effects under ideal circumstances — of 
dietary interventions should be investigated first in highly controlled experimental 
studies. Such studies will usually be of short duration, due to practical and financial 
reasons. This way, it is possible to investigate for example effects on body weight, 
blood lipids and glucose or blood pressure. However, it is almost impossible to look at 
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rare, but important, endpoints such as mortahty or morbidity under these rigorous 
scientific condidons. To get data for these endpoints, increasing power with a meta-
analysis of multiple studies, or the application of observational research, such as 
cohort or case-control studies, seem to be the alternatives. Although observational 
studies might be as credible as randomised trials, in the case of health effects of 
lifestyles that people take up because of health concerns, it may be notoriously 
difficult (5). The reason for this is that the exposure allocation (e.g., fat consumption) 
is not totally unrelated to the prognosis (e.g., as reflected by severity of disease). This 
might lead to an underestimation of the effects of, for example, diet: people at high 
risk will make more efforts to comply but have a worse outcome. So paradoxically, 
observational studies on the effects of diet could better be done in people who are all 
at low risk of (complications of) disease. 
The effectiveness — does an intervention work in real-life — of diet depends not 
only on its efficacy, but to a large extent on adherence to dietary recommendations 
and other biological, psychosocial, cultural and economical factors that determine our 
food choices. Although randomisation could account for such confounders and effect 
modifiers, randomised trials are not suited for the study of long term (>10 years) 
effects of diet. Moreover, randomisation may account for confounding and effect-
modification, but mechanisms by which psychological and cultural aspects, for 
example, interact with outcomes remain unrevealed. Therefore, research should focus 
on other topics in the behavioural science field (6) like the environmental factors 
related to obesity, theoretical constructs promoting long-term adherence, and 
understanding of motivation. 
Finally, the efficiency - is an intervention worth its costs to an individual or society 
— of dietary interventions should be researched in cost-effectiveness or economic 
evaluation studies. Of course, proven efficacy and effectiveness is a prerequisite when 
investigating cost-effectiveness. 
The enormous bulk of evidence from short-term experimental studies, randomised 
tnals, observational studies, or economic evaluation studies may be assessed in 
multiple systematic reviews, all with their own specific focus. Systematic reviews 
should not aim to collect, summarize and analyze all evidence for one disease or 
treatment modality together because this is contradictory to basic scientific principles 
of having a limited and answerable research question. 
Another lesson from our review of systematic reviews is that external validity is an 
underexposed topic in most reviews. At least, studies provided insufficient data to 
judge to whom the results of the study apply. Especially in the topic of diet, which is 
highly interwoven with cultural and economical factors, this may look surprising. 
However, there is evidence for the neglect of consideration of external validity (7). For 
example, there are no accepted guidelines on how external validity of RCTs should be 
assessed, funding agencies, ethics committees and drug licensing bodies hardly 
mention the importance of external validity in their guidelines and existing guidelines 
on the reporting of RCTs, and systematic reviews give very litde space to external 
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validity. Still, it is encouraging that recently a checklist for the evaluation of clinical 
studies with a particular focus on external validity has been published (8). 
Dietary habits of patients with DM2 
In our cohort study of 144 patients newly diagnosed patients with DM2 we, found 
that even after four years of usual care, patients still had favourable energy and fat 
intake compared to diagnosis (chapter 3.1). We conclude that pessimism with respect to 
the willingness of patients to change their diet persistently, seems not justified. On the 
other hand, our results give rise to some concerns. Although the proportion of 
patients who comply with the recommendation of consuming less than 10 energy 
percents of saturated fat increases by a fourfold, four years after diagnosis about 73% 
of patient still do not meet this recommendation. This finding is all the more 
important, because this treatment goal has been sharpened recently to a limit of less 
than 7 energy percents of saturated fat for all patients with DM2. Of course, there will 
undoubtedly be room for improvement in the dietary treatment of patients (see 
chapters 3.2 and 3.3). But it is questionable whether such strict recommendations are 
realistic, especially for people living in a Western society like the Netherlands from 
which our cohort was recruited. What is the use of treatment goals that are so strict 
that meeting them seems an utopia for the individual? 
Would it not be more reasonable to simply encourage patients to eat as less 
saturated fat as possible without referring to specific goals? Otherwise, patients, on the 
one hand, might get frustrated when confronted with goals that seem impossible to 
achieve, and care-providers, on the other hand, might neglect dietary aspects of 
treatment for diabetes and give priority to other more feasible goals. It is also 
important to emphasize that eating habits are, to a certain extent, a characteristic of a 
society as a whole and that also attention should be paid to dietary 'interventions' on 
societal level. Governmental policies and health promotion campaigns directed to the 
general public should be aimed at eating less, but more healthy food. 
Eating behaviour as a predictor for short- and long term dietary changes 
In chapters 3.2 and 3.3, we showed that patients with newly diagnosed DM2 do not 
differ from subjects in the general population with respect to restrained, emotional, 
and external eating behaviour. Moreover, we found that restrained eating predicts low 
energy consumption, and showed not to be a detrimental factor in itself, as has been 
advocated in previous research. Instead, emotional and external eating, also described 
as tendency towards overeadng, were associated with weight gain and high energy 
intake four years after diagnosis. We also found clues that especially women with high 
scores for emotional eating have problems with initial beneficial dietary changes. 
The results from the present study have only limited implications for daily practice. 
First, replication of our study in a larger sample size might learn whether or not eating 
behaviour also predicts long-term adherence to dietary recommendations, or whether 
eating behaviour also predicts energy consumption in men. 
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Second, disturbed eating behaviour deserves more detailed investigation in 
particular whether it is a cause in itself of unfavourable dietary changes, or a 
consequence of psychological mechanisms leading to low dietary adherence and 
weight gain. For example, depression, alexithymia and impulsmty are known to 
(partially) explain emotional eating behaviour and are related to body weight and 
energy and fat consumption. Especially depression or impulsivity may offer a 
promising therapeutic possibility to treat patients for their disability to change their 
diet. 
If our findings can be reproduced one might argue that targeted dietary advice 
recognizing patients' specific type of eating behaviour and/or its underlying 
mechanisms is more effective than standard dietary consultation alone. However, it 
seems logical that such strategies will only be cost-effective if it is integrated in the 
whole package of diabetes treatment. After all, dietary modification has to compete 
with other priorities in diabetes treatment such as exercise, eye and foot care, and 
medication compliance (9). So, if a dietary advice targeted to specific eating behaviour 
is effective, it should be first offered to patients who are to be expected to benefit 
most. These patients will probably be those who have extreme high scores for 
emotional or external eating behaviour, who have enough room for improvement in 
energy and fat consumption or body weight, and who have a high motivation. 
Alpha-glucosidase inhibitors for treatment of type 2 diabetes mellitus 
Alpha-glucosidase inhibitors (AGIs) represent one of the six classes of oral drugs for 
the treatment of DM2 (10). AGIs reversibly inhibit a number of alpha-glucosidase 
enzymes (e.g., glucoamalyse, sucrase, maltase), consequendy delaying the absorption 
of sugars from the gut (11). In a recent study among healthy subjects it was suggested 
that the therapeutic effects of AGIs are not only based on a delayed digestion of 
complex carbohydrates, but also on metabolic effects of colonic starch fermentation 
(12). Acarbose (Glucobay®) is the only AGI available on the Dutch market. The other 
AGIs are miglitol (Glyset®) and vogbbose (Volix®, Basenw). AGIs might be a 
reasonable option as first-line drug in the treatment of patients with DM2 as it 
specifically targets postprandial hyperglycemia, a possible independent risk factor for 
cardiovascular comphcations (13). Moreover, AGIs are expected to have no 
dangerous side effects and cause no weight gain. 
The effectiveness of AGIs in DM2 
In a randomised controlled trial set up to investigate whether acarbose and 
tolbutamide were equivalent with respect to the effects on HbAic, we could not 
confirm, nor rule out clinical equivalence based on predefined criteria (cbapfer 4.1). 
Because acarbose showed a significantly less lowering effect on fasting blood glucose 
and a disadvantageous number of patients who dropped-out mosdy because of side 
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effects, we concluded that tolbutamide is to be preferred above acarbose in patients 
newly diagnosed with DM2. In a Cochrane systematic review on all AGIs we found 
no evidence for beneficial effects on mortahty or (cardiovascular) morbidity {chapter 
4.2). This finding was not due to 'biased interpretation' as suggested by Hanefeld et al. 
(14, 15), but largely because long-term studies with solid data on morbidity and 
mortahty were missing {chapter 4.3.2). Still, we found statistically and clinically 
significant effects for acarbose on HbAu (0.8% decrease), fasting (1.1 mmol/1 
decrease) and post-load (2.3 mmol/1 decrease) blood glucose and BMI (0.2 kg/m2 
decrease) compared with placebo. Compared with sulphonylurea, acarbose was 
inferior with respect to its effect on fasting blood glucose and the occurrence of side-
effects, but superior with respect to its effect on body weight and post-load insulin. 
Too few comparisons with metformin were available to make a fair judgment. 
The place of AGIs in current therapeutic strategies. A comparison with the other oral blood 
glucose lowering drugs 
In 2006, the American Diabetes Association and PLuropean Association for the Study 
of Diabetes together pubhshed a 'consensus statement' on the management of 
hyperglycemia. For all patients, metformin in combination with a lifestyle intervention 
is advised, followed by the addition of either a thiazolidinedione (TZD), a 
sulphonylurea, or insulin when HbAu remains >7%. AGIs are not included in the 
treatment algorithm, but is stated to be an "appropriate choice in selected patients" 
(16). 
The guideline of the British National Institute for Clinical Excellence (2002) states 
that oral medication has to be initiated when lifestyle intervention alone fails. 
Metformin is therapy of first choice and sulphonylurea should be given in case of 
contra-indications for metformin, or should be added when therapy with metformin 
alone fails. TZDs are recommended to be added in case of contraindications for 
metformin, or if the combination of metformin and sulphonylurea fails. AGIs may be 
considered as an alternative glucose-lowering therapy in people unable to use other 
oral drugs (17). 
The guidelines of the Dutch College of General Practitioners (DCGP) have 
changed during the course of our studies. At the time our studies were conducted, 
acarbose was recommended as a drug for the treatment of DM2 when sulphonylurea 
and/or metformin failed, or in case of contra-indications for one of these drugs (18). 
In the current Dutch guideline, however, the only AGI that is available in the 
Netherlands, acarbose, is no longer recommended (19). Instead, TZDs are introduced 
in the guideline to be used when metformin fails in obese patients (BMI >27 kg/m2) 
with existing cardiovascular disease without an increased risk for heart failure. The low 
ranking of AGIs in all of these guidelines suggests that unequivocal evidence proving 
the superiority of the other oral drugs is available. 
The case for metformin seems to be strong: metformin showed to have beneficial 
effects on diabetes-related morbidity (20). Moreover, in meta-analyses metformin 
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compared to placebo showed to decrease HbAic by 0.9% (21) or 1.0% (22). However, 
the cases for sulphonylurea and TZDs are less strong. The beneficial effects on 
microvascular complications that have been observed in sulphonylurea and insulin 
treated patients, are most likely due to the effects of tight glycémie control and not 
due to direct effects of sulphonylurea (23). Moreover, no beneficial effects on diabetes 
related mortality and macrovascular morbidity has been found thus far for 
sulphonylurea. On the contrary, although the results of the University Group Diabetes 
Program suggesting an increased risk of cardiovascular morbidity with the use of 
tolbutamide were heavily criticized (24), sulphonylurea remained under the suspicion 
of unfavourable effects on cardiovascular disease up to now (25, 26). In addition, 
sulphonylureas carry the risk of inducing life threatening hypoglycaemic events. 
TZDs are becoming more popular; this is reflected by the increased expenses of 
these drugs in the Netherlands: from 2 million Euros in 2001 to almost 24 million 
Euros in 2005 (27). The PROACTIVE-study found a statistically significant effect for 
pioglitazone compared to placebo in addition to regular treatment in obese patients 
with DM2 and known cardiovascular morbidity on a secondar}' composite endpoint 
consisdng of total mortality, non-fatal myocardial infarction and cerebrovasular 
accident resulting in a N N T of 50 patients (treatment duration three years) (28). 
However, in a recent Cochrane systematic review with 22 trials on the efficacy of 
pioglitazone, it was concluded that thus far no convincing evidence for effects on 
mortality and morbidity exist and that the previously mentioned result of the 
PROACTIVE-study are hypotheses generating and need reconfirmation (29). This 
precautious approach is underlined by results of a meta-analysis on another TZD, 
rosigbtazone, that showed an increased risk on myocardial infarctions and death from 
cardiovascular disease (30). Moreover, it is important to realise that TZDs cause fluid 
retention and are therefore contra-indicated in patients with or at increased risk for 
heart failure. 
Compared with the evidence for the currently recommended therapy (metformin, 
sulphunylurea, TZDs) as described above, the results of AGI-treatment as studied in 
this thesis, are less unfavourable than could be concluded from the low ranking of 
AGIs in the current guidelines. The effect of AGIs on HbAic is on average only 0.1 to 
0.2% less compared to metformin and TZDs . Moreover, its effect on post-load 
glucose may be superior, although this is based on one comparison only (31) and no 
data from meta-analyses are available. AGIs have a decreasing effect on the Body 
Mass Index, and the safety profile is favourable as there is no evidence for dangerous 
side effects. Most important, there are clues that AGI may prevent cardiovascular 
events in patients with impaired glucose tolerance in the STOP-NIDDM study (32). 
However, this study is heavily debated and the results deserve re-confirmation (33, 
34). In our view, 'evidence' from a study that reported beneficial effects of acarbose 
on myocardial infarctions in patients with DM2 has to be neglected because of 
publication bias, heterogeneity, detection bias and confounding {chapter 4.3.1). The 
results of three recendy performed trials are underway with mortality and morbidity 
endpoints in patients with abnormal glucose tolerance (35, 36) and early diabetes (37). 
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The gastro-intestinal side effects of AGIs are clinically relevant and may affect 
compliance. In this respect, it is of interest that we found evidence that acarbose in a 
low dose (50 mg TID) has similar effects on HbAic and less side effects compared to 
the double dose (100 mg TID) (see: chapter 4.2). 
Altogether, AGIs appear to be a serious therapeutic option in the treatment of 
DM2 as it is has a comparable effect on glycémie control compared to metformin, it 
poses no risk for harmful adverse events, decreases Body Mass Index, it possibly 
reduces the risk for cardiovascular disease and the side-effects may be reduced by 
administering a lower dose without influencing its effect on glycémie control. AGIs 
are not necessarily a drug in the form of a pill as it may also be given as 'smart food' 
or as a food supplement. For example, a soy-bean derived touchi extract, a traditional 
Chinese food in the form of a paste, has shown to have alpha-glucosidase inhibiting 
properties and reduce blood glucose levels (38). 
The effectiveness of alpha-glucosidase inhibitors in patients with 
impaired glucose tolerance or impaired fasting blood glucose 
In order to investigate whether AGIs are able to prevent diabetes and its related 
morbidity and mortality, we performed another Cochrane systematic review 
investigating AGIs for people with IFBG or IGT. We found evidence that acarbose 
reduces the incidence of DM2 in patients with IGT. However, it remains unclear 
whether this should be seen as prevention, delay or masking of diabetes. We also 
found a preventive effect on combined cardiovascular endpomts (RR 0.46, 95% CI 
0.26-0.86, NNT=50) on the occurrence of cardiovascular events, but this finding 
needs to be confirmed in more studies since it is based on only 47 events and the 
study was not originally powered for this goal [chapter 5). In the coming years, more 
data will be available from studies that have already been finished but yet unreported, 
and from studies that are currently ongoing. All together, the results of our review are 
likely not to appear in the advertisements of the manufacturers of AGIs. Thus far, 
lifestyle interventions are still much more effective in reducing the incidence of DM2 
than AGIs (39-41). 
Nevertheless, regardless of data from our review or other studies, the question 
arises whether drug interventions in people with no disease and who do not even feel 
ill is desirable. General Practitioners (GPs) are often confronted with the medical 
consequences of societal problems such as the massive adoption of sedentary lifestyles 
or loneliness and social isolation. But, just like a banker will talk money when 
confronted to problems, a doctor will most likely 'talk medicine' even when 
confronted with non-medical problems. This issue of médicalisation, raised in the 
seventies of the twentieth century, is to date sdii actual and even more complicated 
than before (42, 43). In a focus group study with Welsh doctors and practice nurses 
unnecessaty medicabsation was a major concern with respect to preventive treatments 
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for DM2 (44). This thesis does not provide the answers to the question were the 
border should be between the medical domain and the responsibility of society as a 
whole, governments, schools and, last but not least, the individual himself. But asking 
the question in this philosophical and ethical issue is probably more important than 
any possible answer. 
Final reflections: this thesis in the light of primary care research 
This thesis has dealt with a number of topics related to the treatment of newly 
diagnosed patients with DM2 and its precursors (impaired glucose tolerance and 
impaired fasting blood glucose). One chapter was based on a randomized clinical trial, 
performed in general practice, the other chapters were based on observational 
research of a cohort and critical appraisal of published and unpublished studies. The 
main focus on the analysis of existing data and the sparse use of experimental design, 
could be considered a metaphor for general practice. For the majority of problems, 
the existing knowledge about (patho)physiology and epidemiology in combination 
with the padent's history, physical examination and context will lead to a diagnosis; 
the GP will sparsely use additional tests. 
In this context, we feel that systematic reviews deserve special attention in both 
primary care research and the practice of primary care. In research, high quality 
systematic reviews should be the starting point of new research projects, as this is the 
best way to show how new research questions arise from the current state of evidence. 
Systematic reviews should be regularly updated so that new evidence is integrated in 
what is already known. It is important that systematic reviews meet the highest 
methodological standards. This includes that evidence from high quality studies is 
given more weight than results from low quality studies. As a consequence, 
researchers of the primary studies will be encouraged to apply and report sound 
scientific methods. 
In the practice of primary care, systematic reviews may offer an information-dense 
way to keep up-to-date on a certain topic, on the condition that reviews are accessible 
and presented in a logical and comprehensive way. Therefore, the promotion of 
quahty, quantity, dissemination, readability and the accessibility of systematic reviews 
relevant to people who work in primary care should be high on the primary care 
research agenda. It is no coincidence that this is exacdy the mission statement of the 
renewed Cochrane Primary Health Care Field (45). 
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Chapter 7.1 Summary 
Summary 
In chapter 1 a short introduction about diabetes mellitus type 2 (DM2) and its 
treatment in general practice is given. The focus of the thesis is the evidence base of 
two interventions in the treatment and prevention of DM2. In the first part of the 
thesis, the evidence for the usefulness of dietary treatment was assessed. We focused 
on dietary patterns of patients with DM2, and on factors that determine patients' 
motivation to change their diet. In the second part of this thesis, we assessed the 
effectiveness of alpha-glucosidase inhibitors in the treatment and prevention of DM2. 
In chapter 2, the currently available evidence for the effectiveness of a dietary 
intervention in DM2 was assessed by investigating systematic reviews. A systematic 
review is an appraised method to summarize research in a concise and transparent 
way, and it may enable to draw conclusions beyond the sum of results of separate 
studies. We performed an umbrella systematic review to assess the results, quality and 
external validity of the available systematic reviews on diet in DM2. Six systematic 
reviews met the inclusion criteria. Those reviews investigated dietary interventions 
that were not prespecified (n=3), chromium supplementation (n=l) , fish oil (n=l) , or 
herbs and nutrition supplements (n=l) . In the reviews with only minimal/minor 
quality flaws (4 out of 6), we found beneficial effects of very-low-calone diets and fish 
oil supplements. However, the external validity could not be judged, due to absence of 
relevant data. In addition, we found that the systematic reviews largely failed to 
produce knowledge beyond the sum of the original studies. The quality and usefulness 
of systematic reviews of dietary intervention could possibly improve by application of 
more focused research questions, together with broader inclusion criteria (e.g. the use 
of observational studies). 
The first step in treatment of DM2 is life style modification in the form of exercise 
and diet. If life-style modification fails to control blood glucose levels sufficiently, oral 
medication is prescribed. In chapter 3 we describe our studies on a dietary intervention 
in newly diagnosed type 2 diabetic patients. 
We performed a prospective cohort study in general practice in patients with newly 
diagnosed DM2 in order to investigate dietary habits, dietary changes {chapter 3.1), 
eating behaviour and adherence to diet {chapters 3.2 and 3.3). In 46 general practices 
throughout the Netherlands, 144 patients with newly diagnosed DM2 were recruited 
to be assessed for baseline measurements. In accordance with current guidelines, all 
patients were referred to a registered dietician who offered dietary advice tailored to 
individual needs, in the first weeks after diagnosis. Patients were re-assessed eight 
weeks and four years after diagnosis. 
Although treatment targets for the consumption of dietary fat are well accepted, litde 
is known about the actual fat consumption by newly diagnosed patients or the dietary 
adjustments that they make in the following years. In chapter 3.1, the results of 
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measurements of fat intake in the above-described study population are given. Fat 
consumption was assessed with a 104-item food frequency questionnaire (FFQ), 
reference values were obtained from an age-matched sample of a population-based 
survey. At diagnosis the patients with DM2 had an unfavourable dietary intake 
compared tot the general population with respect to the mean total energy intake, 
cholesterol intake, total fat consumption and the proportion of saturated fat. After 
eight weeks, all levels decreased to values comparable to, or lower than, those 
measured in the general population. After four years, energy and the energy % of 
saturated fat were unchanged, there was a slight increase in the mean intake of total 
fat, and cholesterol consumption had further decreased, compared to eight weeks. 
However, after four years the treatment only 17% and 27% of participating patients 
respectively met the targets regarding consumption of total and saturated fat . We 
concluded that patients with DM2 are able to adapt a more favourable diet after 
diagnosis under regular care, and that they are able to sustain this improvement over 
four years. Still, recommendations with respect to the consumption of total and 
saturated fat are not met. 
It is recognized that life style changes, including diet, may be difficult to implement 
and maintain. Therefore, it is important to identify potential obstacles or supportive 
factors. We investigated the relation between eating behaviour and energy and fat 
consumption and subsequent changes in the previously described cohort of patients 
with DM2 {chapter 3.2). In this study population, energy and fat consumption was 
measured as described above. Eating behaviour was assessed at diagnosis and after 4 
years with the validated Dutch Eating Behaviour Questionnaire (DEBQ); a 
comparable sample of the general population served as a reference. The D E B Q 
distinguishes three types of eating behaviour: (1) emotional eating, that means eating 
more when experiencing negative emotions; (2) external eating behaviour, i.e. easily 
responding to food-related stimuli such as good smells or the look of attractive food; 
(3) restrained eating behaviour, when someone is fixed on losing weight. The 
distribution of the three types of eating behaviour was similar in patients newly 
diagnosed with DM2 and the general population. At diagnosis, external and emotional 
eating behaviour were associated with high energy intake and fat intake, and restrained 
eating behaviour with low energy intake. In women, a high level of external eating 
behaviour significandy related to a decrease in energy intake after eight weeks, whereas 
emotional eating showed not to be related. However, after four years no significant 
correlation was found between changes in energy and fat consumption and the three 
types of eating behaviour. We concluded that patients newly diagnosed with DM2 
have a similar eating behaviour compared with the general population. Further, eating 
behaviour seems to be related more to the quantity (calorie intake), than to the quality 
(e.g., energy % fat) of food consumed. Finally, we concluded that women with high 
scores for emotional eating seem to be less able to make initial dietary changes after 
being diagnosed and having received dietary advice. 
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Dieting is generally considered to lead to weight loss, but it is often suggested that it 
may have the opposite effect. In chapter 3.3, this 'dieting dilemma' was addressed: 
does dieting suppress or promote excessive food intake and weight gain? In the same 
cohort we performed an analysis in which results of the DEBQ at diagnosis and after 
four years were studied in relation to weight gain, change in body mass index, and 
energy intake (FFQ). If the dieting dilemma were true, we would hypothesize that 
restrained eating behaviour was the strongest predictor for weight gain or high energy 
intake four years after diagnosis of DM2. 
We found strong correlations between eating behaviour at diagnosis and after four 
years. This suggests that eating behaviour is an individual trait, and that it remains 
stable over the years. Next, we found that tendency toward overeating (i.e., emotional 
or external eating behaviour) at diagnosis was associated with weight gain and energy 
intake 4 years after diagnosis. In contrast, restrained eating showed no correlation with 
weight loss or gain. These findings suggest that not dietary restraint but emotional and 
external eating behaviour may predict the possible failure of a dietary intervention. 
In chapter 4 we describe the effectiveness of alpha-glucosidase inhibitors (AGI) in the 
treatment of type 2 diabetes mellitus. 
In the previously described cohort we performed a randomized controlled trial 
{chapter 4.1) that was designed to assess equivalence between tolbutamide and 
acarbose with respect to the effect on mean HbAu in newly diagnosed patients with 
DM2. Secondary' objectives were to compare the effects of both treatments on fasting 
and post-load blood glucose and insulin levels, lipids and adverse events. Patients who 
still had a fasting blood glucose between 6.7 and 20 mmol/1 eight weeks after 
diagnosis were randomized to treatment with tolbutamide (n=48) or acarbose (n=48) 
during 30 weeks. Patients received acarbose (titrated step-wise to a maximum of 100 
mg t.i.d.) or tolbutamide (titrated step-wise to a maximum of 2000 mg in three doses) 
in a double-dummy double blind fashion. The two treatments were considered 
equivalent if the two-sided 90% confidence interval (CI) for the difference in HbAu 
levels would be within the range of -0.4 to 0.4%. We found that both agents reduced 
the HbAic and fasting blood glucose levels. The difference in mean HbAic decrease 
was 0.6% in favour of tolbutamide (90% CI 0.3-0.9, 95% CI 0.2-1.0). There were no 
significant differences in postload glucose, fasting and post load insulin levels, or 
lipids. In the acarbose group, significantly more patients discontinued treatment 
because of side effects, mosdy of gastro-intestinal origin. We concluded that these 
results do not show equivalence but favour tolbutamide over acarbose as first medical 
treatment for patients with DM2 in general practice. 
AGIs (acarbose, miglitol, vogbbose) are widely used in the treatment of DM2, but the 
recommendations on when to use AGIs and the evidence used for these 
recommendations appear to be different in various (international guidelines. We 
conducted a systematic bterature review and meta-analysis focusing on the effects of 
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AGIs versus placebo (or any other intervention) with respect to mortality and 
(diabetes-related) morbidity, glycémie control, plasma lipids, insulin levels and body 
weight and side effects {chapter 4.2). In total, 41 studies were included (30 acarbose, 
7 miglitol, 1 voghbose, 3 combinations). There was no evidence for an effect on 
mortality or morbidity. Compared with placebo, AGIs had a beneficial effect on 
HbAic (acarbose -0.8%, 95% CI 0.6-0.9; miglitol -0.7%, 95% CI 0.4-0.9), fasting and 
postload blood glucose and insulin levels. None of the AGIs had an effect on plasma 
lipids. Body mass index decreased by 0.2 kg/m 2 (95% CI 0.1-0.3), compared to 
placebo. When compared with sulfonylurea, AGIs showed inferior glycémie control, 
but more decrease of fasting and postload insulin levels. Side effects of AGIs 
treatment were predominandy gastro-intestinal. When the dose exceeded 50 mg t.i.d., 
the side effects increased, the blood post-load glucose levels showed more decrease, 
but the beneficial effect on HbAic did not increase. Although this effect is probably 
due to lower compliance in the higher dosage ranges, we concluded that there is no 
need for dosages higher than 50 mg acarbose t.i.d. 
The results of our systematic review on AGIs (especially the lack of reported effects 
on morbidity and mortality), prompted us to react on an article by Hanefeld et al. (Eur 
Heart J 2004;25:10-6) in which they suggest that acarbose can prevent myocardial 
infarctions. Their conclusion was based on a meta-analysis of seven randomized 
controlled trials. We commented on their approach, concerning the publication bias, 
heterogeneity, detection bias and confounding factors which are evidently linked to 
this meta-analysis. In chapter 4.3.1 the controversy is given by means of our letter-to-
the-editor and the author's response. Chapter 4.3.2 contains the correspondence on 
the same topic, but now initiated by Hanefeld et al. in reply to the publication of a 
synopsis of our Cochrane analysis in Diabetes Care. 
Two risk factors for the development of DM2 (and cardiovascular disease) are 
impaired glucose tolerance (IGT) or impaired fasting blood glucose (IFBG). Both are 
generally recognized as an expression of abnormal glucose homeostasis that is not 
(yet) severe enough to meet the criteria for DM2. We investigated the current available 
evidence for the effect of AGIs in patients with IGT, IFBG or both by a systematic 
review (chapter 5). We searched for randomized controlled trials of at least one-year 
duration, comparing AGI monotherapy with any other intervention. In total, five trials 
were included (2360 participants). Only one study was at low risk of bias, the others 
were at high risk. Meta-analyses were not possible because of the limited data. Data 
from the first-mentioned study suggest that acarbose decreases the occurrence of 
DM2 (number needed to treat 10) and cardiovascular events (NNT 50, based on 47 
events). However, the study was not initially powered for the latter outcome and this 
finding needs confirmation in more studies. We concluded that the reduced incidence 
of DM2 in patients with IGT/ IFBG treated with acarbose is obvious, but it remains 
unclear whether this should be regarded as prevention, delay or masking of diabetes. 
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In chapter 6, the main conclusions are discussed and suggestions for future research 
and advices for (guidelines for) diabetes care are given. Also, some reflections are 




Chapter 7.2 Samenvatting 
Samenvatting 
Dit proefschrift is gericht op de wetenschappelijke onderbouwing van twee aspecten 
van de behandebng en preventie van diabetes mellitus type 2 (DM2) in de 
huisartspraktijk: dieet en het gebruik van alpha-glucosidaseremmers (AGRs). 
Hoofdstuk 1 omvat een korte inleiding over de behandeling van DM2 in de 
huisartspraktijk en de rol van AGRs en dieet. 
In hoofdstuk 2 onderzochten we het wetenschappelijke bewijs voor de effectiviteit 
van dieet interventies in DM2 aan de hand van systematische reviews. Een 
systematische review is een methode om divers wetenschappelijk onderzoek op een 
bondige en heldere manier samen te vatten zodanig dat conclusies kunnen worden 
getrokken die verder reiken dan de resultaten van de afzonderbjke studies. Wij deden 
een overkoepelende systematische review van de resultaten, kwabteit en externe 
validiteit van bestaande systematische reviews naar dieet interventies voor DM2. Zes 
systematische reviews werden geincludeerd met de volgende onderwerpen: dieet 
interventies zonder nadere specificatie (n=3), chroom suppletie (n=l) , visobe (n=l) , 
en krulden en voedingssupplementen (n=l) . In de methodologisch beste 
systematische reviews (4 van 6) vonden we gunstige effecten van vermageringsdiëten 
(caloriearme maaltijden) op lichaamsgewicht en visobe supplementen op LDL-
cholesterol. Echter, een oordeel over de externe vabditeit was niet mogelijk vanwege 
het ontbreken van belangrijke gegevens. De resultaten van de systematische reviews 
bleken weinig toe te voegen aan de in de originele studies gepresenteerde data. Wij 
concluderen dat de kwabteit en de bruikbaarheid van deze systematische reviews 
verbeterd zou kunnen worden door de vraagstellingen aan te scherpen, en 
tegebjkertijd inclusiecriteria voor studies te verbreden. 
De eerste stap in de behandebng van DM2 is leefstijladvies in de vorm van (meer) 
bewegen en dieetaanpassing. Indien deze maatregelen falen wordt medicatie 
voorgeschreven. In hoofdstuk 3 rapporteren we onze studies naar dieetaanpassing in 
patiënten met een nieuw gediagnosticeerde DM2. 
Wij deden een prospectief onderzoek in een groep nieuw gediagnosticeerde 
patiënten met DM2 in de huisartspraktijk. Het doel was om na te gaan hoe de 
dieetsamenstelling was ten tijde van de diagnose en of dit onder reguüere behandeling 
veranderde na acht weken en vier jaar {hoofdstuk 3.1). Verder keken we naar eetgedrag, 
en of dit voorspellend was voor veranderingen in dieet {hoofdstukken 3.2 en 3.3). In 46 
Nederlandse huisartspraktijken werden 144 patiënten gerekruteerd. Na de diagnose en 
basismeting werden alle patiënten verwezen naar een diëtiste voor een voedingsadvies 
op maat volgens de vigerende richtlijnen. Acht weken en vier jaar later werden alle 
patiënten opnieuw bezocht om metingen te verrichten. 
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Hoewel er welomschreven richtlijnen bestaan over de inname van voedingsvetten 
voor patiènten met DM2 is maar weinig bekend over de eigenlijke vetconsumptie bij 
deze groep en of patiènten hun dieet aanpassen nadat de diagnose is gesteld. In 
hoofdstuk 3.1 rapporteren we de vetconsumptie van de hierboven beschreven 
studiepopulatie. Vet- en energieconsumptie werd gemeten door middel van een 
voedselfrequentie vragenlijst met 104 items. Referentiewaarden voor de algemene 
bevolking kwamen van een bevolkingsonderzoek onder leeftijdsgenoten. Ten tijde van 
de diagnose hadden patiènten met DM2 gemiddeld een hogere inname van energie, 
cholesterol, totaal vet en verzadigde vetten vergeleken met de algemene bevolking. Na 
acht weken daalden deze waarden tot een vergelijkbaar of lager niveau. Na vier jaar 
bleef vervolgens de gemiddelde energie inname en de proportie verzadigd vet gelijk, 
steeg de inname van totaal vet licht, en daalde de inname van cholesterol nog verder. 
Aan de richtlijnen voor de consumptie van totaal en verzadigd vet werd echter maar 
voldaan in 17% (totaal vet) en 27% (verzadigd vet) van de gevallen. We concluderen 
dat patiënten met DM2 in staat zijn verbeteringen aan te brengen in hun 
voedingspatroon en dit vol te houden over meerdere jaren. De behandelrichtli)nen 
met betrekking tot de inname van totaal en verzadigd vet worden daarbij echter 
onvoldoende gehaald. 
Het is lastig om leefstijlveranderingen, waaronder dieet, door te voeren en te 
behouden. Daarom is het belangrijk zicht te hebben op factoren die ondersteunend of 
belemmerend werken. Wi) onderzochten eetgedrag in relatie tot de (verandering in) 
inname van energie en vet, in het eerder beschreven cohort patiënten met DM2 
(hoofdstuk 3.2). Energie en vetconsumptie werd gemeten zoals hiervoor beschreven. 
Eetgedrag werd gemeten ten tijde van de diagnose en na vier jaar met de Nederlandse 
Vragenlijst voor Eetgedrag (NVE). Referentiecijfers werden verkregen van een 
vergelijkbare groep mensen uit de algemene populatie. In de N V E wordt onderscheid 
gemaakt tussen drie typen eetgedrag die in meer of mindere mate naast elkaar bestaan: 
(1) emotioneel eten, dit betekent dat men meer eet als men (negatieve) emoties 
ervaart; (2) extern eten, hierbij reageert men te laagdrempelig op voedingsgerelateerde 
prikkels zoals de reuk of aanblik van appetijtelijk eten; (3) lijngencht eten, als men 
gericht is op afvallen. De mate waarin deze drie typen eetgedrag aanwezig waren was 
gelijk in de patiènten met DM2 vergeleken met de algemene bevolking. Ten tijde van 
de diagnose waren emotioneel en extern eten geassocieerd met hoge energie en vet 
inname, en was lijngencht eten geassocieerd met een lage energie inname. Bij vrouwen 
was een hoge score voor extern eten, maar niet emotioneel eten, gerelateerd met een 
daling in energie inname na acht weken. Na vier jaar follow-up werden geen 
significante correlaties gevonden tussen veranderingen in energie en vetinname en de 
drie typen eetgedrag. Wij concluderen dat patiënten met nieuw gediagnosticeerde 
DM2 een eetgedrag hebben dat vergelijkbaar is met de algemene bevolking. Eetgedrag 
is sterker gerelateerd aan de kwantiteit (energie inname) dan aan de kwabteit (bijv. 
percentage vet) van het eten. Tenslotte concluderen we dat vrouwen met hoge scores 
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voor emotioneel eten minder in staat lijken hun voedingsgewoonten te verbeteren na 
de diagnose DM2. 
Hoewel in het algemeen wordt aangenomen dat men van 'lijnen' afvalt, wordt ook wel 
beweerd dat het juist een tegenovergesteld effect kan hebben. In hoofdstuk 3.3 
onderzochten we dit zogenaamde 'dieting dilemma': zorgt 'lijnen' voor een verbetering 
of verslechtering van overmatige voedselinname en gewichtsstijging? In het 
voornoemde cohort analyseerden we de relade tussen de uitkomsten van de N V E (bij 
diagnose en na vier jaar) en veranderingen in Body Mass Index (BMI) en energie 
inname. Indien 'lijnen' inderdaad een negatieve invloed op energie inname en 
lichaamsgewicht zou hebben, zou lijngericht eten de sterkste voorspeller voor energie 
inname en BMI na vier jaar zijn. 
We vonden sterke correlaties tussen eetgedrag ten tijde van de diagnose en na vier 
jaar. Dit laat zien dat eetgedrag een individueel kenmerk is dat weinig verandert in de 
loop van tijd. Vervolgens vonden we dat een neiging tot overeten (een combinatie van 
extern en emotioneel eten) ten tijde van de diagnose, geassocieerd was met 
gewichtsstijging en energie inname vier jaar later. We vonden geen relatie tussen 
lijngericht eten en gewichtsverandering. Deze resultaten suggereren dat niet lijngericht 
eetgedrag ('lijnen'), maar juist emotioneel en extern eetgedrag mogelijke voorspellers 
zijn voor succes van een diètistische interventie. 
In hoofdstuk 4 beschrijven we de effectiviteit van alpha-glucosidaseremmers (AGRs) 
in de behandeling van DM2. 
In het eerder beschreven cohort van patiënten met nieuw gediagnosticeerde DM2 
deden we een gerandomiseerd onderzoek {hoofdstuk 4.1) om na te gaan of acarbose 
(een AGR) en tolbutamide een gelijk effect hadden op het gemiddelde HbAic. 
Secundaire uitkomsten waren het effect van acarbose en tolbutamide op de nuchtere 
plasma bloedglucose en insuline, bloedglucose en insuline na een orale glucose 
tolerantietest (OGTT), plasma lipiden, en bijwerkingen. Patiënten die acht weken na 
de diagnose en dieetadvies nog een nuchtere bloedglucose tussen 6.7 en 20 mmol/1 
hadden, werden gerandomiseerd in een acarbose (n=48) of tolbutamide (n=48) 
behandelgroep voor een periode van 30 weken. Patiënten kregen dubbel-blind 
acarbose (stapsgewijs getitreerd tot maximaal 100 mg drie maal daags), of tolbutamide 
(stapsgewijs getitreerd tot maximaal 2000 mg in drie doses). De twee behandeling 
werden geacht gelijkwaardig te zijn als het tweezijdige 90% betrouwbaarheidsinterval 
(BI) voor het verschil in HbAic tussen -0.4% en 0.4% zou vallen. We vonden voor 
beide geneesmiddelen een daling in HbAic en nuchtere bloed glucose waarden. Het 
verschil in gemiddelde HbAic was 0.6% in het voordeel van tolbutamide (90% BI 0.3-
0.9, 95% BI 0.2-1.0). Er waren geen significante verschillen in glucose na een OGTT, 
nuchtere insuline, insuline na een OGTT, en plasma lipiden. In de acarbose groep 
stopten significant meer patiënten met de behandeling vanwege bijwerkingen, veelal 
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van gastro-intestinale aard. Wij concluderen dat deze resultaten geen gelijkwaardigheid 
aantonen van acarbose en tolbutamide en eerder wijzen op een voorkeur voor 
tolbutamide in de initiële behandeling van patiënten met DM2 in de huisartspraktijk. 
AGRs (acarbose, miglitol, voghbose) worden algemeen gebruikt in de behandeling van 
DM2, maar de aanbevelingen over in welk geval deze middelen te gebruiken en het 
wetenschappebjke bewijs waar deze aanbevehngen op gestoeld zijn varieert in 
verschillende (internationale richtlijnen. Wij deden een systematische literatuurstudie 
en meta-analyse naar het effect van AGRs versus placebo (of enige andere interventie) 
met betrekking tot mortaliteit en (diabetes gerelateerde) morbiditeit, glykemische 
controle, plasma hpiden, plasma insuline, lichaamsgewicht en bijwerkingen 
(hoofdstuk 4.2). Wij includeerden 41 studies (30 acarbose, 7 miglitol, 1 voghbose, 3 
combinaties) waarin wij geen bewijs vonden voor een effect op mortaliteit en 
morbiditeit. In vergelijking met placebo hadden AGRs een gunstig effect op het 
HbA,c (acarbose -0.8%, 95% BI 0.6-0.9; migütol -0.7%, 95% BI 0.4-0.9), nuchtere 
bloedglucose en postprandiale insuline en glucose. Geen van de AGRs had een effect 
op de plasma hpiden. BMI daalde met 0.2 kg/m2 (95% BI 0.1-0.3) vergeleken met 
placebo. Vergeleken met sulphonylurea hadden AGRs een inferieur effect op 
glykemische controle, maar een groter effect op nuchtere en postprandiale insuline. 
De bijwerkingen van AGRs waren voornamelijk gastro-intestinaal. Bij een dosis hoger 
dan drie maal daags 50 mg namen de bijwerkingen toe, nam het effect op het 
postprandiale bloedglucose toe, maar werd het effect op het HbAic met groter. Dit is 
mogelijk te verklaren door een slechtere therapietrouw in de hogere doseringen. We 
concluderen dat een acarbose dosering hoger dan 150 mg per dag niet zinvol is. 
De resultaten van onze systematische literatuurstudie naar AGRs (met name met 
betrekking tot het ontbreken van bewijs voor effect op mortaliteit en morbiditeit), 
noodzaakten ons te reageren op een studie van Hanefeld et al. (Eur Heart J 
2004;25:10-6) waarin beweerd werd dat acarbose hartinfarcten kan voorkómen. Hun 
bewering was gestoeld op een meta-analyse van zeven gerandomiseerde studies. Wij 
becommentarieerden hun studie met betrekking tot de publicatie bias, heterogeniteit, 
detectie bias en confounders die de resultaten vertekenden. In hoofdstuk 4.3.1 wordt 
deze kritiek beschreven in een brief aan de redactie en het antwoord van de auteurs. 
Hoofdstuk 4.3.2 behelst correspondentie over hetzelfde onderwerp, maar nu op 
initiatief van Hanefeld et al. die in een brief aan de redactie onze Cochrane review 
becommentariëren. 
Gestoorde nuchtere glucose en gestoorde glucose tolerantie zijn risicofactoren voor 
het ontstaan van DM2 en hartvaatziekten. Beide worden gezien als een uiting van een 
gestoord glucose metabolisme dat (nog) met ernstig genoeg is om te voldoen aan de 
criteria voor DM2. Wij onderzochten het effect van AGRs bij patiënten met 
gestoorde nuchtere glucose en/of gestoorde glucose tolerantie in een systematische 
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review {hoofdstuk S). Wij zochten naar gerandomiseerde studies van minstens één 
jaar, waarin AGR monotherapie werd vergeleken met enige andere interventie. Vijf 
studies (2360 deelnemers) werden geïncludeerd. Slechts één studie had een laag risico 
op bias, de andere studies hadden een hoog risico op bias. Vanwege de beperkte 
hoeveelheid data kon geen meta-analyse gedaan worden. Data van de studie met laag 
risico op bias liet zien dat acarbose het risico op DM2 (Number-Needed-to-Treat 
(NNT) 10) en cardiovasculaire aandoeningen (NNT 50, gebaseerd op 47 
gebeurtenissen) verminderde. Echter, deze studie had onvoldoende power om het 
effect op cardiovasculaire aandoeningen te bestuderen en daarom is bevestiging van 
deze uitkomst wenselijk in nieuwe studies. Wij concluderen dat AGRs de incidentie 
van DM2 bij patiënten met gestoorde nuchtere glucose en gestoorde glucose 
tolerantie weliswaar kan verminderen, maar dat het onduidelijk is of dit gezien moet 
worden als preventie, uitstel, of het maskeren van DM2. 
In hoofdstuk 6 bediscussiëren we de belangrijkste resultaten en bespreken we de 
implicaties voor de praktijk en toekomstig onderzoek. Daarnaast wordt dit 




Het begon allemaal met een wetenschappelijke stage over het nut van 
neusseptumcorrecties. Met dit projectie) loodste mi)n copromotor Eloy van de Ijsdonk me 
in 1996 de afdeling binnen. Zijn prikkelende nieuwsgierigheid en enthousiasmerende 
werksti)! hebben mijn vuur voor huisartsgeneeskunde en onderzoek verder opgepookt. Ik 
ben dankbaar dat ik me steeds kon blijven verheugen in zijn opgewekte mentorschap. Met 
de start van het project wat leidde tot dit proefschrift werd ook Peter lj<cassen mijn 
begeleider en copromotor. Van hem leerde ik de noodzakelijke lessen in geduld en 
nauwgezetheid en bovenal om bij alle (schijnbare) zekerheden vraagtekens te plaatsen. 
Bovendien zag ik bij hem dat het zijn van zowel huisarts als onderzoeker (en prins 
carnaval) kan leiden tot een organisch geheel. 
Meer op afstand van het dagelijkse werk, maar zeker zo belangrijk, waren mijn 
promotoren. Guy Kutten komt als directe collega van de dokter die mijn moeder van mij 
'verloste', letterlijk van mijn bakermat. Het is dus logisch dat hij ook aan de basis stond 
van het ACTOL project wat resulteerde in dit proefschrift. Zijn kennis van en passie voor 
diabetes onderzoek, alsmede zijn onvermoeibare aanmoedigingen hebben mij zeer 
geholpen. Meestal op reis, maar altijd dichtbij was Chris van Weel. Vermoedelijk vliegt hij 
steeds tegen de tijdzones in en slaagt er op die manier in voldoende tijd over te houden 
voor het beoordelen en becommentariëren van het vele werk. Zijn vertrouwen voelde als 
een grote steun en zijn strategische en kritische commentaren heb ik zeer gewaardeerd. 
Geen (co)promotor, maar zeker zo waardevol, was Wim de Grauw. Zijn kennis van de 
eerstelijns diabetologie, zijn wetenschappelijke verwondering en onze gezamenlijke 
reflecties op relevante en minder relevante observaties verhoogde mijn werkplezier en de 
kwaliteit van dit proefschrift. Het was ook plezierig dat hij regelmatig wat jonge studentes 
liet opdraven die vervolgens aan mij gingen vragen waar "ons pap" was. Een tweede 
'geheime promotor' was jaap van Binsbergen, die de afdeling kwam versterken toen dit 
proefschrift al een eind gevorderd was, en met zijn kennis van voeding in de 
huisartspraktijk veel steun gegeven heeft. 
Jan Mulder, Keimer Akkermam en Henk van den Hoogen vormden het statistische en 
methodologische geweten van mijn onderzoek. Zodra Jan met een zucht en een lach voor 
de zoveelste keer zijn toverformules toevertrouwde aan SAS, begon op een magische wijze 
de printer op de gang te draaien. Gelukkig was hij steeds weer bereid om zijn hocus-pocus 
tot begrijpelijke kost terug te brengen, dreuzel als ik ben. Reinier werd een maatje in 
systematic reviews en meta-analyses. Door zijn werk, advies en initiatieven werd mijn 
humeur een stuk zonniger en de systematische reviews veel beter. Henk is een verhaal 
apart. Op het veelvuldig verschijnen van zijn naam in de dankwoorden van vele 
proefschriften die ik onder ogen kreeg zou men kunnen promoveren. "Nogal wiedes", zou 
Henk zelf zeggen, "het is een veel voorkomende naam", waarmee hij op de voor hem 
kenmerkende sobere wijze het probleem alweer tot hanteerbare proporties had terug 
gebracht. Naast zijn nuchtere lessen dank ik Henk voor het geheel belangeloos ter 
beschikking stellen van zoon en schoondochter (zie verder) voor dit onderzoek. 
Geen onderzoek zonder data. Hiervoor verdient Carla Walk speciale dank. Zonder 
haar bereidheid om voor dag en dauw te vertrekken naar Hoogeveen, Loppersum, 
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Balleman, Zwartebroek, Gasselterboerveenschemond, Jipsingboermussel, Botshol, of hoe 
al die plaatsen ook heetten, was dit boekje een stuk dunner geworden. Nauwgezet en 
gezellig: het was heerlijk samenwerken met haar. Tegelijkerti)d op het secretariaat zorgde 
Twamiy ]eijsman-Rouwhorst dat één en ander logistiek voortreffelijk liep, en leende Caroline 
Roos haar Spaanse ogen en mond bi) lastig te lezen artikelen voor de reviews. 
Geen data maar vooral genoegen verschaften mijn kamergenoten. Naast de eerder 
genoemde Wim en Jaap zijn dat Envtn klem Woolthuis, Caroline van Wayenburg en Marianne 
Dees. Ik dank hen voor de gezelligheid, de ad-hoc-hulp-in-van-alles-en-nog-wat, de koffie, 
het plagen en het terugplagen. Daarnaast waren de (overige) collega AIOTHOs {Patrick, 
Mark, Annemarie, Enk, Hiske, Tim, Ijeke, Lotte) een welkome bron van inspiratie en hulp. 
Ook buiten de muren van de afdeling ben ik door velen geholpen en ondersteund. Ten 
eerste Heert Tigchelaar. hij bleef altijd bereid om de vragen die ik had naar aanleiding van de 
basismetingen geduldig te beantwoorden. Saskia Meyboom leerde me op haar vriendelijke en 
innemende wijze veel over vragenlijsten, kometen en hoe dik je brood kunt beleggen. 
Annette Stafleu leverde een belangrijke bijdrage in de vorm van gegevens over eetgedrag in 
de algemene bevolking. Tatjana van Strien liet me profiteren van haar uitputtende kennis 
van de wereld van het eetgedrag. Ik heb genoten van de cultuurverschillen tussen de 
medische en gedragswetenschappeli)ke werelden. Uit dezelfde wereld als Tatjana kwamen 
Inge Keus en Kathleen Jenks, die samen met Bruce Willis op een bewonderenswaardige wi)ze 
konden volhouden dat statistiek leuk is. Door hun inspanningen werden de voedingsdata 
een stuk inzichtelijker. Ook voor de systematische reviews kreeg ik zeer welkome hulp bij 
het schrijven van het protocol van Shuang Wang, bibliotheek assistentie van Anja van 
Guluck, en vertaalhulp van Emile van den Hoogen en Natasja Odelevskaia (Russisch), l^eon Bax 
(Japans), Ka Wai Wu en Bas Aarts (Chinees). 
Zonder Henriette Gtesbers had dit proefschrift meer op een gestencild parochiekrantje 
geleken dan op een echt boek. Ik ben zeer dankbaar voor haar vriendschap (samen met 
Bas) en voor het feit dat zij zo kort na de bevalling van ]itse vele uren wilde vnjmaken. Zij 
verzekerde me dat ze als kleine bonus, voor u lezer, met opzet een paar foutjes heeft 
achtergelaten. Degene die ze allemaal vindt maakt kans op een mooie prijs. Wendt u tot de 
paranimfen voor meer info. 
Het ervaren van kunst maakt de geest ontvankelijk voor goede ideeën. Geen toeval dus 
dat ik in het Museu de Arte de Sào Paolo de inval kreeg om Bernard Verhoeven te vragen de 
omslag voor dit proefschrift te ontwerpen. Zijn fantasievolle en associatieve denken, en 
precieze afwerkingen, hebben ervoor gezorgd dat de lading meer dan waardig gedekt 
wordt. 
Gedurende vier jaar was onderzoek nauw verweven met mijn opleiding tot huisarts. Ik 
dank Ben Bottema voor zijn geslaagde inspanningen het gecombineerde opleidingstraject tot 
huisarts en onderzoeker tot een succes te maken. Tijdens de vele terugkomdagen en 
supervisiesessies vormden de 'lessen' van Mechtild Beek, Dick Arts, Paul van Katmjk, Coot 
Kuipers, Hendrik-Jan Vundennk en Karen Luiten de welkome en leerzame verdieping van de 
praktijk. 
199 
Het 'echte' werk mocht ik leren en ervaren van mijn opleiders Paul Westgeest en Jaap 
Scbuurmans. Zi] lieten mi) letterli]k en figuurlijk in hun keuken kijken (Paul, de spa met )us 
d'orange dnnk ik nog altijd) en spaarden daarbij mij en henzelf met 
Zeker zoveel leer ik nog elke dag van mijn patiënten en met in de laatste plaats van 
mijn Lentse collega's: Ton Serrarens, Wil van den Bosch en Henk Sehers Ook met onze 
peperdure maar matig functionerende airco voelt het als een warm bad Laat daar geen 
misverstand over bestaan. Speciale dank aan Henk om me ook tijdens de verdediging 
terzijde te willen staan. 
De onderkoelde humor van Bernadette, de slimme vragen van Agnes, de glupjes van 
Amek, de stijladviezen van Manke, het rookgordijn van Antoinette, de stoïcijnse aanpak van 
Karleen, de centen van \acha en het dirigentschap van Manon Zonder hen geen praktijk en 
al helemaal geen werkplezier. 
Aan het einde van de dag en aan het einde van dit proefschrift kom ik thuis, in Zeeland en 
in Nijmegen. 
Frans en klly Meijer hebben, samen met Tartan, Fions, Rover en Nelson, al sinds heugems 
een bijzondere plaats. Ik heb me altijd met graagte gewenteld in hun gastvrijheid en 
onvermoeibare enthousiasme over studie, opleiding en werk. Hopelijk komen zij nog vaak 
ook in Nijmegen 'wentelen'. 
Mijn vrienden zorgen er ook bij mij voor dat 'thirty-something' best dragelijk is, en het 
adagium 'never a dull moment' is sindsdien onverminderd van kracht gebleven (zie: 
Timmers, 2004) Ik vertrouw erop dat we elkaar met uit het hart verhezen nu we nchting 
'almost-forty' gaan en onze kinderschare groeit. 
Met Gerard, Mieke en Fike Stikkelhroeck deel ik met alleen de liefde voor hun dochter en 
zus. Ik geniet van hun gezelschap en de gedeelte interesses voor alles wat mooi is. 
Mijn ouders hebben altijd de juiste balans gevonden tussen actieve steun en me de 
ruimte geven. Door deze onvoorwaardelijke basis van hefde ben ik gekomen tot waar ik 
nu ben. De opdracht in dit boekje is een kleine blijk van waardering daarvoor Ook aan 
Anneke met haar Jan-Hein en Jonne wil ik dank zeggen voor hun met aflatende steun en 
gezelligheid 
Maar het allerlaatste woord is voor jou, heve Nike. Het berglandschap van het promoveren 
is ons inderdaad met vreemd. In de dalen konden we samen schuilen en je liep naast me 
als ik een moeilijk begaanbaar pad wilde ontdekken. Ik ben dankbaar en gelukkig om nu 
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Stellingen behorend bij het proefschrift 
"Diet and alpha-glucosidase inhibition in the early treatment of type 2 diabetes 
mellitus" 
1. Externe validiteit van wetenschappeli)k onderzoek is een veelal 
onderbelicht onderwerp, (ditproefuhnfl) 
2. Patienten met type 2 diabetes zijn in staat om na de diagnose blijvende 
gunstige aanpassingen in het dieet te maken, (ditproefschrift) 
3. Patienten met type 2 diabetes hebben vergeleken met de algemene 
bevolking een niet afwijkend eetgedrag, (ditproefòihnjt) 
4. Op grond van het beschikbare wetenschappelijke bewijs is het onterecht 
dat alpha-glucosidaseremmers geen plaats meer hebben in de laatste NHG-
standaard. (ditproejsihnjt) 
5 Een dosering van acarbose hoger dan dne maal daags 50 mg heeft weinig 
toegevoegde waarde, (ditproefnhnft) 
6. Alpha-glucosidaseremmers kunnen type 2 diabetes voorkómen. Het blijft 
echter onduidelijk of dit preventie, uitstel of maskenng van de ziekte is. (dit 
proefsihnfl) 
7. In de hedendaagse medische cultuur is het volstrekt logisch om lelijkheid 
een ziekte te noemen. (Medinh Contait 2005;60(6):249) 
8. Ik rotzooi maar wat aan. (Karei Appel) 
9. Als het logisch is, moet het kloppen. (Henk van den Hoogen) 
10. Het ervaren van kunst maakt de geest ontvankelijk voor nieuwe ideeën 
11. Samen leven is de hoeksteen van het gezin. 
Fions van de Laar, 6 maart 2008 


